Sunteți pe pagina 1din 314

MINISTRY OF HEALTH MEDICINES FORMULARY

(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
Antiretroviral combination
therapy of HIV infection in
ADULTS & ADOLESCENT (>
adults and adolescents from
12 years of age):
12 years of age with the
Recommended dose is one
Abacavir Sulphate 600 mg following criteria:
J05AR02964T1001X tablet once daily. Not to be
1 and Lamivudine 300 mg A* i) Patients unsuitable or failed
X used in adults or adolescents
Tablet other HAART treatment
weigh less than 40kg.
ii) Patients who are at high
CHILDREN : Not
risk of renal impairment
recommended
iii) Patients with osteoporosis
or at high risk of bone loss
Only for treatment of:
i) Non insulin dependent
diabetes mellitus (NIDDM)
when diet therapy is
Initially 50 mg daily, increase
insufficient.
A10BF01000T1001X to 3 times daily up to 100 mg
2 Acarbose 50 mg Tablet A/KK ii) Non insulin dependent
X 3 times daily. Max 200 mg 3
diabetes mellitus (NIDDM) in
times daily
combination with existing
conventional oral therapy
where glycaemic control is
inadequate
Reduction of intraocular
pressure in open-angle
250mg 1-4 times a day, the
Acetazolamide 250 mg S01EC01000T1001X glaucoma, secondary
3 B dosage being titrated
Tablet X glaucoma and peri-
according to patient response
operatively in angle-closure
glaucoma
Reduction of intra-ocular
pressure in open-angle Adult : 250-1000mg per
Acetazolamide 500 mg S01EC01000P4001X glaucoma, secondary 24hours, usually in divided
4 B
Injection X glaucoma and peri- doses for amounts over
operatively in angle-closure 250mg daily
glaucoma
Diluted with dextrose 5% and
infused IV. Initial, 150 mg/kg
IV in 200 ml over 60 minutes,
Acetylcysteine 200 mg/ml V03AB23520P3001X Antidote for paracetamol then 50 mg/kg IV in 500 ml
5 A*
Injection X poisoning over 4 hours, followed by 100
mg/kg IV in 1000 ml over 16
hours. Total dose: 300mg/kg
in 20 hour
Prevention of myocardial
infarct, stroke, vascular
Acetylsalicylic Acid 100 mg, B01AC06259T1001X
6 B occlusion and deep vein 1 tablet daily
Glycine 45 mg Tablet X
thrombosis. Transient
ischaemic attacks
300 - 900 mg every 4 - 6
Acetylsalicylic Acid 300 mg N02BA01000T4001X hours as required. Max 4 g
7 C Mild to moderate pain
Soluble Tablet X daily. Use in children not
recommended

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
1 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
ADULT: initially 25-30 mg
i) Severe form of psoriasis daily for 2-4 weeks, then
including erythrodermic adjusted according to
psoriasis and local or response, usually within
generalized pustular range 25-50 mg daily for
psoriasis. further 6-8 weeks (max: 75
ii) Severe disorders of mg daily). In disorders of
D05BB02000C1001
8 Acitretin 10 mg Capsule A* keratinization, such as - keratinization, maintenance
XX
congenital ichthyosis - therapy of less than
pityriasis rubra pilaris - 20mg/day and should not
Darier's disease -other exceed 50mg/day CHILD:
disorders of keratinization 0.5mg/kg daily occasionally
which may be resistant to up to 1 mg/kg daily to a max.
other therapies 35 mg daily for limited
periods
ADULT: initially 25-30 mg
i) Severe form of psoriasis daily for 2-4 weeks, then
including erythrodermic adjusted according to
psoriasis and local or response, usually within
generalized pustular range 25-50 mg daily for
psoriasis. further 6-8 weeks (max: 75
ii) Severe disorders of mg daily). In disorders of
D05BB02000C1002
9 Acitretin 25 mg Capsule A* keratinization, such as - keratinization, maintenance
XX
congenital ichthyosis - therapy of less than
pityriasis rubra pilaris - 20mg/day and should not
Darier's disease -other exceed 50mg/day CHILD:
disorders of keratinization 0.5mg/kg daily occasionally
which may be resistant to up to 1 mg/kg daily to a max.
other therapies 35 mg daily for limited
periods
Infected skin, lesions, cuts,
D08AA03000L6001X Apply undiluted three times
10 Acriflavine 0.1% Lotion C+ abrasions, wounds and
X daily to the affected part.
burns.
i) ADULT: 500 mcg IV daily
for max of 5 days. CHILD:
1.5 mg/m2 once every 3
weeks (if weight less than 10
Actinomycin D i) For solid tumours
L01DA01110P4001X kg, 50 mcg/kg)
11 (Dactinomycin) 500 mcg/ml A ii) Gestational trophoblastic
X ii) 500 mcg IV on Days 2, 4,
Injection disease
6, 8, 10, repeat every 7 - 10
days or 500 mcg IV bolus on
Days 1 and 2, repeat every
15 days

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
2 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
i) Mucocutaneous Herpes
Simplex infection in
immunocompromised and
AIDS patients
i) ADULT: initially 400 mg 5
ii) Primary and recurrent
times daily for 7 - 14 days.
Varicella Zoster infection in
CHILD less than 2 years: 200
immunocompromised and
mg 4 times daily, CHILD
AIDS patients
more than 2 years: 400 mg 4
iii) Severe Kaposi Varicella
times daily
Eruption (Eczema
ii), iii) and iv) ADULT: 200 -
herpeticum)
400 mg 4 times daily. CHILD:
iv) Severe primary HSV
less than 2 years, half adult
infections (eg. Neonatal
dose; more than 2 years,
J05AB01000T1001X herpes, encephalitis, eczema
12 Acyclovir 200 mg Tablet A/KK adult dose
X herpeticum, genital herpes,
v) ADULT: 800 mg 5 times
gingival stomatitis, vaginal
daily for 7 days
delivery with maternal vulva
vi) ADULT: 20 mg/kg
herpes)
(maximum: 800 mg) four
v) Severe and complicated
times daily for 5 days, CHILD
varicella infection (eg.
6 years: 800 mg four times
Encephalitis, purpura
daily. CHILD less than 2
fulminans)
years; 400mg 4 times daily,
vi) Severe zoster infection in
more than 2 years; 800mg 4
paediatrics (eg. Encephalitis,
times daily
purpura fulminans,
immunocompromised
patients and facial, sacral
and motor zoster)
i) Mucocutaneous Herpes
Simplex infection in
immunocompromised and
AIDS patients.
i) ADULT: initially 400 mg 5
ii) Primary and recurrent
times daily for 7 - 14 days.
Varicella Zoster infection in
CHILD less than 2 years: 200
immunocompromised and
mg 4 times daily, CHILD
AIDS patients.
more than 2 years: 400 mg 4
iii) Severe Kaposi Varicella
times daily.
Eruption (Eczema
ii), iii) and iv) ADULT: 200 -
herpeticum).
400 mg 4 times daily. CHILD:
iv) Severe primary HSV
less than 2 years, half adult
infections (eg. Neonatal
dose; more than 2 years,
Acyclovir 200 mg/5 ml J05AB01000L8001X herpes, encephalitis, eczema
13 A* adult dose.
Suspension X herpeticum, genital herpes,
v) ADULT: 800 mg 5 times
gingival stomatitis, vaginal
daily for 7 days
delivery with maternal vulva
vi) ADULT: 20 mg/kg
herpes).
(maximum: 800 mg) four
v) Severe and complicated
times daily for 5 days, CHILD
varicella infection (eg.
6 years: 800 mg four times
Encephalitis, purpura
daily. CHILD less than 2
fulminans).
years; 400mg 4 times daily,
vi) Severe zoster infection in
more than 2 years; 800mg 4
paediatrics (eg. Encephalitis,
times daily.
purpura fulminans,
immunocompromised
patients and facial, sacral
and motor zoster).

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
3 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
ADULT: 5 mg/kg by IV
infusion 8 hourly for 5 days,
doubled to 10mg/kg every 8
hourly in varicella-zoster in
the immunocompromised
and in simplex encephalitis
(usually given for at least 10
days in encephalitis; possibly
for 14 - 21 days). NEONATE
& INFANT up to 3 months
with disseminated herpes
Treatment and prophylaxis of
simplex: 20mg/kg every 8
herpes simplex in
J05AB01000P4001X hourly for 14 days (21 days in
14 Acyclovir 250 mg Injection A* immunocompromised, severe
X CNS involvement), varicella-
initial genital herpes and
zoster 10-20mg/kg every 8
Varicella -Zoster
hourly usually for 7 days.
CHILD, 3 months - 12 years:
Herpes simplex or Varicella
Zoster: 250 mg/m2 8 hourly
for 5 days, doubled to 500
mg/m2 8 hourly for varicella-
zoster in the
immunocompromised and in
simplex encephalitis (usually
given for 10 days in
encephalitis)
Apply 1 cm 5 times daily.
S01AD03000G5101 Only for the treatment of
15 Acyclovir 3% Eye Ointment A* Continue for at least 3 days
XX herpes simplex keratitis
after healing
Herpes simplex infections of
D06BB03000G1001 the skin, including initial and Apply every 4 hours for 5 - 10
16 Acyclovir 5% Cream A*
XX recurrent labial and genital days
herpes simplex infections
i) Mucocutaneous Herpes
Simplex infection in
i) ADULT: initially 400 mg 5
immunocompromised and
times daily for 7 - 14 days.
AIDS patients.
CHILD less than 2 years: 200
ii) Primary and recurrent
mg 4 times daily, CHILD
Varicella Zoster infection in
more than 2 years: 400 mg 4
immunocompromised and
times daily.
AIDS patients.
ii), iii) and iv) ADULT: 200 -
iii) Severe Kaposi Varicella
400 mg 4 times daily. CHILD:
Eruption (Eczema
less than 2 years, half adult
herpeticum).
dose; more than 2 years,
J05AB01000T1002X iv) Severe primary HSV
17 Acyclovir 800 mg Tablet A/KK adult dose.
X infections (eg. Neonatal
v) ADULT: 800 mg 5 times
herpes, encephalitis, eczema
daily for 7 days
herpeticum, genital herpes,
vi) ADULT: 20 mg/kg
gingival stomatitis, vaginal
(maximum: 800 mg) four
delivery with maternal vulva
times daily for 5 days, CHILD
herpes).
6 years: 800 mg four times
v) Severe and complicated
daily. CHILD less than 2
varicella infection (eg.
years; 400mg 4 times daily,
Encephalitis, purpura
more than 2 years; 800mg 4
fulminans).
times daily.
vi) Severe zoster infection in
paediatrics (eg. Encephalitis,

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
4 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
purpura fulminans,
immunocompromised
patients and facial, sacral
and motor zoster).
i) Third line treatment of: -
Severe rheumatoid arthritis -
Psoriatic arthritis - Ankylosing
spondylitis after failure of
conventional DMARDs or
other biologics
ii)Treatment of adults with
moderate to severe chronic
plaque psoriasis who have
not responded to, have
contraindication or are
i) Severe rheumatoid arthritis,
unable to tolerate
Psoriatic arthritis, Ankylosing
phototherapy and/or systemic
spondylitis: Subcutaneous 40
therapies including acitretin,
mg every other week
methotreaxate and
ii) Chronic plaque psoriasis:
cyclosporine
Initial, 80 mg SC, followed by
iii) Crohn's Disease
40 mg SC every other week
a) For treatment of
starting one week after the
moderately to severely active
initial dose
Crohn's Disease in adult
iii) & iv) Crohn's disease &
Adalimumab 40 mg L04AB04000P5001X patients who have
18 A* Ulcerative colitis: 160mg at
Injection X inadequate response to
week 0 (dose can be
conventional therapy
administered as four
b) For treatment of
injections in one day or as
moderately to severely active
two injections per day for two
Crohn's Disease in adult
consecutive days) and 80mg
patients who have lost
at week 2. After induction
response to or are intolerant
treatment, the recommended
to infliximab
maintenance dose is 40mg
iv) Ulcerative Colitis - For
every other week via
treatment of moderately to
subcutaneous injection.
severely active ulcerative
colitis in adult patients who
have had an inadequate
response to conventional
therapy including
corticosteroids and 6-
mercaptopurine or
azathioprine, or who are
intolerant to or have medical
contraindications for such
therapies
Acne vulgaris where
comedones, papules and
Apply once daily to the
D10AD03000G1001 pustules predominate in
19 Adapalene 0.1% Cream A* affected areas after washing
XX those sensitive to benzoyl
at bedtime
peroxide or topical tretinoin
[third line treatment]
Acne vulgaris where
Apply once daily to the
D10AD03000G3001 comedones, papules and
20 Adapalene 0.1% Gel A* affected areas after washing
XX pustules predominate in
at bedtime
those sensitive to benzoyl

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
5 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
peroxide or topical tretinoin
[third line treatment]

i) Treatment of chronic
HBeAg positive and HBeAg
negative hepatitis B infection
in adults with compensated
Adult (18-65 years): 10mg
liver function (lamivudine
Once Daily Renal Dose
should be tried first)
Adjustment : 10mg every
Adefovir Dipivoxil 10 mg J05AF08000T1001X ii) Lamivudine-resistant
21 A* 48hours (30-49ml/min); 10mg
Tablet X chronic hepatitis B virus
every 72hours (10-29ml/min);
infection with either
10mg every 7 days
compensated or
(Hemodialysis)
decompensated hepatitis
function (only by hepatologist
and gastroenterologist for
approved indications)
ADULT: Initially: 3 mg given
as a rapid IV bolus (over 2
seconds). Second dose: If
the first dose does not result
in elimination of the
supraventricular tachycardia
Rapid conversion of with in 1 or 2 minutes, 6 mg
Adenosine 3 mg/ml C01EB10000P3001X
22 B paroxysmal supraventricular should be given also as a
Injection X
tachycardia to sinus rhythm rapid IV bolus. Third dose: If
the second dose does not
result in elimination of the
supraventicular tachycardia
with in 1-2 minutes, 12 mg
should be given also as a
rapid IV bolus
Adrenaline Acid 1 mg by intravenous injection
C01CA24123P3001 Cardiopulmonary
23 (Epinephrine) Tartrate 1 B repeated every 3-5 minutes
XX resuscitation
mg/ml Injection according to response
The recommended dose is
2mg aflibercept, equivalent to
0.05mL (50 μL) given as
Treatment of neovascular intra-vitreal injection.
Aflibercept 40mg/ml S01LA05000P3001X
24 A* (wet) age-related macular Aflibercept treatment is
solution vial for injection X
degeneration (wet AMD). initiated with one injection per
month for three consecutive
doses, followed by one
injection every two months.
The recommended dose is
N06AX22000T1001X 25mg once daily at bedtime,
25 Agomelatine 25 mg Tablet A* Major depression
X maybe increased to 50mg
once daily at bedtime.
i) Child 12-24months: 200mg
as a single dose
ii) Adult & Child above 2
i) Single or mixed infestations
P02CA03000T1001X years: 400mg as a single
26 Albendazole 200 mg Tablet C+ of intestinal parasites
X dose for 3 consecutive days;
ii) Strongyloides infection
Child 12 - 24months: 200mg
as a single dose for 3
consecutive days

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
6 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
i) Child 12-24months: 200mg
as a single dose
ii) Adult & Child above 2
i) Single or mixed infestations
Albendazole 200 mg/5 ml P02CA03000L8001X years: 400mg as a single
27 C+ of intestinal parasites
Suspension X dose for 3 consecutive days;
ii) Strongyloides infection
Child 12 - 24months: 200mg
as a single dose for 3
consecutive days
D08AX08000L9901X Use as antiseptic and Apply to the skin undiluted or
28 Alcohol 70% Solution C+
X disinfectant when needed
1 tablet once weekly
Osteoporosis in [70mg/5600 IU]. Patient
postmenopausal women with should receive supplemental
a history of vertebral fracture calcium or vitamin D, if
and whom oestrogen dietary vitamin D inadequate.
replacement therapy is The tablet should be taken at
contraindicated. Review least half and hour before the
treatment after 2 years and if first food, beverage, or
there is positive response, medication of the day with
Alendronate Sodium 70 mg
M05BB03972T1002 treatment may be continued plain water only. To facilitate
29 and Cholecalciferol 5600 IU A*
XX up to 5 years and then re- delivery to stomach and thus
Tablet
evaluate. Treatment should reduce the potential for
be stopped if there is no esophageal irritation, it
positive response after 5 should only be swallowed
years. Otherwise, patient upon arising for the day with
needs to be given drug a full glass of water and
holiday for 1 to 2 years and patient should not lie down
then continue treatment shall for at least 30 minutes and
the benefit outweigh the risk. until after their first food of
the day.
Osteoporosis in
postmenopausal women with
a history of vertebral fracture
and whom oestrogen
replacement therapy is 70 mg once weekly. Swallow
contraindicated. Review the tablet whole with a full
treatment after 2 years and if glass of plain water only on
there is positive response, an empty stomach at least 30
Alendronate Sodium 70 mg M05BA04520T1001 treatment may be continued minutes before breakfast
30 A*
Tablet XX up to 5 years and then re- (and any other oral
evaluate. Treatment should medication); stand or sit
be stopped if there is no upright for at least 30
positive response after 5 minutes and do not lie down
years. Otherwise, patient until after eating breakfast
needs to be given drug
holiday for 1 to 2 years and
then continue treatment shall
the benefit outweigh the risk.
i) Renal osteodystrophy in
patients on haemodialysis Initial dose ADULT and
ii) Hypoparathyroidism and CHILD above 20kg body
pseudohypoparathyroidism weight: 1 mcg daily; CHILD
Alfacalcidol 0.25 mcg A11CC03000C1001
31 A/KK iii) Adjunct to the under 20kg body weight: 0.05
Capsule XX
management of tertiary mcg/kg/day. Maintenance
hyperparathyroidism dose : 0.25 mcg to 2 mcg
iv) Rickets and osteomalacia daily
v) Osteoporosis

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
7 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
i) Renal osteodystrophy in
patients on haemodialysis Initial dose ADULT and
ii) Hypoparathyroidism and CHILD above 20kg body
pseudohypoparathyroidism weight: 1 mcg daily; CHILD
A11CC03000C1002
32 Alfacalcidol 1 mcg Capsule A/KK iii) Adjunct to the under 20kg body weight: 0.05
XX
management of tertiary mcg/kg/day. Maintenance
hyperparathyroidism dose : 0.25 mcg to 2 mcg
iv) Rickets and osteomalacia daily
v) Osteoporosis
i) Renal osteodystrophy in
patients on haemodialysis
ii) Hypoparathyroidism and
pseudohypoparathyroidism
A11CC03000D5001
33 Alfacalcidol 2 mcg/ml Drops A* iii) Adjunct to the NEONATES : 0.1 mcg/kg/day
XX
management of tertiary
hyperparathyroidism
iv) Rickets and osteomalacia
v) Osteoporosis
Treatment of:
i) Renal osteodystrophy in
Adult: Initially, 1 mcg daily.
patients on haemodialysis
Maintenance: 0.25-1 mcg
ii) Hypoparathyroidism and
daily. Child: Premature
Alfacalcidol 2 mcg/ml A11CC03000P3001 pseudohypoparathyroidism
34 A* infants and neonates: 0.05-
Injection XX iii) Adjunct to the
0.1 mcg/kg daily; <20 kg:
management of tertiary
0.05 mcg/kg daily. Elderly:
hyperparathyroidism
0.5 mcg daily.
iv) Rickets and osteomalacia
v) Osteoporosis
For use as short acting Initial dose: 20 - 40 mcg/kg.
Alfentanil HCl 0.5 mg/ml N01AH02110P3001 narcotic analgesic in short Supplemental dose: 15
35 A*
Injection XX procedures and day-care mcg/kg or infusion 0.5 - 1.0
surgical procedures mcg/kg/min
Treatment of functional
G04CA01110T1001 symptoms related with
36 Alfuzosin HCl 10 mg Tablet A* 10 mg once a day pre bed
XX benign prostatic hypertrophy
(BPH)
20 mg/kg of body weight
administered once every 2
weeks as an intravenous
infusion. Monitoring It is
suggested that patients be
monitored periodically for IgG
antibody formation. Patients
who experience Infusion-
associated reactions
Alglucosidase alfa 5 mg/ml A16AB07000P4001X Infantile-onset Pompe suggestive of hypersensitivity
37 A*
Injection X disease may be tested for IgE
antibodies to alglucosidase
alfa. Treated patients who
experience a decrease in
benefit despite continued
treatment with Alglucosidase
Alfa, in whom antibodies are
suspected to play a role, may
be tested for neutralization of
enzyme uptake or activity.

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
8 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
To be diluted with an equal
R01A000999L5001X
38 Alkaline Nasal Douche B To remove nasal plug volume of warm water before
X
use
i) Frequent and disabling
attacks of gouty arthritis (3 or
more attacks/year).
ii) Clinical or radiographic
signs of erosive gouty
arthritis. Initial dose: 100-300 mg
M04AA01000T1002 iii) The presence of daily. Maintenance: 300-600
39 Allopurinol 100 mg Tablet A/KK
XX tophaceous deposits. mg daily. Maximum: 900 mg
iv) Urate nephropathy. daily
v) Urate nephrolithiasis.
vi) Impending cytotoxic
chemotherapy or
radiotherapy for lymphoma or
leukaemia
i) Frequent and disabling
attacks of gouty arthritis (3 or
more attacks/year).
ii) Clinical or radiographic
signs of erosive gouty
arthritis. Initial dose: 100-300 mg
M04AA01000T1001 iii) The presence of daily. Maintenance: 300-600
40 Allopurinol 300 mg Tablet A/KK
XX tophaceous deposits. mg daily. Maximum: 900 mg
iv) Urate nephropathy. daily
v) Urate nephrolithiasis.
vi) Impending cytotoxic
chemotherapy or
radiotherapy for lymphoma or
leukaemia
Induction: 45 mg/m2 daily for
30 - 90 days. Maintenance:
45 mg/m2 daily for 2 weeks
All-Trans Retinoic Acid 10 L01XX14000C1001X Acute promyelocytic
41 A* every 3 months. Renal/or
mg Capsule X leukaemia
hepatic insufficiency:
25mg/m2 daily for 30-90
days. Refer to protocols
0.25 - 0.5 mg 3 times daily
(elderly or delibitated 0.25
N05BA12000T1001X mg 2-3 times daily),
42 Alprazolam 0.25 mg Tablet A/KK Anxiety disorders
X increased if necessary to a
total dose of 3 mg/day. Not
recommended for children
0.25 - 0.5 mg 3 times daily
(elderly or delibitated 0.25
N05BA12000T1002X mg 2-3 times daily),
43 Alprazolam 0.5 mg Tablet A Anxiety disorders
X increased if necessary to a
total dose of 3 mg/day. Not
recommended for children
0.25 - 0.5 mg 3 times daily
(elderly or delibitated 0.25
N05BA12000T1003X mg 2-3 times daily),
44 Alprazolam 1 mg Tablet A Anxiety disorders
X increased if necessary to a
total dose of 3 mg/day. Not
recommended for children

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
9 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
0.05 - 0.1 mcg/kg/min by
For treatment of congenital
Alprostadil 500 mcg/ml C01EA01000P3001X continuous IV infusion, then
45 A* heart diseases which are
Injection X decreased to lowest effective
ductus arteriosus dependent
dose
0.9 mg/kg (maximum of 90
mg) infused over 60 minutes
with 10% of the total dose
administered as an initial
intravenous bolus. Treatment
Alteplase 50 mg per vial B01AD02000P4001X Thrombolytic treatment of must be started as early as
46 A*
Injection X acute ischaemic stroke. possible within 4.5 hours
after onset of stroke
symptoms and after
exclusion of intracranial
haemorrhage by appropriate
imaging technique.
Aluminium Hydroxide 600 A02AB01250T1001X Dyspepsia, 600 mg- 1.2 g 4 times daily
47 A
mg Tablet X hyperphosphataemia and at bedtime or as required
Initial dose: 100 mg daily and
is increased to 100 mg twice
daily (not later than 4 p.m.)
Amantadine HCl 100 mg N04BB01110C1001
48 B Parkinson's disease after a week. Elderly over 65
Capsule XX
years: less than 100 mg or
100 mg at intervals of more
than 1 day
ADULT: (IM or IV): 15
mg/kg/day 8 - 12 hourly for 7
- 10 days. Maximum: 1.5
g/day. CHILD: 15 mg/kg/day
Amikacin 125 mg/ml J01GB06183P3003X Infections due to susceptible 8 - 12 hourly. Maximum: 1.5
49 A
Injection X organisms g/day. Neonates: Initial
loading dose of 10 mg/kg
followed by 7.5 mg/kg/day 12
hourly. Maximum
15mg/kg/day
ADULT: (IM or IV): 15
mg/kg/day 8 - 12 hourly for 7
- 10 days. Maximum: 1.5
g/day. CHILD: 15 mg/kg/day
Amikacin 250mg/ml J01GB06183P3002X Infections due to susceptible 8 - 12 hourly. Maximum: 1.5
50 A
Injection X organisms g/day. Neonates: Initial
loading dose of 10 mg/kg
followed by 7.5 mg/kg/day 12
hourly. Maximum
15mg/kg/day
i) Initially 1 - 2 tab daily
i) Diuretic as an adjunct to
Amiloride HCl 5 mg & adjusted according to
C03EA01900T1001X the management of
51 Hydrochlorothiazide 50 mg B response. Max : 4 tabs daily.
X oedematous states
Tablet ii) 1 -2 tabs daily as a single
ii) Hypertension
or divided dose
Dose to be individualised.
ADULT usually 500-2000 ml
B05BA01910P3001X Source of amino acids in
52 Amino Acids Injection A by IV. ADULT usual
X patients needing IV nutrition
requirement for amino acid:
1-2 g/kg/day

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
10 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
Source of amino acids and Dose to be individualised.
Amino Acids with B05BA10910P3002X
53 A electrolytes in patients ADULT usual requirement for
Electrolytes Injection X
needing IV nutrition amino acid 1-2 g/kg/day
Source of amino acids, Dose to be individualised.
Amino Acids with Glucose B05BA10910P3003X carbohydrate and electrolytes ADULT usual requirement for
54 A
with Electrolytes Injection X in patients needing IV amino acid 1-2 g/kg/day,
nutrition carbohydrate 4-6 g/kg/day
Dose to be individualised.
Source of amino acids, ADULT: 500 - 2000 ml daily
Amino Acids, Glucose and
B05BA10910P3001X carbohydrate, lipid and given by IV. ADULT usual
55 Lipid with Electrolytes A
X electrolytes in patients requirement for amino acid 1-
Injection
needing IV nutrition 2 g/kg/ day, carbohydrate 4-6
g/kg/day, lipid 2-3 g/kg/day
Adult: Loading dose: 5 mg/kg
(ideal body weight) or 250-
500 mg (25 mg/ml) by slow
inj or infusion over 20-30 min.
Reversible airways Maintenance infusion dose:
Aminophylline 25 mg/ml R03DA05000P3001
56 B obstruction, acute severe 0.5 mg/kg/hr. Max rate: 25
Injection XX
brochospasm mg/min. Child: Loading dose:
same as adult dose.
Maintenance dose: 6 mth-9
yr: 1 mg/kg/hr and 10-16 yr:
0.8 mg/kg/hr.
200 mg 3 times daily for 1
week, then reduced to 200
mg twice daily for another
C01BD01110T1001X
57 Amiodarone 200 mg Tablet A* Arrhythmias week. Maintenance dose,
X
usually 200 mg daily or the
minimum required to control
the arrhythmia
Initial infusion of 5mg/kg via
large venous access over 20-
120 minutes with ECG
Arrhythmias when other
Amiodarone 50 mg/ml C01BD01110P3001 monitoring; subsequent
58 A* drugs are contraindicated or
Injection XX infusion given if necessary
ineffective
according to response up to
a maximum of 1.2 g in 24
hours
Treatment of psychoses, Predominantly negative
particularly acute or chronic episodes: 50-300 mg once
schizophrenia disorders daily adjusted according to
characterized by positive the patient?s response.
symptoms(e.g. delusion, Mixed episodes with positive
N05AL05000T1001X hallucinations, thought and negative symptoms: 400-
59 Amisulpride 100 mg Tablet A*
X disorders) and/or negative 800 mg/day in 2 divided
symptoms(e.g. blunted doses adjusted according to
emotions, emotional and the patient?s response.
social withdrawal) including Should be taken on an empty
when the negative symptoms stomach (Preferably taken
predominate before meals)
Treatment of psychoses, Predominantly negative
particularly acute or chronic episodes: 50-300 mg once
N05AL05000T1002X schizophrenia disorders daily adjusted according to
60 Amisulpride 400 mg Tablet A*
X characterized by positive the patient?s response.
symptoms(e.g. delusion, Mixed episodes with positive
hallucinations, thought and negative symptoms: 400-

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
11 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
disorders) and/or negative 800 mg/day in 2 divided
symptoms(e.g. blunted doses adjusted according to
emotions, emotional and the patient?s response.
social withdrawal) including Should be taken on an empty
when the negative symptoms stomach (Preferably taken
predominate before meals)
Initially 25mg 3 times a day.
Maintenance: 25-100mg daily
in divided doses.
Hospitalized patient:
100mg/day &gradually
Amitriptyline HCl 25 mg N06AA09110T1001X increase to 200-300mg/day.
61 B Depression
Tablet X ADOLESCENT and
ELDERLY: initially 20-
30mg/day in divided doses w/
gradual increments. CHILD
under 16 years are not
recommended
Doses range from amlodipine
besylate 5 mg/valsartan 160
mg to amlodipine besylate 10
Essential hypertension in
mg/valsartan 320 mg
Amlodipine 10 mg and C09DB01935T1003X patients whose blood
62 A/KK ORALLY once daily, with
Valsartan 160 mg Tablet X pressure is not adequately
dose titration occurring every
controlled by monotherapy
1 to 2 weeks if necessary.
MAX amlodipine besylate 10
mg/valsartan 320 mg
C08CA01000T1002X 5 mg once daily. Max: 10 mg
63 Amlodipine 10 mg Tablet B Hypertension
X once daily
Doses range from amlodipine
besylate 5 mg/valsartan 160
mg to amlodipine besylate 10
Essential hypertension in
mg/valsartan 320 mg
Amlodipine 5 mg and C09DB01935T1002X patients whose blood
64 A/KK ORALLY once daily, with
Valsartan 160 mg Tablet X pressure is not adequately
dose titration occurring every
controlled by monotherapy
1 to 2 weeks if necessary.
MAX amlodipine besylate 10
mg/valsartan 320 mg
C08CA01000T1001X 5 mg once daily. Max: 10 mg
65 Amlodipine 5 mg Tablet B Hypertension
X once daily
One tablet daily i) A patient
whose blood pressure is not
adequately controlled on dual
therapy with amlodipine
besylate/valsartan/HCTZ. ii)
For convenience, patients
Treatment of essential receiving valsartan,
Amlodipine besylate 10mg,
hypertension. This fixed amlodipine and HCTZ from
valsartan 160mg, C09DX01941T1001X
66 A/KK combination drug is not seperate tablets may be
hydrochlorothiazide 12.5mg X
indicated for the initial switched to amlodipine
tablet
therapy of hypertension. besylate/valsartan/HCTZ
containing the same
component dosses. Dosage
may be increased after 2
weeks. The maximum
antihypertensive effect of
amlodipine

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
12 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
besylate/valsartan/HCTZ is
reached within 2 weeks of
change in dose. The
maximum recommended
dose of amlodipine
besylate/valsartan/HCTZ is
10/320/25 mg. It can be
taken with or without food. It
is recommended to take it
with some water.
One tablet daily
i) A patient whose blood
pressure is not adequately
controlled on dual therapy
with amlodipine
besylate/valsartan/HCTZ.
ii) For convenience, patients
receiving valsartan,
amlodipine and HCTZ from
seperate tablets may be
switched to amlodipine
besylate/valsartan/HCTZ
Treatment of essential
Amlodipine besylate 10mg, containing the same
hypertension. This fixed
valsartan 160mg, C09DX01941T1002X component dosses. Dosage
67 A/KK combination drug is not
hydrochlorothiazide 25mg X may be increased after 2
indicated for the initial
tablet weeks. The maximum
therapy of hypertension.
antihypertensive effect of
amlodipine
besylate/valsartan/HCTZ is
reached within 2 weeks of
change in dose. The
maximum recommended
dose of amlodipine
besylate/valsartan/HCTZ is
10/320/25 mg. It can be
taken with or without food. It
is recommended to take it
with some water.
One tablet daily
i) A patient whose blood
pressure is not adequately
controlled on dual therapy
with amlodipine
besylate/valsartan/HCTZ.
ii) For convenience, patients
Treatment of essential receiving valsartan,
Amlodipine besylate
hypertension. This fixed amlodipine and HCTZ from
5mg,valsartan C09DX01941T1004X
68 A/KK combination drug is not seperate tablets may be
160mg,hydrochlorothiazide X
indicated for the initial switched to amlodipine
12.5mg tablet
therapy of hypertension. besylate/valsartan/HCTZ
containing the same
component dosses. Dosage
may be increased after 2
weeks. The maximum
antihypertensive effect of
amlodipine
besylate/valsartan/HCTZ is

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
13 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
reached within 2 weeks of
change in dose. The
maximum recommended
dose of amlodipine
besylate/valsartan/HCTZ is
10/320/25 mg. It can be
taken with or without food. It
is recommended to take it
with some water.
Amlodipine 5mg/losartan
50mg OR amlodipine
5mg/losartan 100mg orally
once daily. MAXIMUM
DOSE: amlodipine
5mg/losartan 100mg. No
Treatment of essential dosage adjustment in mild
hypertension in adults renal impairment. Not
Amlodipine Camsylate 5 mg
C09DB06935T1002X patients whose blood recommended in moderate to
69 and Losartan Potassium A/KK
X pressure is not adequately severe renal impairment or in
100 mg Tablet
controlled on either patients on dialysis. Not
monotherapy recommended in patients
who require lower dose of
losartan (25mg). Not
recommended in patients <
18 years as safety and
efficacy is not established in
this group
Amlodipine 5mg/losartan
50mg OR amlodipine
5mg/losartan 100mg orally
once daily. MAXIMUM
DOSE: amlodipine
5mg/losartan 100mg. No
Treatment of essential dosage adjustment in mild
hypertension in adults renal impairment. Not
Amlodipine Camsylate 5 mg
C09DB06935T1001X patients whose blood recommended in moderate to
70 and Losartan Potassium 50 A/KK
X pressure is not adequately severe renal impairment or in
mg Tablet
controlled on either patients on dialysis. Not
monotherapy recommended in patients
who require lower dose of
losartan (25mg). Not
recommended in patients <
18 years as safety and
efficacy is not established in
this group
Adults, the elderly and
children over 12 years: 10-
Ammonium Bicarbonate, R05CA04900L2101X 20ml, repeated after 4 hours
71 C Cough
Tincture Ipecac, etc Mixture X if required. Not more than 4
doses to be taken in any 24
hours.
Apply to affected nail once or
sometimes twice a week after
Amorolfine 5 % Nail D01AE16110L5001X
72 A* Fungal nail infections filling and cleansing, allow to
Lacquer X
dry, treat finger nail for 6
months, toe nail for 9 - 12

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
14 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
months (review at intervals of
3 months)

Mild to Moderate infection:


25mg/kg/day (based on
Amoxicillin dose) in 2 divided
Amoxicillin & Clavulanate J01CR02961F2102X Infections caused by
73 A/KK dose. Severe infection:
228 mg/5 ml Syrup X susceptible organisms
45mg/kg/day (based on
Amoxicillin dose) in 2 divided
dose
Infections caused by
CHILD less than 3 months:
susceptible organisms.
30mg/kg 12 hourly. 3 months
Amoxicillin 1 g & Respiratory tract, skin, soft
J01CR02961P4002X - 12 years: 30mg/kg 6 - 8
74 Clavulanate 200 mg A tissue, GUT infection,
X hourly. ADULT: 1.2 g by IV or
Injection septicaemia, peritonitis, post-
intermittent infusion 6 - 8
operative infection &
hourly
osteomyelitis
Infections caused by ADULT: 250 - 500 mg 3
J01CA04012C1001X susceptible strains of gram times daily. CHILD: 20 - 40
75 Amoxicillin 250 mg Capsule B
X positive and gram negative mg/kg/day in divided doses 8
organisms hourly
Infections due to beta-
lactamase producing strain
where amoxicillin alone is not ADULT & CHILD more than
Amoxicillin 500 mg & J01CR02961T1002X appropriate. Respiratory 12 years: Mild to moderate
76 A/KK
Clavulanate 125 mg Tablet X tract, skin, soft tissue, GUT infections: 625 mg twice
infection, septicaemia, daily.
peritonitis, post-operative
infection & osteomyelitis
Infections caused by
CHILD less than 3 months:
susceptible organisms.
30mg/kg 12 hourly. 3 months
Amoxicillin 500 mg and Respiratory tract, skin, soft
J01CR02961P4001X - 12 years: 30 mg/kg 6 - 8
77 Clavulanate 100 mg A tissue, GUT infection,
X hourly. ADULT: 1.2 g by IV or
Injection septicaemia, peritonitis, post-
intermittent infusion 6 - 8
operative infection and
hourly
osteomyelitis
Infections caused by ADULT: 250 - 500 mg 3
J01CA04012C1002X susceptible strains of gram times daily. CHILD: 20 - 40
78 Amoxicillin 500 mg Capsule B
X positive and gram negative mg/kg/day in divided doses 8
organisms hourly
CHILD less than 10 years:
Infections caused by
125 - 250 mg 8 hourly.
Amoxicillin Trihydrate 125 J01CA04012F1001X susceptible strains of gram
79 B CHILD less than 20 kg: 20 -
mg/5 ml Syrup X positive and gram negative
40 mg/kg/day in 3 - 4 divided
organisms
doses
Amphotericin B 0.15% Eye S01A000801D2002X Fungal infection of the
80 A 1 drop hourly or 2 hourly
Drops X cornea
Amphotericin B 0.25% Eye S01A000801D2003X Fungal infection of the
81 A 1 drop hourly or 2 hourly
Drops X cornea
ADULT: 0.25 mg/kg/day by
IV infusion, gradually
Amphotericin B 50 mg J02AA01801P4001X increase if tolerated to 1
82 A Systemic fungal infections
Injection X mg/kg/day. Maximum in
severe cases: 1.5 mg/kg
daily or on alternate days.

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
15 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
For neonates, lower doses
are recommended
ADULT: (1-) 2-6g daily
CHILDREN: (25-) 50-
Ampicillin Sodium &
J01CR01961F2101X Treatment of susceptible 100mg/kg daily
83 Sulbactam Sodium 250 A
X bacterial infections PREMATURE AND
mg/5 ml Suspension
NEWBORNS: 25-50mg/kg
daily
ADULT: 375-750mg twice
Ampicillin Sodium & daily CHILDREN AND
J01CR01961T1001X Treatment of susceptible
84 Sulbactam Sodium 375 mg A/KK INFANTS: 25-50mg/kg/day in
X bacterial infections
Tablet 2 divided doses, if ≥ 30kg
use an adult dose
ADULT: 1.5 - 12 g/day in
divided doses 6 - 8 hourly.
Maximum: 4 g Sulbactam.
CHILD: 150-300 mg/kg/day 6
- 8 hourly. Prophylaxis of
Ampicillin Sodium 1g &
J01CR01961P4002X Treatment of susceptible surgical infections: 1.5 - 3 g
85 Sulbactam Sodium 500mg A
X bacterial infections at induction of anaesthesia.
Injection
May be repeated 6 - 8 hourly.
NEONATES: First week of
life, 75mg/kg/day in divided
doses every 12 hour

ADULT: 1.5 - 12 g/day in


divided doses 6 - 8 hourly.
Maximum: 4 g Sulbactam per
Ampicillin Sodium 500 mg &
J01CR01961P4001X Treatment of susceptible day. CHILD: 150-
86 Sulbactam Sodium 250 mg A
X bacterial infections 300mg/kg/day 6 - 8 hourly.
Injection
Prophylaxis: 1.5 -3 g at
induction of anaesthesia.
May be repeated 6 - 8 hourly
250 - 500 mg IM/IV every 4 -
6 hours. Maximum: 400
Treatment of susceptible mg/kg/day. Meningitis: 2 g 6
Ampicillin Sodium 500 mg J01CA01520P4001X bacterial infections (non beta- hourly. CHILD: 150
87 B
Injection X lactamase-producing mg/kg/daily IV in divided
organisms); meningitis doses. Usual children dose
less than 10 years, half adult
dose
CHILD: 50 - 100 mg/kg/day 4
Treatment of susceptible
times daily. Under 1 year:
Ampicillin Trihydrate 125 J01CA01012F2101X bacterial infections (non beta-
88 B 62.5 - 125 mg 4 times daily, 1
mg/5 ml Suspension X lactamase-producing
- 10 years: 125 - 250 mg 4
organisms)
times daily
Treatment of hormone
responsive metastatic or
L02BG03000T1001X
89 Anastrozole 1 mg Tablet A* locally advanced breast 1 mg daily
X
cancer after failure of
tamoxifen
Treatment of invasive
Loading dose of 200 mg on
candidiasis, including
day 1, then 100 mg once
Anidulafungin 100mg J02AX06000P3001X candidemia in adults when
90 A* daily thereafter for at least 14
Injection X intolerance or resistance to
days after the last positive
Amphotericin B or
culture.
Fluconazole

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
16 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
ADULT: Instill 1 drop, 3 - 4
Antazoline HCl, Hay fever, conjunctivitis,
times daily, into the lower
Tetrahydrozoline HCl and S01GA52110D2001 allergic conjunctivitis, vernal
91 A/KK eyelid. CHILD 2 - 12 years :
Benzalkonium Cloride Eye XX keratoconjunctivitis and
Instill 1 drop daily or twice
Drops eczematosa
daily
Prevention of Rh(D)
sensitisation to Rh(D)- i) Antepartum prophylaxis:
negative woman: The recommended dose is a
i) Pregnancy/delivery of single dose of 300mcg
Rh(D)-positive infant administered by IV or IM
ii) Abortion/threatened injection ii) Postpartum
abortion, ectopic pregnancy prophylaxis: 300mcg should
Anti RhD Gamma Globulin
J06BB01000P3001X or hydatidiform mole be administered as soon as
92 300 mcg/2 ml Injection (150 B
X iii) Transplacental possible after delivery and no
mcg = 750 IU)
haemorrhage resulting from later than 72 hours
antepartum haemorrhage, thereafter, by IV or IM route.
amniocentesis, chorionic If the 72-hour limit is
biopsy or obstetric exceeded, anti-Rh (D)
manipulative procedures e.g. immunoglobulin must be
external version or abdominal administered anyway.
trauma
i) To be used when
conventional anti-rejection
therapy is not successful
ii) Treatment of aplastic
anaemia not responding to
oxymethalone after 3
months, in which there is
persistent pancytopenia with
repeated attacks of 10 - 30 mg/kg body weight
septicaemia and bleeding. daily. Slow IV infusion (over
Antilymphocyte/Antithymocy
L04AA03000P3001X iii) Severe aplastic anaemia at least 4 hours) diluted in
93 te Immunoglobulin (from A*
X with the following 250 - 500 ml Normal Saline.
Horse) Injection
parameters: For Graft versus host disease
a) Granulocyte less than treatment:40 mg/kg/day
0.5x109/L b) Platelet less
than 20x109/L
c) Reticulocyte less than
20x109/L
iv) As a conditioning regime
prior to transplant.
v) Graft-versus-host disease
treatment
20 iu/kg; half by IM and half
Antirabies Immunoglobulin J06BB05000P3001X Treatment of rabies, post-
94 B by infiltration around the
(Human) 300 iu/2ml X exposure
wound
i) Prophylaxis of acute graft
i) 1.0 - 1.5 mg/kg/day for 2 - 9
rejection
days after transplantation of
ii) Treatment of acute graft
a kidney, pancreas or liver,
rejection
for 2 - 5 days after heart
Antithymocyte iii) Prophylaxis of acute and
L04AA04000P3001X transplantation
95 Immunoglobulin (from A* chronic graft versus host
X ii) 1.5 mg/kg/day for 3 - 14
rabbit) Injection disease
days iii) 2.5 - 5.0 mg/kg/day
iv) Treatment of steroid-
for 4 days
resistant, acute graft versus
iv )2.5 - 5.0 mg/kg/day for 5
host disease v)Treatment of
days
aplastic anemia

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
17 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
v )2.5 - 3.5 mg/kg/day for 5
days

Initial dose of 100ml of


reconstituted antivenene
given by slow intravenous
infusion (2ml/min).
Treatment of patients who Subsequent dose can be
exhibit manifestations of given every 12 hours
J06AA03000P3002X
96 Antivenene Cobra Injection B systemic envenoming according to the clinical
X
following a bite by Cobra symptoms. As product may
(Naja kaouthia). differ from batches and
manufacturer, it is strongly
recommended to refer to the
product insert on dosing
recommendation.
Initial dose of 30ml of
reconstituted antivenene
given by slow intravenous
infusion (2ml/min).
Treatment of patients who Subsequent dose can be
exhibit manifestations of given every 6 hours
Antivenene Pit Viper J06AA03000P3001X systemic envenoming according to the clinical
97 B
Injection X following a bite by Malayan symptoms. As product may
Pit Viper (Calloselasma differ from batches and
rhodostoma). manufacturer, it is strongly
recommended to refer to the
product insert on dosing
recommendation.

Treatment of patients who 1000 units by IV infusion over


Antivenene Serum (Sea J06AA03000P3003X exhibit manifestations of 1/2 to 1 hour. In severe
98 B
snake) 1000 units Injection X systemic envenoming cases 3000 -10000 units may
following a bite by sea snake. be required
Recommended initial dose is
Treatment of patients who
20ml by intravenous infusion.
exhibit manifestations of
The injection should be given
systemic envenoming
very slowly as 5 minutes by
following a bite by Indian
Antivenene Serum Snake J06AA03000P3004X direct slow intravenous route
99 B Cobra (Naja naja), Common
Polyvalent Injection X or 1hour by infusion. If
Krait (Bungarus caeruleus),
symptoms continue, further
Russell's Viper (Daboia
doses are administered as
russelli) and Saw-scaled
required until symptoms
Viper (Echis carinatus).
completely disappear.
In combination with other
125 mg 1 hour prior to
antiemetic agents for
chemotherapy on Day 1. To
prevention of delayed nausea
A04AD12000C1002 be given as part of a 3-day
100 Aprepitant 125 mg Capsule A* and vomiting associated with
XX regimen that includes a
initial and repeat course of
corticosteroid and a 5-HT3
highly emetogenic
antagonist
chemotherapy
In combination with other
80 mg once daily in the
antiemetic agents for
A04AD12000C1001 morning on Days 2 and Day
101 Aprepitant 80 mg Capsule A* prevention of delayed nausea
XX 3. To be given as part of a 3-
and vomitting associated with
day regimen that includes a
initial and repeat course of

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
18 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
highly emetogenic corticosteroid & a 5-HT3
chemotherapy antagonist

All patients should receive a


1 ml IV test dose at least 10
minutes prior to loading dose.
Initially 2 million KIU bolus
Aprotinin 10,000 KIU/ml B02AB01000P3001X Only for Open Heart Surgery
102 A* followed by 2 million KIU in
Injection X (extracorporeal circulation)
heart-lung machine followed
by a slow infusion of 500,000
KIU/hr until end of surgery.
CHILD: 20,000 KIU/kg/day
D02AX00000G1001 As a soap or apply to the skin
103 Aqueous Cream C+ Dry skin
XX as an emollient cream
i) Treatment of acute
Schizophrenia: 10 or 15
episodes of schizophrenia
mg/day. Maintenance dose:
and for maintenance of
15 mg/day. Bipolar mania:
N05AX12000T1001X clinical improvement during
104 Aripiprazole 10mg Tablet A* Starting dose: 15 or 30
X continuation therapy.
mg/day. Dose adjustment
ii) Treatment of acute manic
should occur at intervals of
episodes associated with
not less than 24 hour
bipolar I disorder
i) Treatment of acute
episodes of schizophrenia Schizophrenia: 10 or 15
and for maintenance of mg/day. Maintenance dose:
clinical improvement during 15 mg/day. Bipolar mania:
N05AX12000T1002X
105 Aripiprazole 15mg Tablet A* continuation therapy. Starting dose: 15 or 30
X
ii) Treatment of acute manic mg/day. Dose adjustment
episodes associated with should occur at intervals of
bipolar I disorder not less than 24 hour

Induction: 0.15 mg/kg/day IV


until bone marrow remission.
Total induction dose ≤ 60
Relapsed acute doses. Consolidation : 0.15
promyelocytic leukaemia mg/kg/day IV for 25 doses in
Arsenic Trioxide 1 mg/ml L01XX27550P3001X
106 A* (APML). To be prescribed by 5 weeks (5 days per week,
Injection X
consultant haematologist followed by 2 days
only interruption; treatment should
begin 3-6 weeks after
completion of induction
therapy).
ADULT and CHILD over 12
years weighing over 35 kg : 4
tablets as a single dose at
the time of initial diagnosis,
again 4 tablets after 8 hours
and then 4 tablets twice daily
Artemether 20mg + P01BE52981T1001X Acute uncomplicated
107 B (morning and evening) on
Lumefantrine 120mg X falciparum malaria
each of the following two
days (total course comprises
24 tablets). INFANT and
CHILD weighing 5 kg to less
than 35 kg : A 6 dose
regimen with 1 to 3 tablets

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
19 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
per dose, depending on
bodyweight

Weight 5-8kg, Age 6-11


months, Dose: One tablet
25/55mg OD x 3 days Weight
Treatment of acute
: 9-17kg, Age 1-6 years,
uncomplicated Plasmodium
Artesunate 100 mg and Dose : Two tablet 25/55mg
P01BF02000T1002X falciparummalaria, resulting
108 Mefloquine HCI 220 mg A OD x 3 days Weight :18-
X either from P. falciparum
Tablet 29kg, Age 7-12 years, Dose
mono-infection or mixed
:One tablet 100/220mg OD x
infection with P. vivax.
3 days Weight ≥30kg, Age
≥13 years, Dose:Two tablet
100/220mg OD x 3 days
Weight 5-8kg, Age 6-11
months, Dose: One tablet
25/55mg OD x 3 days Weight
Treatment of acute
: 9-17kg, Age 1-6 years,
uncomplicated Plasmodium
Artesunate 25 mg and Dose : Two tablet 25/55mg
P01BF02000T1001X falciparummalaria, resulting
109 Mefloquine HCI 55 mg A OD x 3 days Weight :18-
X either from P. falciparum
Tablet 29kg, Age 7-12 years, Dose
mono-infection or mixed
:One tablet 100/220mg OD x
infection with P. vivax.
3 days Weight ≥30kg, Age
≥13 years, Dose:Two tablet
100/220mg OD x 3 days
2.4mg of artesunate/kg body
weight, by intravenous (IV) or
intramuscular (IM) injection,
at 0, 12 and 24 hours, then
once daily until oral treatment
can be substituted. For adults
Treatment of severe malaria
and children with severe
P01BE03000P3001X caused by Plasmodium
110 Artesunate 60 mg Injection A malaria or who are unable to
X falciparum in adults and
tolerate oral medicines,
children
artesunate 2.4 mg/kg body
weight IV or IM given on
admission (time = 0), then at
12 hrs and 24 hrs, then once
a day for 5-7 days is the
recommended treatment.
ADULT: 100-250 mg once or
twice daily CHILD: 100 mg
Ascorbic Acid 100 mg A11GA01000T1002X
111 C+ Vitamin C deficiency three times daily for one
Tablet X
week followed by 100mg
daily until symptoms abate.
ADULT: 100-250 mg once or
twice daily CHILD: 100 mg
Ascorbic Acid 500 mg A11GA01000T1003X
112 C+ Vitamin C deficiency three times daily for one
Tablet X
week followed by 100mg
daily until symptoms abate.
Ascorbic Acid 500 mg/2 ml A11GA01000P3001 For prevention and treatment Therapeutic: Not less than
113 B
Injection XX of scurvy 250 mg daily in divided doses

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
20 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
For second or third line i) Schizophrenia: - Acute
treatment in adult for: treatment in adults:
i) Schizophrenia Recommended starting and
ii) Bipolar Disorder - target dose of asenapine is
Monotherapy: Acute 5mg given twice daily. -
treatment of manic or mixed Maintenance dose: 5mg
Asenapine 10mg Sublingual N05AH05253T7002X episodes associated with twice daily.
114 A*
Tablet X Bipolar I disorder. - ii) Bipolar Disorder: -
Adjunctive therapy: As Monotherapy: 10mg twice
adjunctive therapy with either daily. Adjunctive therapy:
lithium or valproate for the 5mg twice daily with lithium
acute treatment of manic or or valproate. Dose can be
mixed episodes associated increased to 10mg twice daily
with Bipolar I Disorder. based on clinical response.
For second or third line i) Schizophrenia: - Acute
treatment in adult for: treatment in adults:
i) Schizophrenia Recommended starting and
ii) Bipolar Disorder - target dose of asenapine is
Monotherapy: Acute 5mg given twice daily. -
treatment of manic or mixed Maintenance dose: 5mg
Asenapine 5mg Sublingual N05AH05253T7001X episodes associated with twice daily.
115 A*
Tablet X Bipolar I disorder. - ii) Bipolar Disorder: -
Adjunctive therapy: As Monotherapy: 10mg twice
adjunctive therapy with either daily. Adjunctive therapy:
lithium or valproate for the 5mg twice daily with lithium
acute treatment of manic or or valproate. Dose can be
mixed episodes associated increased to 10mg twice daily
with Bipolar I Disorder. based on clinical response.
Hypertension and arrythmias;
Hypertension, angina
C07AB03000T1002X 50 - 100 mg daily, Angina;
116 Atenolol 100 mg Tablet B pectoris, myocardial
X 100 mg daily, Myocardial
infarction and arrhythmias
infarction; individualised
Hypertension and arrythmias;
Hypertension, angina
C07AB03000T1001X 50 - 100 mg daily, Angina;
117 Atenolol 50 mg Tablet B pectoris, myocardial
X 100 mg daily, Myocardial
infarction and arrhythmias
infarction; individualised
CHILD and ADOLESCENTS
up to 70 kg: Initially 0.5
Attention deficit hyperactivity
mg/kg/day for at least 7 days,
disorder (ADHD) in children 6
then increased according to
years and older who do not
response. Maintenance: 1.2
respond to methylphenidate
Atomoxetine HCl 10 mg N06BA09110C1001 mg/kg/day. ADULTS and
118 A* or who have intolerable
Capsule XX ADOLESCENTS more than
effects or have tics.
70 kg: Initially 40 mg/day for
Diagnosis should be made
at least 7 days then
according to DSM IV criteria
increased according to
or the guidelines in ICD-10
response. Maintenance: 80
mg/day. Max 100 mg/ day
Attention deficit hyperactivity CHILD and ADOLESCENTS
disorder (ADHD) in children 6 up to 70 kg: Initially 0.5
years and older who do not mg/kg/day for at least 7 days,
respond to methylphenidate then increased according to
Atomoxetine HCl 18 mg N06BA09110C1002
119 A* or who have intolerable response. Maintenance: 1.2
Capsule XX
effects or have tics. mg/kg/day. ADULTS and
Diagnosis should be made ADOLESCENTS more than
according to DSM IV criteria 70 kg: Initially 40 mg/day for
or the guidelines in ICD-10 at least 7 days then

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
21 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
increased according to
response. Maintenance: 80
mg/day. Max 100 mg/ day
CHILD and ADOLESCENTS
up to 70 kg: Initially 0.5
Attention deficit hyperactivity
mg/kg/day for at least 7 days,
disorder (ADHD) in children 6
then increased according to
years and older who do not
response. Maintenance: 1.2
respond to methylphenidate
Atomoxetine HCl 25 mg N06BA09110C1003 mg/kg/day. ADULTS and
120 A* or who have intolerable
Capsule XX ADOLESCENTS more than
effects or have tics.
70 kg: Initially 40 mg/day for
Diagnosis should be made
at least 7 days then
according to DSM IV criteria
increased according to
or the guidelines in ICD-10
response. Maintenance: 80
mg/day. Max 100 mg/ day
CHILD and ADOLESCENTS
up to 70 kg: Initially 0.5
Attention deficit hyperactivity
mg/kg/day for at least 7 days,
disorder (ADHD) in children 6
then increased according to
years and older who do not
response. Maintenance: 1.2
respond to methylphenidate
Atomoxetine HCl 40 mg N06BA09110C1004 mg/kg/day. ADULTS and
121 A* or who have intolerable
Capsule XX ADOLESCENTS more than
effects or have tics.
70 kg: Initially 40 mg/day for
Diagnosis should be made
at least 7 days then
according to DSM IV criteria
increased according to
or the guidelines in ICD-10
response. Maintenance: 80
mg/day. Max 100 mg/ day
CHILD and ADOLESCENTS
up to 70 kg: Initially 0.5
Attention deficit hyperactivity
mg/kg/day for at least 7 days,
disorder (ADHD) in children 6
then increased according to
years and older who do not
response. Maintenance: 1.2
respond to methylphenidate
Atomoxetine HCl 60mg N06BA09110C1005 mg/kg/day. ADULTS and
122 A* or who have intolerable
Capsule XX ADOLESCENTS more than
effects or have tics.
70 kg: Initially 40 mg/day for
Diagnosis should be made
at least 7 days then
according to DSM IV criteria
increased according to
or the guidelines in ICD-10
response. Maintenance: 80
mg/day. Max 100 mg/ day
Hypercholesterolaemia and
C10AA05000T1002X coronary heart disease 10 mg once daily. Maximum:
123 Atorvastatin 20 mg Tablet A/KK
X intolerant or not responsive 80 mg daily
to other forms of therapy
Hypercholesterolaemia and
C10AA05000T1001X coronary heart disease 10 mg once daily. Maximum:
124 Atorvastatin 40 mg Tablet A/KK
X intolerant or not responsive 80 mg daily
to other forms of therapy
Hypercholesterolaemia and
C10AA05000T1004X coronary heart disease 10 mg once daily. Maximum:
125 Atorvastatin 80 mg Tablet A/KK
X intolerant or not responsive 80 mg daily
to other forms of therapy

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
22 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
Initial intravenous bolus dose
of 6.75mg (using 7.5mg/ml
To delay imminent preterm solution for injection).
birth in pregnant women with Immediately followed by a
i) Regular uterine continuous high dose
contractions of at least 30 infusion (loading infusion 300
seconds duration at a rate of mcg/min using 7.5mg/ml
≥ 4 per 30 minutes concentrate for solution for
Atosiban 7.5 mg/ml G02CX01122P3001
126 A* ii) A cervical dilation of 1 to 3 infusion) during three hours,
Injection XX
cm (0 - 3 nulliparas) and followed by lower infusion of
effacement of ≥ 50% 100mcg/min up to 45 hours.
iii) Age ≥ 18 years Duration of treatment should
iv) A gestational age from 28 not exceed 48 hours. Total
until 33 completed weeks dose given during a full
v) A normal foetal heart rate. course should not exceed
330mg of the active
substance.
Adult & childn >2 mth 0.3-0.6
mg/kg IV. Endotracheal
intubation dose: 0.5-0.6
Muscle relaxant in general
mg/kg. Supplementary dose:
Atracurium Besylate 10 mg M03AC04197P3001 anaesthesia, Endotracheal
127 A* 0.1-0.2 mg/kg as required.
/ml in 2.5 ml Injection XX intubation, Aid controlled
Continuous infusion rates of
ventilation.
0.3-0.6 mg/kg/hr to maintain
neuromuscular block during
long surgical procedure.
Adult & childn >2 mth 0.3-0.6
mg/kg IV. Endotracheal
intubation dose: 0.5-0.6
Muscle relaxant in general
mg/kg. Supplementary dose:
Atracurium Besylate 10 mg M03AC04197P3002 anaesthesia, Endotracheal
128 A* 0.1-0.2 mg/kg as required.
/ml in 5 ml Injection XX intubation, Aid controlled
Continuous infusion rates of
ventilation.
0.3-0.6 mg/kg/hr to maintain
neuromuscular block during
long surgical procedure.
Atropine Sulphate 0.3%,
Subconjunctival injection to
Cocaine HCl 1.7%, S01F000183P3001X
129 A dilate pupils resistant to 1 - 2 drops
Adrenaline Acid Tartrate X
topical mydriatics
0.03% Mydriatic Injection
PREOPERATIVE
MYDRIASIS: one drop of a
1% solution supplemented
Determination of refraction, with one drop of 2.5 or 10%
strabismus, iritis and phenylephrine prior to
Atropine Sulphate 1% Eye S01FA01183D2001X
130 B iridocyclitis, after extra or surgery.
Drops X
intracapsular extraction of ANTERIOR UVEITIS or
lens POSTOPERATIVE
MYDRIASIS : one drop of a
1% or 2% solution up to 3
times a day

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
23 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
i) Adult: 300-600 mcg IM/SC
30-60 minutes before
anaesthesia. Alternatively,
300-600 mcg IV immediately
before induction of
anaesthesia. Child: >20 kg:
300-600 mcg; 12-16 kg: 300
mcg; 7-9 kg: 200 mcg; >3 kg:
100 mcg. Doses to be given
via IM/SC admin 30-60
i) Reduce vagal minutes before anaesthesia.
inhibition,salivary and ii) Adult: 500 mcg every 3-5
bronchiol secretion in minutes. Total: 3 mg. Max
anaesthesia Dosage: 0.04 mg/kg body
ii) Reversal of excessive weight.
bradycardia iii) Adult 0.6-1.2 mg before or
Atropine Sulphate 1mg/ml A03BA01183P3001X
131 B iii) Reversal of effect of with anticholinesterase
Injection X
competitive muscle relaxants iv) Adult: 0.6-1 mg IV/IM/SC,
iv) Overdosage with other repeated every 2 hr.
compounds having v) Adult: 2 mg IV/IM, every
muscarinic action 10-30 minutes until
v) Organophosphate muscarinic effects disappear
poisoning or atropine toxicity appears.
In severe cases, dose can be
given as often as every 5
minutes. In moderate to
severe poisoning, a state of
atropinisation is maintained
for at least 2 days and
continued for as long as
symptoms are present. Child:
20 mcg/kg given every 5-10
minutes.
Recommended starting dose
for the first treatment cycle,
First line therapy for for all patients regardless of
intermediate-2 and high risk baseline haematology
Azacitidine Powder for MDS, CMMOL with 10-29% laboratory values, is
L01BC07000P4001X
132 suspension for injection A* blasts with no transplant 75mg/m2 of body surface
X
100mg/vial option and elderly AML with area. Injected
20-30% blasts and subcutaneously. Daily for 7
multilineage dysplasia. days, followed by a rest
period of 21 days (28 day
treatment cycle)
i) Adult: 1-5 mg/kg/day.
Adjust dose according to
clinical response and
haematological tolerance.
Dose may also be given via
i) Prophylaxis of rejection in
IV administration.
L04AX01000T1001X organ and tissue transplant
133 Azathioprine 50 mg Tablet A ii) Adult: 1-3 mg/kg/day.
X ii) Auto-immune diseases
Discontinue treatment if there
iii) Rheumatoid arthritis
is no improvement after 12
week.
iii) Adult: Initially, 1
mg/kg/day given in 1-2
divided doses for 6-8 week,

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
24 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
may increase by 0.5 mg/kg
every 4 week until response
or up to 2.5 mg/kg/day.
Maintenance: Reduce dose
gradually to achieve the
lowest effective dose.
Apply twice daily (sensitive
D10AX03000G1001 skin, once daily for 1st week).
134 Azelaic Acid 20% Cream A* Acne vulgaris
XX Treatment should not exceed
6 months
CHILD 36 - 45 kg: 400 mg,
26 - 35 kg: 300mg, 15 - 25 kg
Treatment of complicated 200 mg, less than 15 kg: 10
Azithromycin 200 mg/5 ml J01FA10011F1001X respiratory tract infections not mg/kg. To be taken daily for
135 A*
Granules X responding to standard 3 days or to be taken as a
macrolides single dose on day 1, then
half the daily dose on days 2
-5
i) Treatment of complicated
respiratory tract infection not
responding to standard
macrolides
ii) Adult treatment of
uncomplicated genital i) 500 mg daily for 3 days
J01FA10011T1001X
136 Azithromycin 250 mg Tablet A* infections due to Chlamydia ii) 1 g as a single dose
X
trichomatis or susceptible iii) 1 g weekly
Neisseria gonorrhoea
iii) Prophylaxis against
Mycobacterium avium
complex in patients with
advanced HIV
500 mg IV as a single daily
dose for a minimum of two
Azithromycin 500 mg J01FA10011P4001X Only for treatment of severe days followed by 500 mg oral
137 A*
Injection X atypical pneumonia dose as a single daily dose to
complete a 7 - 10 days
course
ADULT: 400 mg twice daily.
Infections caused by
Severe infection: 800 mg
J01CA06000T1001X ampicillin-sensitive gram
138 Bacampicillin 400 mg Tablet B twice daily. CHILD more than
X positive& gram negative
25 kg: 12.5 - 25 mg/kg 12
microorganisms
hourly
ADULT: 5 mg 3 times daily.
Max: 80 mg daily. CHILD:
M03BX01000T1001 Spasticity of the skeletal
139 Baclofen 10 mg Tablet B 0.75 - 2 mg/kg daily (more
XX muscle
than 10 years, maximum: 2.5
mg/kg daily)
B05CB10907L5001X For irrigation during ocular
140 Balanced Salt Solution A Irrigate as directed
X surgery
For irrigation during
Balanced Salt Solution
intraocular surgery especially
PLUS (fortified with sodium B05CB10905L5001X
141 A in patients with poor cornea Irrigate as directed
bicarbonate, glucose & X
endothelium and poorly
glutathione)
controlled diabetes
For x-ray examination of the i) Up to 150 ml of a 50% -
Barium Sulphate V08BA01183L8001X
142 B alimentary tract: i) 200% suspension orally
Suspension X
Oesophagus ii) Up to 300 ml of a 30% -

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
25 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
ii) Stomach and duodenum 200% suspension orally
iii) Colon iii) Up to 2 litre of a 30% -
200% suspension orally
ADULT & CHILD 2 years and
above & 35 kg or more: 20
mg /dose. 2 years or more
Prophylaxis of acute organ
L04AC02000P3001X but less than 35kg: 10
143 Basiliximab 20 mg Injection A* rejection in de novo renal
X mg/dose. First dose given
transplantation.
within 2 hours before start of
transplantation and second
dose 4th day after transplant
81 mg intravesically once
weekly for 6 weeks, followed
L03AX03000P3001X
144 BCG 81 mg/3 ml A* Superficial bladder cancer by treatments at 3, 6, 12, 18,
X
and 24 months after initial
treatment
0.1 ml by intradermal
BCG Vaccine Freeze-Dried J07AN01000P4001X For the prevention of
145 C+ injection. INFANT under 12
Injection X tuberculosis
months: 0.05 ml
Adults: The usual
maintenance dose is one to
two inhalations (200-400
mcg) twice daily.If
needed,the dose can be
increased up to 1600
Beclomethasone Prophylaxis of asthma
R03BA01133A2101X mcg/day divided in two to
146 Dipropionate 100 mcg/dose B especially if not fully
X four doses : Children 6-12
Inhaler controlled by bronchodilators
years old: One inhalation
(200 mcg) two times daily
and dose may be increased
up to 800 mcg/day in divided
two to four doses if
necessary.
Regular treatment of asthma
where use of a combination
product (inhaled
Dose recommended for
corticosteroid and long-acting
patients 18 years and above.
beta2 agonist) is appropriate
One or two inhalations twice
Beclomethasone in:
daily. The maximum daily
dipropionate 100mcg and i.Patients not adequately
R03AK07986A2101X dose is 4 inhalations daily.
147 formoterol fumarate A/KK controlled with inhaled
X No need to adjust dose in
dihydrate 6mcg pressurized corticosteroids and 'as
elderly patients. There are no
inhalation solution needed' inhaled short-acting
data available for use in
beta2 agonist or
patients with hepatic or renal
ii.Patients already adequately
impairment.
controlled on both inhaled
corticosteroids and long-
acting beta2-agonists
ADULT: 1 - 2 puff twice daily.
Beclomethasone Prophylaxis of asthma May increase to 2 puff 2 - 4
R03BA01133A2102X
148 Dipropionate 200 mcg/dose A/KK especially if not fully times daily CHILD: 1 puff
X
Inhaler controlled by bronchodilators twice daily. May increase to 1
puff 2 - 4 times daily

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
26 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
ADULT and CHILD over 6
years: Apply 100 mcg (2
sprays) into each nostril twice
Prophylaxis and treatment of daily or 50 mcg (1 spray) into
Beclomethasone
R01AD01133A4101 perennial and seasonal each nostril 3 - 4 times/day.
149 Dipropionate 50 mcg/dose A/KK
XX allergic rhinitis and Maximum 400 mcg daily (8
Nasal Spray
vasomotor rhinitis sprays). When symptoms
controlled, reduce dose to 50
mcg (1 spray) into each
nostril twice daily
Wash and dry baby's bottom.
Apply by spreading the
Benzalkonium 0.01% D08AJ01000G1001X Prevention and treatment of cream evenly paying
150 B
Cream X nappy rash particular attention to the fold
of the skin, after every nappy
change
Low level disinfectant
Cleaning purposes: Dilute 1
Benzalkonium Chloride V07AV00100L9908X suitable for general cleaning
151 C in 10. Disinfection, use
Disinfectant Solution X and disinfection of hard
undiluted
surface
i) Treatment of mild to
moderately severe infections i) ADULT: 1.2 mega units IM
Benzathine Penicillin 2.4 J01CE08702P4001X
152 B due to Penicillin G-sensitive ii) For syphillis: 2.4 mega
MIU (1.8 g) Injection X
organisms units weekly for 1 - 3 weeks
ii) Treatment of syphillis
ADULT: Initially 1 mg daily,
i) Parkinson's disease
increase gradually.
N04AA01110T1001X ii) Drug induced
153 Benzhexol 2 mg Tablet B Maintenance: 5 - 15 mg daily
X parkinsonism
in 3 - 4 divided doses. (Max
iii) Dystonias
15mg/day)
Benzoic Acid Compound
D01AE12952G5001 Apply sparingly to affected
154 Half Strength (Paed) C Tinea infections of the skin
XX area once or twice daily
Ointment
Benzoic Acid Compound D01AE12952G5002 Tinea infections of thickened Apply sparingly to affected
155 C
Ointment XX skin of palms and soles area once or twice daily
Apply undiluted to the skin 1
or 2 times daily. Duration of
Benzoin Compound D08AX00000L5001X Infected skin, lesions, cuts,
156 C therapy, may be weeks to
Tincture X abrasions, wounds and burns
months depending on the
infection being treated
Apply 1-2 times daily
D10AE01241G3002 Mild to moderate acne
157 Benzoyl Peroxide 10% Gel B preferably after washing with
XX vulgaris
soap and water
Apply 1-2 times daily
D10AE01241G3001 Mild to moderate acne
158 Benzoyl Peroxide 5% Gel B preferably after washing with
XX vulgaris
soap and water
Used as a 30 seconds gargle
or rinse, undiluted. ADULT
Benzydamine HCl 0.15% A01AD02110M2001 For relief of painful condition 15 ml. CHILD less 12 years
159 B
Solution XX of the oral cavity 5-15 ml. Uninterrupted
treatment should not be more
than 7 days

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
27 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
ADULTS and CHILDREN
OVER 12 YEARS: 2-4 sprays
Temporary relief of painful (1-2mg) directly onto the
conditions of the mouth and sore/inflamed area and
throat including tonsillitis, swallow gently. Repeat every
sore throat, radiation 1 1/2 to 3 hours as
mucositis, aphthous ulcers, necessary. CHILDREN 6-12
pharyngitis, swelling, YEARS: 2 sprays (1mg)
Benzydamine Hydrochloride A01AD02110A4201X
160 A* redness, inflammatory directly onto sore/ inflamed
3.0 mg/ml throat spray X
conditions, post-orosurgical area and swallow gently.
and periodontal procedures. Repeat every 11/2 to 3 hours
(For pediatric and as necessary. CHILDREN
otorhinolaringology use. UNDER 6 YEARS: Not
Restrict to patients who are recommended. Uninterrupted
not able to gargle) treatment should not exceed
seven days, unless under
medical supervision
After bath, apply over the
whole body, neck down and
leave on for 24 hours then
wash off. Reapply for another
Benzyl Benzoate 12.5 % P03AX01252L2001X Scabies and pediculosis, for
161 C 24 hours, the first repeat
Emulsion (Child) X child under 2 years
application should be within 5
days of the initial application,
a third application may be
required in some cases
After bath, apply over the
whole body, neck down and
leave on for 24 hours then
wash off. Reapply for another
Benzyl Benzoate 25 % P03AX01000L2002X
162 C+ Scabies and pediculosis 24 hours, the first repeat
Emulsion (Adult) X
application should be within 5
days of the initial application,
a third application may be
required in some cases
i) Adult: 600mg - 3600mg (1 -
6 mega units) daily, divided
into 4 to 6 doses. Higher
doses (24 mega units) in
divided doses may be given
in serious infections such as
meningitis. Child 1 month to
i) Infections caused by 12 years old: 100mg/kg/day
Benzylpenicillin 1 mega unit J01CE01702P4001X
163 B susceptible organisms in 4 divided doses, not
(600 mg) Injection X
ii) Infective endocarditis exceeding 4g/day; Infants 1 -
4 weeks: 75mg/kg/day in 3
divided doses; Newborn
Infants: 50mg/kg/day in 2
divided doses
ii) 7.2 to 12g (12 - 20 mega
units) maybe given daily in
divided doses
1-2 drops every 15 minutes
Benzylpenicillin 10,000 S01AA14702D2002X
164 B Eye infection or accordingly to needs of the
units/ml Eye Drops X
patient

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
28 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
Benzylpenicillin 2,500 1-2 drops every 15 minutes
S01AA14702D2001X
165 units/ml (1.5 mg/ml) Eye B Eye infection or accordingly to needs of the
X
Drops patient
i) ADULT: 600 - 1200 mg IM
4 times daily, increased if
necessary in more serious
i) Infections caused by
Benzylpenicillin 5 mega J01CE01702P4002X infections. CHILD: 50 - 100
166 B susceptible organisms
units (3 g) Injection X mg/kg body weight daily IV in
ii) Infective endocarditis
2 - 4 divided doses
ii) ADULT: 7.2 g daily by slow
IV infusion in 6 divided doses
Treatment of newborn baby
100 mg/kg (4 ml/kg) body
with birth weight of 700 g or
weight intratracheally up to 4
greater undergoing
Beractant Intratracheal doses in 1st 48 hr. Doses
R07AA02000L8001X mechanical ventilation for
167 Suspension (200 mg A* should not be given more
X respiratory distress
phospholipids in 8 ml vial) frequently than 6 hrly. To be
syndrome, whose heart rate
administered as soon as
and arterial oxygenation are
possible.
continuously monitored
i) Meniere's Syndrome as
defined by the following core
Given in doses of 8 to 16 mg
symptoms: - Vertigo (with
orally 3 times daily (total 24
Betahistine Dihydrochloride N07CA01110T1002X nausea/vomiting). - Hearing
168 A/KK to 48 mg/day) preferably with
16 mg Tablet X loss (Hardness of hearing). -
food. CHILD not
Tinnitus (ringing in the ears)
recommended
ii) Symptomatic treatment of
vestibular vertigo
i) Meniere's Syndrome as
defined by the following core
symptoms: - Vertigo (with
Betahistine Dihydrochloride N07CA01110T1003X nausea/vomiting). - Hearing 24-48mg in divided doses
169 A*
24 mg Tablet X loss (Hardness of hearing). - daily
Tinnitus (ringing in the ears)
ii) Symptomatic treatment of
vestibular vertigo
i) Meniere's Syndrome as
defined by the following core
Given in doses of 8 to 16 mg
symptoms: - Vertigo (with
orally 3 times daily (total 24
Betahistine Dihydrochloride N07CA01110T1001X nausea/vomiting). - Hearing
170 A/KK to 48 mg/day) preferably with
8 mg Tablet X loss (Hardness of hearing). -
food. CHILD not
Tinnitus (ringing in the ears)
recommended
ii) Symptomatic treatment of
vestibular vertigo
Suppression of inflammatory
0.5 - 9 mg daily in divided
and allergic disorders,
Betamethasone 0.5 mg H02AB01000T1001X doses. CHILD: 0.5 - 7.5
171 A congenital adrenal
Tablet X mg/m2/day divided every 6 -
hyperplasia, cerebral
12 hours
oedema
Apply sparingly to affected
Eczemas, prurigo nodularis,
Betamethasone 17-Valerate D07AC01256G1001 area 2 - 3 times daily then
172 B limited psoriasis in
0.01-0.05% Cream XX reduced to once daily when
appropriate in sites
improvement occurs
Apply sparingly to affected
Eczema, prurigo nodularis,
Betamethasone 17-Valerate D07AC01256G5001 area 2 - 3 times daily then
173 B limited psoriasis in
0.01-0.05% Ointment XX reduced to once daily when
appropriate in sites
improvement occurs

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
29 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
Apply sparingly to affected
Eczemas, prurigo nodularis,
Betamethasone 17-Valerate D07AC01256G1002 area 2 - 3 times daily then
174 A psoriasis (excluding
0.1% Cream XX reduced to once daily when
widespread plaque psoriasis)
improvement occurs
Apply sparingly to affected
Eczema, prurigo nodularis,
Betamethasone 17-Valerate D07AC01256G5002 area 2-3 times daily then
175 A psoriasis (excluding
0.1% Ointment XX reduced to once daily when
widespread plaque psoriasis)
improvement occurs
Apply 2 - 3 drops every 2 - 3
Betamethasone Disodium S03BA03162D1001X Non-infected inflammatory
176 B hours, reduce frequency
Phoshate 0.1% Ear Drops X conditions
when relief obtained
Apply 2 - 3 drops every 2 - 3
Betamethasone Disodium S03BA03162D1002X Non-infected inflammatory
177 B hours, reduce frequency
Phoshate 0.5% Ear Drops X conditions
when relief obtained
1 - 2 drops every 1 - 2 hours
Betamethasone Disodium S01BA06162D2001X Non-infected inflammatory
178 A until controlled then reduce
Phosphate 0.1% Eye Drops X conditions of the eyes
frequency
Betamethasone Disodium
S01BA06162G5101 Non-infected inflammatory 2 - 4 times daily or at night
179 Phosphate 0.1% Eye A
XX conditions of the eyes when used with eye drops
Ointment
Betamethasone Disodium Apply 2 - 3 drops 3 - 4 times
S03CA06991D1001
180 Phosphate and Neomycin B Allergic dermatosis in the ear daily, reduce frequency when
XX
Sulphate 0.5% Ear Drops relief obtained
Betamethasone Disodium
S01CA05991D2001 Infected inflammatory
181 Phosphate and Neomycin A 2 - 3 drops every 2 - 3 hours
XX conditions of the eyes
Sulphate Eye Drops
Usual intravenous doses are
Pre-operative and in serious
up to 9 mg/day of the sodium
trauma or illness, shock, as
phosphate salt only. CHILD:
Betamethasone Sodium adjunctive therapy in
H02AB01162P3001X IM: 0.5 - 7.7 mg base/m2/day
182 Phosphate 4 mg/ml B rheumatoid disorders, ocular,
X divided every 6 - 12 hours.
Injection dermatologic and respiratory
ADOLESCENT and ADULT,
allergic and inflammatory
IM: 0.6 - 9 mg divided every
states
12 - 24 hours
Chronic open-angle
Betaxolol 0.25% Eye S01ED02110D2001 One to two drops in the
183 A glaucoma, ocular
Suspension XX affected eye(s) twice daily
hypertension
50 mg once daily (morning or
evening), with or without
food. Take on the same time
Advanced prostate cancer in each day. Adult: When used
L02BB03000T1001X combination with LHRH with gonadorelin analogue:
184 Bicalutamide 50 mg Tablet A*
X analogue therapy or surgical Usual dose: 50 mg once
castration. daily. May be started with or
at least 3 days before starting
gonadorelin analogue
therapy.
Lowering of intraocular
pressure in patients with
open-angle glaucoma and
Bimatoprost 0.03% S01EE03000D2001X ocular hypertension who are 1 drop in affected eye(s)
185 A*
Ophthalmic Solution X intolerant of other intraocular once daily at evening
pressure lowering
medications or insufficiently
responsive to another

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
30 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
intraocular pressure lowering
medication
i) ADULT and CHILD over 10
years: 10 mg, CHILD less
i) Constipation than 10 years 5 mg insert
Bisacodyl 10 mg A06AB02000S2002X ii) Bowel preparation for rectally
186 C
Suppository X radiological procedures and ii) ADULT 10-20 mg, CHILD
surgery over 4 years 5 mg the
following morning before
procedures insert rectally
i) ADULT and CHILD over 10
years: 10 mg, CHILD less
i) Constipation than 10 years 5 mg insert
A06AB02000S2001X ii) Bowel preparation for rectally
187 Bisacodyl 5 mg Suppository C
X radiological procedures and ii) ADULT 10-20 mg, CHILD
surgery over 4 years 5 mg the
following morning before
procedures insert rectally
i) ADULT and CHILD over 10
years 5-10 mg, CHILD 4-10
years 5 mg. To be taken at
i) Constipation
night for effect on the
A06AB02000T1001X ii) Bowel preparation for
188 Bisacodyl 5 mg Tablet C following morning
X radiological procedures and
ii) ADULT 10-20 mg the night
surgery
before procedures, CHILD
over 4 years 5 mg the night
before procedures
As a mild antiseptic for
wounds and abscesses.
Bismuth Subnitrate,
R01AX30984G6001 Sterile gauze impregnated As directed for local
189 Iodoform and Liquid B
XX with paste for packing application
Paraffin Paste
cavities after otorhinological
surgery
Treatment of stable moderate
Bisoprolol Fumarate 2.5 mg C07AB07000T1001X to severe congestive cardiac 1.25 mg once daily to 5 - 10
190 B
Tablet X failure in addition to ACEI's mg daily
and diuretics
Treatment of stable moderate
Bisoprolol Fumarate 5 mg C07AB07000T1002X to severe congestive cardiac 1.25 mg once daily to 5 - 10
191 B
Tablet X failure in addition to ACEI's mg daily
and diuretics
15 - 30 mg weekly in divided
doses or 10 - 20 mg/m2 once
Squamous cell carcinoma,
or twice weekly or 10 mg/m2
germ cell tumours,
slow bolus in 15 minutes D1
Bleomycin HCl 15 mg L01DC01110P4001X lymphomas. Routes: SC, IM,
192 A and D15. Total
Injection X IV (either as bolus or as
dosage:should not exceed
infusion over 24 hours), intra-
300 mg. CHILD: 10 - 15
arterial, intra-pleural
mg/m2 over 6 hours every 3 -
4 weeks
Boric Acid with Spirit 2% S02AA03000D1001X 3 drops instilled into affected
193 C Perforated eardrum
w/v Ear Drops X ear 3 - 4 times daily
i) Treatment of multiple 1.3 mg/ m2/dose given as IV
L01XX32000P3001X myeloma in patient who have bolus injection twice weekly
194 Bortezomib 3.5 mg Injection A*
X received at least one prior for two weeks (days 1, 4, 8,
therapy. and 11) followed by a 10- day

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
31 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
ii) For use in combination rest period (days 12-21). At
with conventional therapy for least 3 days should elapse
the treatment of previously between consecutive doses
untreated multiple myeloma of bortezomib
patients who are not eligible
for haematopoietic stem cell
transplantation.

For the treatment of


pulmonary arterial
hypertension (PAH) in
patients with WHO Class III Initially 62.5 mg bd for 4
C02KX01000T1001X or IV symptoms, to improve weeks, then increase to the
195 Bosentan 125 mg tablet A*
X exercise ability and decrease maintenance dose of 125 mg
the rate of clinical worsening bd
(To be used by those who
are trained and specialized in
treating and managing PAH)
Lowering of intraocular
Brimonidine Tartrate 0.15% S01EA05123D2001X pressure in patients with 1 drop in the affected eye(s)
196 A*
Ophthalmic X open-angle glaucoma or 3 times daily
ocular hypertension
Adult: Initially, 6-18 mg daily
in divided doses. Doses up to
N05BA08000T1002X
197 Bromazepam 3 mg Tablet A Anxiety disorders 60 mg daily have been used.
X
Elderly: Max initial dose: 3
mg daily
Secretolytic therapy in acute
and chronic 4 to 8 mg SC, IM or IV 2 - 3
Bromhexine HCl 4 mg/2 ml R05CB02110P3001 bronchopulmonary diseases times daily (maximum 24mg/
198 A
Injection XX associated with abnormal day). Elderly: Max initial
mucous secretion and dose: 3 mg daily.
impaired mucous transport
1) Adults: 10 ml three times a
Secretolytic therapy in acute
day.Can increase up to 15 ml
and chronic
four times a day.
Bromhexine HCl 4 mg/5 ml R05CB02110L1001X bronchopulmonary diseases
199 B 2)Children 5 to 12 years : 5
Elixir X associated with abnormal
ml four times a day
mucous secretion and
3)Children 2 to 5 years: 5 ml
impaired mucous transport
two times a day
Secretolytic therapy in acute
ADULT and CHILD more
and chronic
than 12 years : 8 mg 3 times
Bromhexine HCl 8 mg R05CB02110T1001X bronchopulmonary diseases
200 B daily, 6 - 12 years : 4 mg 3
Tablet X associated with abnormal
times daily, 2 - 6 years : 4 mg
mucous secretion and
2 times daily
impaired mucous transport
i) Initially 1 - 1.25 mg at
bedtime increased gradually,
usual dose: 7.5 mg daily in
divided doses. Max 30 mg
i) Hypogonadism or
Bromocriptine Mesilate 10 G02CB01196T1003 daily
201 A/KK Galactorrhoea
mg Tablet XX ii) 1.25 - 2.5 mg at bedtime
ii) Acromegaly
for 3 days and may be
increased by 1.25 - 2.5 mg
every 3 - 7 days up to 30 mg
a day in divided doses

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
32 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
i) Initially 1 - 1.25 mg at
bedtime increased gradually,
usual dose: 7.5 mg daily in
divided doses. Max 30 mg
i) Hypogonadism or daily
Bromocriptine Mesilate 2.5 G02CB01196T1001
202 A/KK Galactorrhoea ii) 1.25 - 2.5 mg at bedtime
mg Tablet XX
ii) Acromegaly for 3 days and may be
increased by 1.25 - 2.5 mg
every 3 - 7 days up to 30 mg
a day in divided doses

i) Initially 1 - 1.25 mg at
bedtime increased gradually,
usual dose: 7.5 mg daily in
divided doses. Max 30 mg
i) Hypogonadism or
Bromocriptine Mesilate 5 G02CB01196T1002 daily
203 A/KK Galactorrhoea
mg Tablet XX ii) 1.25 - 2.5 mg at bedtime
ii) Acromegaly
for 3 days and may be
increased by 1.25 - 2.5 mg
every 3 - 7 days up to 30 mg
a day in divided doses
ADULT: Initially 1 - 2 mg
Maintenance treatment of
twice daily. CHILD 3 months
Budesonide 1 mg/2 ml R03BA02000A3002X asthma as prophylactic
204 B - 12 years of age : 500 mcg -
Nebuliser Solution X therapy especially if not fully
1 mg. Maintenance dose :
controlled by bronchodilators
half of the above doses
ADULT: 200 - 1600 mcg daily
in 2 - 4 divided doses.
Maintenance treatment of Maintenance with twice daily
Budesonide 100 mcg/dose R03BA02000A2101X asthma as prophylactic dosing. CHILD more than 7
205 B
Inhaler X therapy especially if not fully years 200 - 800 mcg, 2 - 7
controlled by bronchodilators years 200 - 400 mcg. To be
taken orally in 2 - 4 divided
doses
Asthma Maintenance therapy
i) Regular treatment of
Adult ≥18 yr 160 mcg to 320
asthma where use of a
mcg bd. Some patients may
combination (inhaled
require up to a max of 640
corticosteroid and long-acting
mcg bd. Adolescent 12-17 yr
beta2-agonist) is appropriate:
160 mcg to 320 mcg bd.
- Patients not adequately
Childn 6-11 yr 160 mcg bd,
controlled with inhaled
<6 yr Not recommended.
corticosteroids and 'as
Maintenance & relief Adult
needed' inhaled short-acting
≥18 yr 320 mcg/day either as
beta2-agonists. or
Budesonide 160 mcg and 160 mcg bd or 320 mcg
R03AKO7989A2101 - Patients already adequately
206 Formoterol 4.5 mcg A/KK either morning or evening.
XX controlled on both inhaled
Inhalation For some patients a
corticosteroids and long-
maintenance dose of 320
acting beta2-agonists.
mcg bd may be appropriate.
ii) Symptomatic treatment of
Patients should take 160 mcg
patients with severe COPD
additional inhalation as
(FEV1 <50% predicted
needed in response to
normal) and a history of
symptoms. If symptoms
repeated exacerbations, who
persist after a few minutes,
have significant symptoms
an additional inhalation
despite regular therapy with
should be taken. Not more
long-acting bronchodilators.
than 960 mcg should be

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
33 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
taken on any single occasion.
A total daily dose of more
than 1280 mcg is not
normally needed, however a
total daily dose of up to 1920
mcg could be used for a
limited period. Patients using
more than 1280 mcg daily
should seek medical advice,
should be reassessed & their
maintenance therapy
reconsidered. Childn &
adolescent <18 yr Not
recommended. COPD Adult
≥18 yr 320 mcg bd.

ADULT: 200 - 1600 mcg daily


in 2 - 4 divided doses.
Maintenance treatment of Maintenance with twice daily
Budesonide 200 mcg/dose R03BA02000A2102X asthma as prophylactic dosing. CHILD more than 7
207 B
Inhalation X therapy especially if not fully years 200 - 800 mcg, 2 - 7
controlled by bronchodilators years 200 - 400 mcg. To be
taken orally in 2 - 4 divided
doses
Asthma; Maintenance
therapy: Adult ≥18 yr 160
mcg to 320 mcg bd. Some
patients may require up to a
max of 640 mcg bd.
i) Regular treatment of Adolescent 12-17 yr 160 mcg
asthma where use of a to 320 mcg bd. Children 6-11
combination (inhaled yr 160 mcg bd, <6 yr Not
corticosteroid and long-acting recommended. Maintenance
beta2-agonist) is & relief: Adult ≥18 yr 320
appropriate:- mcg/day either as 160 mcg
- Patients not adequately bd or 320 mcg either morning
controlled with inhaled or evening. For some
corticosteroids and 'as patients a maintenance dose
needed' inhaled short-acting of 320 mcg bd may be
beta2-agonists. or appropriate. Patients should
Budesonide 320 mcg and R03AK07989A2102X
208 A/KK - Patients already adequately take 160 mcg additional
Formoterol 9 mcg Inhalation X
controlled on both inhaled inhalation as needed in
corticosteroids and long- response to symptoms. If
acting beta2-agonists. symptoms persist after a few
ii) Symptomatic treatment of minutes, an additional
patients with severe COPD inhalation should be taken.
(FEV1 <50% predicted Not more than 960 mcg
normal) and a history of should be taken on any
repeated exacerbations, who single occasion. A total daily
have significant symptoms dose of more than 1280 mcg
despite regular therapy with is not normally needed,
long-acting bronchodilators. however a total daily dose of
up to 1920 mcg could be
used for a limited period.
Patients using more than
1280 mcg daily should seek
medical advice, should be

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
34 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
reassessed & their
maintenance therapy
reconsidered. Children &
adolescent less than 18 yr:
Not recommended. COPD;
Adult more than or equal to
18 yr: 320 mcg bd.

ADULT: Initially 1 - 2 mg
Maintenance treatment of
twice daily. CHILD 3 months
Budesonide 500 mcg/2 ml R03BA02000A3001X asthma as prophylactic
209 B - 12 years of age : 500 mcg -
Nebuliser Solution X therapy especially if not fully
1 mg. Maintenance dose :
controlled by bronchodilators
half of the above doses
ADULT and CHILD 6 years
and older. Rhinitis: 2 spray
Budesonide 64mcg Nasal R01AD05000A4103 Seasonal allergic, perennial into each nostril once daily in
210 A
Spray XX rhinitis and nasal polyposis the morning or 1 spray into
each nostril twice daily. Nasal
polyps : 2 spray twice daily
IV injection: 1 - 2 mg
Bumetanide 0.5 mg/ml C03CA02000P3001 Oedema used in furosemide repeated after 20 mins. IV
211 A*
Injection XX allergic patient infusion: 2 - 5 mg over 30 -
60 mins
C03CA02000T1001X Oedema used in furosemide 1 mg in the early evening. Up
212 Bumetanide 1 mg Tablet A*
X allergic patient to 5 mg daily in severe cases
Infuse at 6 - 15 ml/hour. Not
Bupivacaine 0.125% N01BB01110P3004X Epidural analgesia for
213 A to exceed 2 mg/kg in a single
Epidural Injection X postoperative pain relief.
dose.
ADULT: 2 - 4 ml. Not to
Bupivacaine 0.5 % Heavy N01BB01110P3003X
214 A Used for spinal anaesthesia exceed 2 mg/kg in a single
Injection X
dose
Regional nerve block or
epidural block: 15 - 30 ml.
For peripheral sympathetic Nerve block of finger or toe: 2
N01BB01110P3002X nerve and epidural (excluding - 6 ml. Maximum: 2 mg/kg
215 Bupivacaine 0.5 % Injection B
X caudal) anaesthesia and body weight in any 4 hours
obstetrics anaesthesia period, equivalent to 25 - 30
ml in adults of average
weight
10 - 40 ml (0.25 %) or
Bupivacaine 0.5 % with maximum : 2 mg/kg body
N01BB51975P3001X Regional nerve block or
216 Adrenaline 1:200,000 B weight in any 4 hours period,
X epidural block.
Injection equivalent to 25 - 30 ml of
0.5% solution

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
35 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
Once weekly transdermal
patch/for hospital use only.
Patient aged 18 years and
over. Initial dose: 5 mcg/hr
Treatment of non-malignant For elderly: Renal
pain of moderate intensity impairment. No special dose
when an opioid is necessary adjustments necessary in
for obtaining adequate patients with renal
Buprenorphine 10mcg/hr N02AE01110M7001 analgesia. Not suitable for impairment Hepatic
217 A*
transdermal patch XX the treatment of acute pain. impairment Patients with
Restrictions: For elderly hepatic insufficiency should
patients or patients with be carefully monitored during
comorbidities/difficult to the treatment with
swallow buprenorphine patch.
Alternate therapy should be
considered. Patch should be
used with cautions in severe
hepatic impairment patient
Once weekly transdermal
patch/for hospital use only.
Patient aged 18 years and
over. Initial dose: 5 mcg/hr
For elderly: Renal
Treatment of non-malignant
impairment. No special dose
pain of moderate intensity
adjustments necessary in
when an opioid is necessary
patients with renal
for obtaining adequate
impairment Hepatic
Buprenorphine 5mcg/hr N02AE01110M7003 analgesia. Not suitable for
218 A* impairment Patients with
transdermal patch XX the treatment of acute pain.
hepatic insufficiency should
Restrictions: For elderly
be carefully monitored during
patients or patients with
the treatment with
comorbidities/difficult to
buprenorphine patch.
swallow
Alternate therapy should be
considered. Patch should be
used with cautions in severe
hepatic impairment patient

i) ADULT: Initial: 2 - 4 mg
daily. Maintenance: 0.5 - 2
mg daily. Stop when white
blood cell less than 20 x
i) Chronic myeloid leukaemia 109/L. CHILD: 60 mcg/kg
(CML) and other body weight daily
L01AB01000T1001X myeloproliferative diseases ii) CHILD: Induction 60
219 Busulfan 2 mg Tablet A
X ii) Haemopoietic stem cell mcg/kg body weight daily
transplant (HSCT)- refer to (maximum 4 mg) if
specific protocols leucocytes more than
20,000/mm3 and platelets
more than 100,000/mm3.
Maintenance 10 - 30mcg/kg
(maximum 2 mg daily)

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
36 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
For use in combination with
cyclophosphamide as a
0.8 mg/kg of ideal body
conditioning regimen prior to
weight or actual body weight,
allogeneic hematopoietic
whichever is lower via central
stem cell transplantation
venous catheter as a 2-hour
(HSCT) for chronic
infusion on the basis of every
L01AB01000P3001X myelogenous leukemia in
220 Busulfan 6 mg/ml Injection A* 6 hours for 4 days, for a total
X selected cases with high risk
of 16 doses. For obese or
of liver toxicity and
severely obese patients, IV
intolerance to oral busulfan.
Busulfan should be
To be prescribed by
administered based on
paediatric oncologist and
adjusted ideal body weight
consultant haematologist
trained in transplant only.
i) 0.5mg per week given in 1
i) Treatment of
or 2 (one-helf of one 0.5mg
hyperprolactinaemic
tablet) doses per week
disorders
G02CB03000T1001 ii) HIV mothers only: Prevent
221 Cabergoline 0.5 mg Tablet A* ii) Prevention of puerperal
XX lactation 2 tab first day after
lactation and suppression of
delivery. Interruption of
lactation in HIV infected
laction: 0.25mg 12 hourly for
mothers only
2 days
Soothes and relieves nappy
rashes, prickly heat, minor
D04AX00000G1001 Apply to the affected area as
222 Calamine Cream C+ skin irritations, insect bites
XX required, 1-3 times daily
and sunburn, Pruritic skin
conditions.
Soothes and relieves nappy
rashes, prickly heat, minor Apply to the skin as required
D04AX00000L8001X
223 Calamine Lotion C+ skin irritations, insect bites and allow to dry, 1-3 times
X
and sunburn, Pruritic skin daily
conditions.
Soothes and relieves nappy
rashes, prickly heat, minor Apply to the skin as required
Calamine with 0.25 - 0.5% D04AX00952L6001X
224 C skin irritations, insect bites and allow to dry, 1 - 3 times
Menthol Lotion X
and sunburn, Pruritic skin daily
conditions.
Calamine with 0.5% Phenol D04AX00952G1001 Apply to the affected area as
225 C For use as a mild astringent
Cream XX required
Apply to the skin as required
Calamine with 2 - 6% D04AX00952L6002X
226 C Acne vulgaris and allow to dry, 1 - 3 times
Precipitated Sulphur Lotion X
daily
ADULT Apply to the affected
skin lesions twice daily.
Maintenance therapy may be
achieved with less frequent
application. The weekly dose
Calcipotriol 50 mcg/g D05AX02000G1001 Only for the treatment of
227 A* should not exceed 100 g.
Cream XX Psoriasis Vulgaris
CHILD over 6 years, apply
twice daily. 6-12 years
maximum 50gm weekly, over
12 years maximum 75gm
weekly

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
37 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
ADULT Apply to the affected
skin lesions twice daily.
Maintenance therapy may be
achieved with less frequent
application. The weekly dose
Calcipotriol 50 mcg/g D05AX02000G5001 Only for the treatment of
228 A* should not exceed 100 g.
Ointment XX Psoriasis Vulgaris
CHILD over 6 years, apply
twice daily. 6-12 years
maximum 50gm weekly, over
12 years maximum 75gm
weekly
Calcipotriol 50 mcg/ml D05AX02000L9901X Only for the treatment of Apply to scalp twice daily.
229 A*
Scalp Solution X Psoriasis Vulgaris Maximum 60 mL weekly.
Apply once daily up to 4
Calcipotriol Hydrate 50
weeks with maximum weekly
mcg/g & Betamethasone D05AX52952G5001
230 A* Resistant plaque psoriasis dose of 100g and maximum
Dipropionate 0.5 mg/g XX
treatment area 30% of body
Ointment
surface
Should be applied to affected
areas once daily. The
recommended treatment
period is 4 weeks for scalp
areas and 8 weeks for non-
Calcipotriol monohydrate 50 Topical treatment of scalp
D05AX52952G3001 scalp areas. The body
231 mcg/g and Betamethasone A* and non-scalp plaque
XX surface area treated with
dipropionate 0.5 mg/g Gel psoriasis vulgaris in adults
calcipotriol containing
products should not exceed
30% and maximum dose
should not exceed 15g or
100g/ week
5-10 IU per kg body weight in
500mL physiological saline
daily by i.v. infusion over at
Calcitonin (synthetic H05BA01000P3002X least 6 hours or by slow i.v.
232 A* Acute hypercalcaemia
Salmon) 100 IU Injection X injection in 2-4 divided doses
spread over the day. Renal
impairment: Dosage
adjustment needed.
Calcitonin (Synthetic
H05BA01000A4101X
233 Salmon) 200 IU Nasal A* Osteoporosis 200 units daily
X
Spray
5-10 IU per kg body weight in
500mL physiological saline
daily by i.v. infusion over at
Calcitonin (Synthetic H05BA01000P3001X least 6 hours or by slow i.v.
234 A* Acute hypercalcaemia
Salmon) 50 IU Injection X injection in 2-4 divided doses
spread over the day. Renal
impairment: Dosage
adjustment needed.

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
38 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
i) 0.25 mcg 2 times daily
ii) Initial dose 0.25 mcg. In
i)Established
patients with normal or only
postmenopausal
slightly reduced serum
osteoporosis
calcium levels, doses of 0.25
ii) Renal osteodystrophy in
mcg every other day is
A11CC04000C1001 patients on haemodialysis
235 Calcitriol 0.25 mcg Capsule A/KK sufficient
XX iii)Hypoparathyroidism and
iii) 0.25 mcg/day given in the
rickets
morning
iv)Secondary
iv) ADULT and CHILD 3
hyperparathyroidism in renal
years and older : Initially 0.25
failure
mcg/ml. CHILD less than 3
years : 10 to 15 ng/kg/day
Management of
Initially dose, depending on
hypocalcaemia and/or
severity, 1 mcg (0.02 mg/kg)
A11CC04000P3001 secondary
236 Calcitriol 1 mcg/ml Injection A* to 2 mcg 3 times weekly,
XX hyperparathyroidism in
approximately every other
patients undergoing chronic
day
renal dialysis
Management of
Initially dose, depending on
hypocalcaemia and/or
severity, 1 mg (0.02 mg/kg)
A11CC04000P3002 secondary
237 Calcitriol 2 mcg/ml Injection A* to 2 mg 3 times weekly,
XX hyperparathyroidism in
approximately every other
patients undergoing chronic
day
renal dialysis
ADULT: Typical oral doses of
calcium carbonate range
from about 3gm to 7gm daily
in divided dose. US National
Foundation suggest the
i) Elemental calcium
calcium-based phosphate
Calcium Carbonate 500 mg A12AA04121C1001X supplementation ii)
238 B binder should not exceed
Capsule X Phosphate binder in chronic
1.5gm daily in those with
renal failure patients
kidney failure. CHILD (12-18
years old): 1.25gm 3 or 4
times daily with or before
meals and adjusted as
necessary.
To be used only for
elemental calcium
Calcium Carbonate 500 mg A12AA04121T1001X supplementation and Initial 2.5 g daily and
239 B
Tablet X phosphate binding activity in increased up to 17 g daily
patients with chronic renal
failure
The maximum infusion rate
Calcium Chloride Dihydrate, depends on the needs of the
Sodium Chloride, patient in fluid replacement
Replacement of extracellular
Magnesium Chloride and electrolytes, patient’s
fluid losses in the case of
Hexahydrate, Sodium B05BB01905P6002X weight, clinical condition, and
240 A isotonic dehydration, where
Acetate X biological status. Adults,
acidosis is present or
Trihydrate,Potassium elderly, adolescents:500ml-
imminent.
Chloride, and Malic Acid 3L/24hr. Babies, children:
Solution 20ml to 100ml/kg/24 hr.

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
39 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
IM (Lead encephalopathy):
1000 mg/m (2)/day IM in
divided equal doses 8 to 12
hours apart, for 5 days.
Therapy is interrupted for 2 to
4 days, and followed by an
additional 5-day course of
Calcium Disodium Edetate V03AB03999P3001X therapy, if indicated. Do not
241 A Lead Poisoning
200 mg Injection X exceed the recommended
daily dosage. IV: 1000 mg/m
(2)/day administered IV over
8 to 12 hours for 5 days.
Therapy is interrupted for 2 to
4 days, and followed by an
additional 5-day course of
therapy, if indicated.
i) 1-2 g (2.25-4.5 mmol).
CHILD 50 mg/kg
ii) ADULT 1g (2.2 mmol) by
i)Acute hypocalcaemia
Calcium Gluconate 10% A12AA03000P3001X slow IV injection followed by
242 B ii)Hypocalcaemic tetany
Injection X continuous infusion of 4 g
iii)Cardiac resuscitation
(8.8 mmol) daily
iii) IV or intracardiac injection,
10 ml
For prophylaxis of calcium
Calcium Lactate 300 mg A12AA05125T1001X ADULT 1-5 g daily in divided
243 C deficiency and treatment of
Tablet X doses
chronic hypocalcaemia
15 - 30g daily in 2-3 divided
Calcium Polystyrene V03AE01999F2101X Hyperkalemia resulting from doses. Each dose should be
244 A
Sulphonate Powder X acute or chronic renal failure suspended in 30 - 50ml of
water and administered orally
i) Metastatic breast cancer in
i) & ii) 1250 mg/m2 twice
elderly and poor performance
daily (morning and evening)
status patients and refractory
for 2 weeks, every 21 days.
to taxanes.
iii) Recommended for a total
ii) Metastatic colon cancer,
of 24 weeks (8 cycles of 2
first line in elderly and poor
weeks of drug administration
performance status patients.
L01BC06000T1002X and 1 week rest period.
245 Capecitabine 150 mg Tablet A* iii) Colon cancer, adjuvant
X iv) In combination with a
therapy for stage III (Duke's
platinum on day 1, give
Stage C) following surgery.
capecitabine 1250 mg/m2
iv) First line treatment of
twice daily for 14 days.
patients with advanced
Repeated every 3 weeks for
gastric cancer in combination
8 cycles or optimum number
with a platinum-based
of cycles
regimen
i) Metastatic breast cancer in i) & ii) 1250 mg/m2 twice
elderly and poor performance daily (morning and evening)
status patients and refractory for 2 weeks, every 21 days
to taxanes iii) Recommended for a total
ii) Metastatic colon cancer, of 24 weeks (8 cycles of 2
L01BC06000T1001X
246 Capecitabine 500 mg Tablet A* first line in elderly and poor weeks of drug administration
X
performance status patients and 1 week rest period
iii) Colon cancer, adjuvant iv) In combination with a
therapy for stage III (Duke's platinum on day 1, give
Stage C) following surgery iv) capecitabine 1250 mg/m2
First line treatment of twice daily for 14 days.

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
40 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
patients with advanced Repeated every 3 weeks for
gastric cancer in combination 8 cycles or optimum number
with a platinum-based of cycles
regimen
i) Initially 12.5 mg twice daily.
Maintenance: 25-50 mg 2 - 3
times daily, may be
increased to maximum 450
mg/day in divided doses
ii) Initially 6.25 - 12.5 mg 3
times daily, increase after
several days to 25 - 50 mg 3
i) Hypertension
times daily
C09AA01000T1002X ii) Congestive heart failure
247 Captopril 25 mg Tablet B iii) Start 3 days after MI
X iii) Post-myocardial infarction
Initially 6.25 mg daily,
iv) Diabetic nephropathy
gradually increased to 37.5
mg daily in divided doses.
May increase after several
week to 150 mg/day in
divided doses if needed and
tolerated
iv)75 - 100 mg daily in
divided dose.
Instill no more than 0.5 ml
Carbachol 0.01% S01EB02100D2001X For intraocular use for miosis
248 A gently into the anterior
Intraocular Solution X during surgery
chamber
ADULT: Initially, 100-200 mg
once or twice daily gradually
increased by increments of
100-200 mg every 2 week.
Maintenance: 0.8-1.2 g daily
in divided doses. CHILD: 10-
Carbamazepine 100 mg/5 N03AF01000L9001X 15 years: 0.6-1 g daily; 5-10
249 A Epilepsy
ml (2% w/v) Syrup X years: 400-600 mg daily; 1-5
years: 200-400 mg daily; less
than or equal to 1 year: 100-
200 mg daily. Alternatively,
10-20 mg/kg body weight
daily in divided doses. Max:
Adult: 1.6 g daily
ADULT: Initial, 200 mg twice
daily for the first week, may
increase dosage by 200
mg/day at weekly intervals
until optimal response is
Carbamazepine 200 mg CR N03AF01000T5001X obtained. Maximum 1.6
250 A Epilepsy
Tablet X g/day. CHILD: usual
maximum dosage 1000
mg/day in children 12-15
years of age, 1200 mg/day in
patients above 15 years of
age

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
41 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
i) ADULT: 100 - 200 mg 1 - 3
times daily increased
gradually to usual dose of 0.8
- 1.2 g daily in divided doses.
CHILD: Up to 1 year: 100 -
200 mg daily; 1 - 5 yrs: 200 -
400 mg daily; 5 - 10 years:
400 - 600 mg daily; 10 - 15
years: 0.6 - 1 g daily
ii) The initial dosage of 200 to
Carbamazepine 200 mg N03AF01000T1001X i) Epilepsy
251 B 400mg should be slowly
Tablet X ii) Trigeminal neuralgia
raised daily until freedom
from pain is achieved
(normally at 200mg 3 to 4
times daily). The dosage
should then be gradually
reduced to the lowest
possible maintenance level.
In elderly patients, an initial
dose of 100mg twice daily is
recommended.
ADULT: Initial, 200 mg twice
daily for the first week, may
increase dosage by 200
mg/day at weekly intervals
until optimal response is
Carbamazepine 400 mg CR N03AF01000T5002X obtained. Maximum 1.6
252 A Epilepsy
Tablet X g/day. CHILD: usual
maximum dosage 1000
mg/day in children 12-15
years of age, 1200 mg/day in
patients above 15 years of
age
Contact irritant dermatitis, Apply sparingly and rub into
Carbamide (Urea) 10 % D02AE01000G1001 infantile eczemas, acute and affected area 2 - 3 times daily
253 B
Cream XX chronic allergic eczemas, and when required after
icthyosis, hyperkeratotic cleansing skin
A single IV dose of 100mcg
(1ml) is adminitered by bolus
Prevention of uterine atony injection, slowly over
and postpartum hemorrhage 1minute, only when delivery
Carbetocin 100 mcg/ ml H01BB03000P2001X
254 A* following elective cesarean of the infant has been
Injection X
section under epidural or completed by caesarean
spinal anaesthesia section under epidural or
spinal anaesthesia, before or
after delivery of the placenta.
ADULT: Initially, 10-60mg
daily in divided doses given 8
hourly. Maintenance: 5 to
H03BB01000T1001X 20mg daily. CHILDREN > 6
255 Carbimazole 5 mg Tablet B Hyperthyroidism
X years: Initially 15mg daily in
divided doses. CHILDREN 1-
6 years: Initially 7.5mg daily
in divided doses

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
42 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
360 - 400 mg/m2 BSA, by IV
infusion over 15 mins to 1
hour on Day 1 every 4
weeks. Alternatively,
prescription may be based on
Adult solid tumours, Area Under Curve (AUC)
Carboplatin 150 mg L01XA02000P4001X
256 A* paediatric tumours. Salvage calculations. CHILD: 500-600
Injection X
therapy for lymphoma mg/m2 over 1 hour once
every 3 weeks. Salvage
regimes in lymphomas - refer
to specific protocols. Starting
dose in renal impairment,
please refer to product insert.
360 - 400 mg/m2 BSA, by IV
infusion over 15 mins to 1
hour on Day 1 every 4
weeks. Alternatively,
prescription may be based on
Adult solid tumours, Area Under Curve (AUC)
Carboplatin 450 mg L01XA02000P4002X
257 A* paediatric tumours. Salvage calculations. CHILD: 500-600
Injection X
therapy for lymphoma mg/m2 over 1 hour once
every 3 weeks. Salvage
regimes in lymphomas - refer
to specific protocols. Starting
dose in renal impairment,
please refer to product insert.
Initially 250 mcg deep IM inj.
The dose may be repeated at
Carboprost Tromethamine G02AD04999P3001 Postpartum haemorrhage
258 A* intervals of 15-90 min if
250 mcg Injection XX refractory to oxytocin
necessary. Max total dose: 2
mg.
Dilute 20 ml to 1 L of Ringer
solution (cooled to 2-8 °C
prior to use). Initial rapid
Cardioplegia solution
For myocardial instillation into aortic root at
containing Potassium
B05XA16934P3001X preservation(prevent 300 ml/m² body surface
259 Chloride, Magnesium A*
X myocardial damage) during area/min for 3 minutes.
chloride & Procaine HCl
cardiac surgery Should myocardial activity
Injection
persist or recur instill at
300ml/m² body surface
area/min for 2 minutes
3.125 mg twice daily for 2
weeks, then 6.25 mg twice
daily for 2 weeks, then 12.5
Treatment of stable moderate
mg twice daily for 2 weeks
C07AG02000T1002 to severe congestive cardiac
260 Carvedilol 25 mg Tablet A/KK then 25 mg twice daily
XX failure in addition to ACEI's
(titrated up to the highest
and diuretics
tolerated level). Max: <85 kg:
25 mg bid; >85 kg: 50 mg
bid.
3.125 mg twice daily for 2
weeks, then 6.25 mg twice
Treatment of stable moderate
daily for 2 weeks, then 12.5
C07AG02000T1001 to severe congestive cardiac
261 Carvedilol 6.25 mg Tablet A/KK mg twice daily for 2 weeks
XX failure in addition to ACEI's
then 25 mg twice daily
and diuretics
(titrated up to the highest
tolerated level). Max: <85 kg:

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
43 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
25 mg bid; >85 kg: 50 mg
bid.
i) Confirmed systemic fungal
infection in patients who are
refractory or intolerant to
other fungal therapies.
ii) For pediatric patient (12
month and older) for the
i) Invasive aspergillosis &
following indications :
invasive candidiasis: ADULT:
a) Empirical therapy for
Initially, 70 mg infused over 1
presumed fungal infections in
hour followed by subsequent
febrile, neutropenic patients
doses of 50 mg/day.
b) Treatment of invasive
Oesophageal candidiasis:
Caspofungin Acetate 50 mg J02AX04122P4001X candidiasis, including
262 A* ADULT: 50 mg by slow IV
Injection X candidemia and the following
infusion over approximately 1
Candida infections ; intra-
hour
abdominal abscesses,
ii) For all indications, a
peritonitis and pleural space
loading dose of 70mg/m2 on
infections
D1 followed by maintenance
c) Treatment of esophageal
dose of 50mg/m2 od.
candidiasis
d) Treatment of invasive
Aspergillosis in patients who
are refractory to or intolerant
of others therapy (eg :
Amphotericin B)
For adult and pediatric
i) Invasive aspergillosis &
patient (12 month and older)
invasive candidiasis: ADULT:
for the following indications:
Initially, 70 mg infused over 1
a) Treatment of invasive
hour followed by subsequent
candidiasis, including
doses of 50 mg/day.
candidemia and the following
Oesophageal candidiasis:
Candida infections ; intra-
ADULT: 50 mg by slow IV
abdominal abscesses,
infusion over approximately 1
Caspofungin Acetate 70 mg J02AX04122P4002X peritonitis and pleural space
263 A* hour daily
Injection X infections
ii) Child (12months to 17
b) Treatment of invasive
years) : For all indication) A
Aspergillosis in patients who
single 70mg/m2 loading dose
are refractory to or intolerant
(not to exceed an actual dose
of others therapy (eg :
of 70mg) by slow IV infusion
Amphotericin B)
over 1hour; followed by
c) Treatment of esophageal
50mg/m2 (not to exceed an
candidiasis (need to follow
actual dose of 70mg)
the current indications)
Infections caused by
susceptible organisms
CHILD :> 1 mth: 20 mg/kg
including Staphylococcus
daily in 3 divided doses,
aureus and H. influenzae,
Cefaclor 125 mg/5 ml J01DC04000F2101X increased to 40 mg/kg daily if
264 A treatment of sinusitis and
Suspension X necessary, <1 yr: 62.5 mg tid,
infections involving the
1-5 yr: 125 mg tid, >5 yr: 250
respiratory tract, skin and
mg tid. Maximum: 1 g daily
skin structure, bone and joint,
and urinary tract

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
44 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
i) 375 mg twice daily
i) Adult pharyngitis, tonsillitis,
ii) 375 mg or 500 mg twice
skin& soft tissue infections
J01DC04010T5001X daily
265 Cefaclor 375 mg MR Tablet A ii) Bronchitis
X iii) 750mg twice daily
iii) Pneumonia
iv) 375mg twice daily or 500
iv) Lower UTI
mg once daily
ADULT: 250 mg 3 times daily
Infections caused by
for 10 days. For severe
susceptible organisms
infections, double the
including Staphylococcus
dosage. Maximum: 4 g daily.
aureus and H. influenzae,
J01DC04000C1002X CHILD :> 1 mth: 20 mg/kg
266 Cefaclor 500 mg Capsule A treatment of sinusitis and
X daily in 3 divided doses,
infections involving the
increased to 40 mg/kg daily if
respiratory tract, skin and
necessary, <1 yr: 62.5 mg tid,
skin structure, bone and joint,
1-5 yr: 125 mg tid, >5 yr: 250
and urinary tract
mg tid. Maximum: 1 g daily
ADULT: Uncomplicated
Infection caused by
infections: 500 - 1000 mg 2 -
cefazolin-sensitive
3 times daily. Moderately
microorganism, infection of
severe and severe infections:
the respiratory tract,
500 - 1000 mg 3 - 4 times
Cefazolin Sodium 1 g J01DB04520P3001X urogenital tract, skin and soft
267 A daily. Severe life-threatening
Injection X tissue, bile duct, bones and
infections: 1 - 1.5 g 4 times
joint, endocarditis, systemic
daily. Rarely, dose up to 12 g
septic infection, peri-
daily. CHILDREN >1 month:
operative/ surgical
25-50mg/kg/day in 3-4
prophylaxis
divided dose
Febrile neutropenia, ADULT: 1 - 2 g twice daily for
septicaemia, lower most infections. For severe
respiratory tract infection, infections including febrile
J01DE01110P4002X
268 Cefepime 1 g Injection A* urinary tract infection, skin neutropenia: 2 g 3 times
X
and skin structure infections, daily. CHILD:2 mth - 16 yr:
gynaecologic and intra- ≤40 kg: 50 mg/kg every 8-12
abdominal infections hr for 7-10 days
Febrile neutropenia, ADULT: 1 - 2 g twice daily for
septicaemia, lower most infections. For severe
respiratory tract infection, infections including febrile
J01DE01110P4001X
269 Cefepime 500 mg Injection A* urinary tract infection, skin neutropenia: 2 g 3 times
X
and skin structure infections, daily. CHILD: 2 mth - 16 yr:
gynaecologic and intra- ≤40 kg: 50 mg/kg every 8-12
abdominal infections hr for 7-10 days
ADULT: 1 - 2 g twice daily IM
or IV. By IV, adult dose may
be doubled. Maximum: 16 g
daily in divided doses. CHILD
Cefoperazone Sodium 1 g J01DD12520P4002X Infections due to gram-
270 A & INFANT: 50 - 200
Injection X negative bacteria
mg/kg/day in 2 - 4 divided
doses. NEONATE less than
8 days: 50 - 200 mg/kg/day
12 hourly
ADULT: 1 - 2 g twice daily IM
or IV. By IV, adult dose may
be doubled. Maximum: 16 g
Cefoperazone Sodium 2 g J01DD12520P4003X Infections due to gram-
271 A daily in divided doses. CHILD
Injection X negative bacteria
& INFANT: 50 - 200
mg/kg/day in 2 - 4 divided
doses. NEONATE less than

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
45 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
8 days: 50 - 200 mg/kg/day
12 hourly

ADULT: 1 - 2 g twice daily. In


severe or refractory
infections the daily dosage of
i) Treatment of infections due sulbactam/cefoperazone may
to multi-drug resistance be increased up to 8g (4g
Cefoperazone Sodium 500 pathogens producing B- cefopreazone activity)
J01DD62000P4001X
272 mg & Sulbactam Sodium A lactamase CHILD: 40 - 80 mg/kg/day in
X
500 mg Injection ii) Treatment of infections 2 to 4 equally divided doses;
caused by Acinetobacter in serious or refractory
species infections, may increase to
160mg/kg/d in 2 - 4 equally
divided doses.

ADULT: 1 - 2 g twice daily IM


or IV. By IV, adult dose may
be doubled. Maximum: 16 g
daily in divided doses. CHILD
Cefoperazone Sodium 500 J01DD12520P4001X Infections due to gram-
273 A & INFANT: 50 - 200
mg Injection X negative bacteria
mg/kg/day in 2 - 4 divided
doses. NEONATE less than
8 days: 50 - 200 mg/kg/day
12 hourly
ADULT: 1 g 12 hourly (up to
J01DD01520P4002X Infections due to gram- 12 g/day in severe cases).
274 Cefotaxime 1 g Injection A
X negative bacteria CHILD: 50 - 180 mg/kg/day
in 4 - 6 divided doses
ADULT: 1 g 12 hourly (up to
Cefotaxime 500 mg J01DD01520P4001X Infections due to gram- 12 g/day in severe cases).
275 A
Injection X negative bacteria CHILD: 50 - 180 mg/kg/day
in 4 - 6 divided doses
600mg administered every
Treatment of complicated
12 hours by intravenous
skin and soft tissue infections
infusion over 60 minutes for
(cSSTI) in adults Restriction:
Ceftaroline Fosamil 600mg 5-14 days. Dose adjustment
J01D102000P4001X Restricted for only
276 Powder for concentrate for A* in renal impairment: - CrCl >
X complicated SSTI in patients
solution for infusion 30 to ≤50 ml/min : 400mg
who are unable to tolerate or
every 12 hours - CrCl <
not responding to
30ml/min is not
vancomycin.
recommended
ADULT: 1 g 8 hourly or 2 g
12 hourly. In severe
J01DD02520P4003X Severe gram negative
277 Ceftazidime 1 g Injection A infections: 2 g 8 hourly.
X bacterial infections
CHILD: 25 - 150 mg/kg/day
in 2 - 3 divided doses
ADULT: 1 g 8 hourly or 2 g
12 hourly. In severe
J01DD02520P4004X Severe gram negative
278 Ceftazidime 2 g Injection A infections: 2 g 8 hourly.
X bacterial infections
CHILD: 25 - 150 mg/kg/day
in 2 - 3 divided doses
ADULT: 1 g 8 hourly or 2 g
12 hourly. In severe
Ceftazidime 250 mg J01DD02520P4001X Severe gram negative
279 A infections: 2 g 8 hourly.
Injection X bacterial infections
CHILD: 25 - 150 mg/kg/day
in 2 - 3 divided doses

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
46 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
ADULT: 1 g 8 hourly or 2 g
12 hourly. In severe
Ceftazidime 500 mg J01DD02520P4002X Severe gram negative
280 A infections: 2 g 8 hourly.
Injection X bacterial infections
CHILD: 25 - 150 mg/kg/day
in 2 - 3 divided doses
i) 250 mg by deep IM
injection
J01DD04520P4001X i) Gonorrhoea
281 Ceftriaxone 0.25 g Injection A/KK ii) single IM injection 250 mg
X ii) Chancroid
only. For severe infection up
to 100 mg/kg/day
ADULT: 1 - 2 g once daily.
Severe infection: 4 g daily at
12 hour intervals. INFANT &
CHILD, 3 weeks - 12 years:
20 - 80 mg/kg body weight
J01DD04520P4002X Infections caused by
282 Ceftriaxone 0.5 g Injection A daily. CHILD with body
X susceptible organisms
weight 50 kg or more: adult
dose. NEONATE up to 2
weeks: 20 - 50 mg/kg body
weight daily, not to exceed
50 mg/kg
ADULT: 1 - 2 g once daily.
Severe infection: 4 g daily at
12 hour intervals. INFANT &
CHILD, 3 weeks - 12 years:
20 - 80 mg/kg body weight
J01DD04520P4003X Infections caused by
283 Ceftriaxone 1g Injection A daily. CHILD with body
X susceptible organisms
weight 50 kg or more: adult
dose. NEONATE up to 2
weeks: 20 - 50 mg/kg body
weight daily, not to exceed
50 mg/kg
ADULT: 250 mg twice daily;
Upper and lower respiratory
UTI: 125 mg twice daily.
Cefuroxime Axetil 125 mg J01DC02233T1001X tract, genito-urinary tract,
284 A/KK CHILD:30 mg/kg/day in 2
Tablet X skin & soft tissue and urinary
divided doses, up to 500 mg
tract infections (UTI)
daily
Cefuroxime Axetil 125 mg/5 J01DC02233F2101X Infections caused by 30 mg/kg/day in 2 divided
285 A
ml Suspension X susceptible organisms doses, up to 500 mg daily.
ADULT: 250 mg twice daily;
Upper and lower respiratory
UTI: 125 mg twice daily.
Cefuroxime Axetil 250 mg J01DC02233T1002X tract, genito-urinary tract,
286 A/KK CHILD:30 mg/kg/day in 2
Tablet X skin & soft tissue and urinary
divided doses, up to 500 mg
tract infections (UTI)
daily
ADULT: 750 mg every 6 - 8
hours as IM or IV. Severe
infections: 1.5 g every 6 - 8
Infections caused by
Cefuroxime Sodium 1.5 g J01DC02520P4003X hours as IV. CHILD: 30 - 100
287 A susceptible organisms,
Injection X mg/kg/day in 3 - 4 divided
surgical prophylaxis
doses or 2-3 divided doses in
neonates. Surgical
prophylaxis: 1.5 g IV
ADULT: 750 mg every 6 - 8
Infections caused by
Cefuroxime Sodium 250 mg J01DC02520P4001X hours as IM or IV. Severe
288 A susceptible organisms,
Injection X infections: 1.5 g every 6 - 8
surgical prophylaxis
hours as IV. CHILD: 30 - 100

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
47 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
mg/kg/day in 3 - 4 divided
doses or 2-3 divided doses in
neonates. Surgical
prophylaxis: 1.5 g IV
ADULT: 750 mg every 6 - 8
hours as IM or IV. Severe
infections: 1.5 g every 6 - 8
Infections caused by
Cefuroxime Sodium 750 mg J01DC02520P4002X hours as IV. CHILD: 30 - 100
289 A susceptible organisms,
Injection X mg/kg/day in 3 - 4 divided
surgical prophylaxis
doses or 2-3 divided doses in
neonates. Surgical
prophylaxis: 1.5 g IV
i) ADULTS: 200 mg once
daily. May increase to 200
mg bid, if necessary. CHILD
not recommended ii) 100mg
twice daily, increased if
necessary to 200 mg 2 times
daily; CHILD not
recommended iii) 400mg as
a single dose on first day
i) Osteoarthritis ii)
followed by 200mg once daily
M01AH01000C1001 Rheumatoid Arthritis iii)
290 Celecoxib 200 mg Capsule A on subsequent days iv)
XX Acute pain iv) Ankylosing
Initial, 200 mg once daily or
Spondylitis
100 mg twice daily; if no
effect after 6 weeks, may
increase to max. 400 mg
daily in 1-2 divided doses. If
no response following 2
weeks of treatment with 400
mg/day, consider
discontinuation and
alternative treatment
i) ADULTS: 200 mg once
daily. CHILD not
recommended
ii) 100 mg twice daily,
increased if necessary to 200
mg 2 times daily; CHILD not
recommended
iii) 400 mg as a single dose
on first day followed by 200
i) Osteoarthritis
mg once daily on subsequent
M01AH01000C1002 ii) Rheumatoid Arthritis
291 Celecoxib 400 mg Capsule A* days
XX iii) Acute pain iv) Ankylosing
iv) Initial, 200 mg once daily
Spondylitis
or 100 mg twice daily; if no
effect after 6 weeks, may
increase to max. 400 mg
daily in 1-2 divided doses. If
no response following 2
weeks of treatment with 400
mg/day, consider
discontinuation and
alternative treatment
Respiratory tract infections, CHILD: 25 - 100 mg/kg/day
Cephalexin Monohydrate J01DB01010F2101X
292 B ear, nose and throat every 6 hourly. Maximum: 4 g
125 mg/5 ml Syrup X
infections, urinary tract daily

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
48 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
infections, obstetric and
gynaecologic infections

i) 250 mg 6 hourly
i) Respiratory tract infection, ii) 250 - 500 mg 6 hourly
urinary tract infection iii) 1 - 1.5 g 3 times daily or 4
Cephalexin Monohydrate J01DB01010C1001X
293 B ii) Complicated, recurrent or times daily. Maximum: 6
250 mg Capsule X
chronic infections, bronchitis g/day Child: 25-100 mg/kg
iii) Pneumonia daily in divided doses. Max: 4
g daily.
i) 250 mg 6 hourly
i) Respiratory tract infection, ii) 250 - 500 mg 6 hourly
urinary tract infection iii) 1 - 1.5 g 3 times daily or 4
Cephalexin Monohydrate J01DB01010T1001X
294 B ii) Complicated, recurrent or times daily. Maximum: 6
250 mg Tablet X
chronic infections, bronchitis g/day Child: 25-100 mg/kg
iii) Pneumonia daily in divided doses. Max: 4
g daily.
i) 250 mg 6 hourly
i) Respiratory tract infection, ii) 250 - 500 mg 6 hourly
urinary tract infection iii) 1 - 1.5 g 3 times daily or 4
Cephalexin Monohydrate J01DB01010C1002X
295 B ii) Complicated, recurrent or times daily. Maximum: 6
500 mg Capsule X
chronic infections, bronchitis g/day Child: 25-100 mg/kg
iii) Pneumonia daily in divided doses. Max: 4
g daily.
i) 250 mg 6 hourly
i) Respiratory tract infection, ii) 250 - 500 mg 6 hourly
urinary tract infection iii) 1 - 1.5 g 3 times daily or 4
Cephalexin Monohydrate J01DB01010T1002X
296 B ii) Complicated, recurrent or times daily. Maximum: 6
500 mg Tablet X
chronic infections, bronchitis g/day Child: 25-100 mg/kg
iii) Pneumonia daily in divided doses. Max: 4
g daily.
ADULT and CHILD over 6
Urticaria, allergic dermatoses
years: 10 mg daily or 5 mg
R06AE07110T1001X (insect bites, atopic eczema),
297 Cetirizine HCl 10 mg Tablet A/KK twice daily. Child 2-6 years: 5
X perennial rhinitis, allergic
mg once daily or 2.5 mg
rhinitis
twice daily
D08AJ04000L6001X As shampoo and cleansing
298 Cetrimide 1-2% Lotion. C+ Apply to affected area
X agent
Prevention of premature Given by SC 0.25 mg/day,
ovulation in patients given either in the morning
undergoing a controlled beginning on the day 5 or 6
H01CC02122P4001
299 Cetrorelix 0.25 mg Injection A* ovarian stimulation, followed of ovarian stimulation or in
XX
by oocyte pick-up and the evening beginning on day
assisted reproductive 5, and continued until
techniques ovulation induction
For neo-adjuvant treatment
Administered once a week.
of KRAS wild type metastatic
The very first dose is 400mg
colorectal cancer with the
cetuximab per m2 body
aim of liver resection with the
surface area with a
following conditions:
recommended infusion
Cetuximab 5 mg/ml Solution L01XC06000P5002X i) The primary colorectal
300 A* period of 120 minutes. All
for Infusion X tumour has been resected or
subsequent weekly doses
is potentially resected.
are 250mg per m2 body
ii) The metastatic disease is
surface area each with a
confined to the liver and is
recommended infusion
unresectable
period of 60 minutes. The
iii) The patient is fit enough to

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
49 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
undergo surgery to resect the maximum infusion rate must
primary colorectal tumour not exceed 10mg/min.
and to undergo liver surgery
if the metastases become
resectable after treatment
with cetuximab.
iv)The treatment is limited to
16 weeks
i) ADULT 0.5-1 g given 3-4
times daily. CHILD half adult
dose.
ii) Need to be dissolved in
liquid (slurry consistency).
ADULT and CHILD over 12
years: initial 30-100 g or 1-2
i) Diarrhoea and food g/kg; repeat initial dose as
poisoning soon as possible or 20-50 g
Charcoal, Activated 250 mg A07BA01000T1001X ii) Reduce absorption of every 2-6 hours. CHILD over
301 C
Tablet X drugs, plant, inorganic poison 1-12 years, 25-50 g or 1-2
and chemicals in poisoning g/kg; may repeat half the
cases initial dose every 2-6 hour as
needed. CHILD to 1 year of
age, 1 g/kg; may repeat half
the initial dose every 2-6
hours as needed. For
maximum efficacy administer
within 1 hour after ingestion
of toxic compound
ADULT: Acute poisoning: 50
- 100g in suspension. Severe
Emergency treatment of
Charcoal, Activated 50 g A07BA01000F1001X poisoning: 50 - 100g as an
302 A acute oral poisoning and
Granules X initial dose followed by 20g
drug overdose
every 4 - 6 hours.
CHILDREN: 1g/kg/dose
ADULT: 0.5 - 1 g (max 2 g)
with plenty of water at
bedtime. CHILD: Neonate:
30-50 mg/kg; up to 100
mg/kg may be used with
respiratory monitoring. 1 mth-
Chloral Hydrate 200 mg/5 N05CC01010L2101X
303 B Preoperative sedation 12 yr: 30-50 mg/kg (max: 1
ml Mixture X
g); up to 100 mg/kg (max: 2
g) may be used; 12-18 yr: 1-2
g. Doses to be taken 45-60
minutes before procedure.
May be given rectally if oral
route is not available.
General: Initial: 0.1 -0.2
mg/kg body weight daily for 4
- 8 weeks maintanance:
given either by reduced daily
Low grade lymphoma,
L01AA02000T1001X dosage or intermittent course
304 Chlorambucil 2 mg Tablet A chronic lymphocytic
X of treatment. Chronic
leukaemia. Ovarian cancer
Lymphocytic Leukaemia:
initial : 0.15mg/kg/day untill
total leukocyte count has
fallen to 10,000peruL, then

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
50 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
resumed treatment untill 4
weeks after the end of the
first course then continued at
a dosage 0.1mg/kg/day.
Instill 1 drop of a 0.5%
solution every 2 hr. Increase
Chloramphenicol 0.5% Eye S01AA01000D2001X Broad spectrum antibiotic in dosage interval upon
305 C
Drops X superficial eye infections improvement. To continue
treatment for at least 48 hr
after complete healing
Treatment of ocular ADULT and CHILD : Apply to
infections involving the the conjunctiva, a thin strip
Chloramphenicol 1% Eye S01AA01000G5101
306 C conjunctiva and/or cornea (approximately 1 cm) of
Ointment XX
caused by chloramphenicol ointment every 3 hours or
susceptible organisms more frequently
CHILD: 25 - 50 mg/kg/day in
4 divided doses. Severe
infections, premature& full-
Typhoid fever, salmonella
term infants less than 2
Chloramphenicol 125 mg/5 J01BA01126L8001X infections, meningitis,
307 B weeks: 25mg/kg/day in
ml Suspension X cholera, anaerobic and
divided doses. Full-term
rickettsial infections
infants more than 2 weeks:
up to 50mg/kg/day in divided
doses
ADULT: 500 mg 4 times daily
Treatment of typhoid,
or 50 mg/kg/day in 4 divided
Chloramphenicol 250 mg J01BA01126C1001X paratyphoid fevers,
308 B doses. Maximum dose: 4
Capsule X bronchopneumonia and
g/day. CHILD: 25 - 100
enteric infection
mg/kg/day in 4 divided doses
Apply 2 - 3 drops into the ear
Chloramphenicol 5% w/v S02AA01000D1001X Acute otitis media, otitis
309 C 2 - 3 times daily. Not to be
Ear Drops X externa with perforation
used for long term
Adult: 50 to 100 mg/kg/day in
4 divided doses. Premature
Treatment of typhoid, and full-term neonates: 25
Chloramphenicol Sodium J01BA01520P4001X paratyphoid fevers, mg/kg/day in 4 divided
310 B
Succinate 1 g Injection X bronchopneumonia and doses. Full-term infants >2
enteric infection wk: 50 mg/kg/day in 4 divided
doses. Children: 50-100
mg/kg/day in 4 divided doses
Chlorhexidine Gluconate R02AA05137M2001 Rinse mouth with 10 ml for
311 C As a gargle
0.2 % Mouthwash XX about 1 minute twice daily
Skin Preparation: Use
Chlorhexidine Gluconate 2%
in Isopropyl Alcohol 70% and
Chlorhexidine Gluconate D08AC52137L9902X Use as disinfectant in central allow to dry. Catheter
312 C
2% in Alcohol 70% Solution X venous catheter care bundle acces:Apply to catheter ports
or hubs prior to accessing the
line for administering fluids or
injections
Surgical hand disinfection:
Apply 5ml to clean hands and
Surgical hand
Chlorhexidine Gluconate D08AC02137M9901 forearms for 1 min. Rinse
313 C+ scrub/disinfection, pre-op
4% Scrub XX and repeat with another 5ml
skin preparation
for a further 2 mins and then
rinse and dry. General skin

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
51 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
disinfection: Apply
appropriate quantity to wet
area and scrub for 1 min.
Rinse thoroughly & dry

i) Preoperative skin
disinfection
Chlorhexidine Gluconate D08AC02137L9901X i) & iii) 1 : 10 in 70 % Alcohol
314 C+ ii) Wounds or burns
5% Solution X ii) 1 : 100
iii) Emergency disinfection of
instruments
Pre-op surgical hand
disinfection: Spread 5ml
throughly over both hands
and forearms, rubbing
vigorously. When dry apply a
further 5ml and repeat
Chlorhexidine Gluconate procedure. Antiseptic hand
5% Solution 1:10 in 70% D08AC52137L9901X To be used undiluted for disinfection on the ward:
315 C+
alcohol with lanolin as X hand and skin disinfections Spread 3ml throughly over
emollient the hands and wrist rubbing
vigorously until dry.
Disinfection of patient's skin:
Prior to surgery, apply to a
sterile swab and rub
thoroughly over the operation
site for a minimum of 2 mins
V07AV00000F9901X
316 Chlorinated Lime Powder C Antiseptic and disinfectants Not applicable
X
Apply to affected areas
Chlorinated Lime Solution & D08A000999G9901X
317 C Wound or ulcer undiluted as a cleansing
Buffered Acetate Solution X
agent
ADULT 600 mg base stat,
300 mg 6 - 8 hours later and
a further 300 mg on each of 2
following days. CHILD 3 - 4
Chloroquine Phosphate 250
P01BA01162T1001X Treatment of malaria - acute years: 150 mg base stat, 75
318 mg Tablet (150 mg C
X attack mg 6 hours later, then 75 mg
Chloroquine base)
daily for 2 days. CHILD 5 - 8
years : 300 mg stat, 150 mg
6 hours later, then 150 mg
daily for 2 days
10 - 20 mg IM or SC,
repeated if required. Not to
Chlorpheniramine Maleate R06AB04253P3001X
319 B Allergic conditions exceed 40 mg in 24 hours.
10 mg/ml Injection X
10 - 20 mg over 1 minute by
slow IV
CHILD 2 - 5 years : 1 mg
Symptomatic treatment of every 4 - 6 hours (maximum
Chlorpheniramine Maleate R06AB04253L9001X
320 C allergic conditions responsive 6 mg daily) 6 - 12 years : 2
2 mg/5 ml Syrup X
to antihistamine mg every 4 - 6 hours
(maximum 12 mg daily)
ADULT: 4 mg every 4 - 6
Symptomatic treatment of
Chlorpheniramine Maleate R06AB04253T1001X hours. Maximum 24 mg daily.
321 C allergic conditions responsive
4 mg Tablet X CHILD 2 - 5 years : 1 mg
to antihistamines
every 4 - 6 hours (maximum

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
52 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
6 mg daily) 6 - 12 years : 2
mg every 4 - 6 hours
(maximum 12 mg daily)

ADULT: Initial dose - 25 mg 3


times daily according to
response up to 1 g daily.
PAEDIATRIC: Up to 5 years:
Chlorpromazine HCl 100 N05AA01110T1002X Psychosis mania and
322 B 0.5 mg/kg body weight every
mg Tablet X agitation
4 - 6 hours (Maximum 40 mg
daily). CHILD 6 - 12 years: A
third to half adult dose
(Maximum 75 mg daily)
ADULT: Initial dose - 25 mg 3
times daily according to
response up to 1 g daily.
PAEDIATRIC: Up to 5 years:
Chlorpromazine HCl 25 mg N05AA01110T1001X Psychosis mania and
323 B 0.5 mg/kg body weight every
Tablet X agitation
4 - 6 hours (Maximum 40 mg
daily). CHILD 6 - 12 years: A
third to half adult dose
(Maximum 75 mg daily)
Apply thin strip
Chlortetracycline 1% Eye S01AA02000G5101 Eye infections requiring a (approximately 1 cm) to the
324 B
Ointment XX broad spectrum antibiotic conjuctiva 2 to 4 hourly or
more frequently.
Apply directly to affected
Chlortetracycline 1-3 % D06AA02000G1001
325 B Bacterial skin infections area twice daily as required
Cream XX
for 1 - 2 weeks
Prophylactic ADULT: First
dose of 0.5 ml SC/IM
followed after 1 - 4 weeks by
a second dose of 1 ml.
CHILD: 1 - 5 years: 0.1 ml
(1st dose), 0.3 ml (2nd dose).
J07AE01000P3001X CHILD; 5 - 10 years: 0.3 ml
326 Cholera Vaccine B Immunisation of cholera
X (1st dose), 0.5ml (2nd dose).
Booster: For optimum long-
term protection, a booster
dose is recommended for
adults after 2 years. Children
2-6 years should receive a
booster dose after 6 months.
i) Hypercholesterolemia
ii) Familial
hypercholesterolemia - Hypercholesterolemia:
heterozygous Adjunct: initial, 4 g orally 1-2
C10AC01000M4001 iii) Generalized times daily, maintenance, 8
327 Cholestyramine Resin 4 G A
XX atherosclerosis to 16 g in divided doses, max
iv) Diarrhoea due to bile acid 24 g daily CHILD: 50 - 150
malabsorption mg/ kg 6 - 8 hourly oral
v) Pruritus of skin associated
with partial biliary obstruction
For relief of the pain and
Choline Salicylate 8.7%,
N02BA03900G3001 discomfort in mouth ulcers
328 Cetylkonium Chloride B Apply to area 4 times daily
XX and sores, infant teething
0.01% Dental Gel
and denture irritation

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
53 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
i) Women undergoing
superovulation prior to 250 mcg 24-48 hour after the
Choriogonadotropin Alfa assisted reproductive last administration of an FSH
G03GA01000P5001
329 250 mcg/0.5 ml Injection in A* techniques such as in-vitro or hMG preparation, when
XX
Prefilled Syringe fertilization (IVF) optimal stimulation of
ii) Anovulatory or oligo- follicular growth is achieved.
ovulatory women
i) & ii) Induction of ovulation:
5000 - 10,000 units one day
i)Treatment of infertile
following last dose of
Chorionic Gonadotrophin women to induce ovulation
G03GA01000P4001 menotropin. Up to 3 repeat
330 Human (HCG) 5000 IU A* ii) As a luteal support in
XX injections of 5000 units each
Injection controlled ovarian
may be given within the
hyperstimulation cycles
following 9 days to prevent
insufficiency corpus luteum
For adults and adolescents
Prophylactic treatment of
over 12 years of age with
asthma in adults,
mild to moderate asthma is
R03BA08000A2101X adolescents and children
331 Ciclesonide 160mcg Inhaler A* 160 to 640mcg per day:
X over 6 years (follow current
severe asthma dose may be
indication) Not meant for 6
increased to 1280mcg per
yo)
day.
i & ii) Initially 12.5 - 15
mg/kg/day, beginning on the
day before transplant.
Maintenance approx 12.5
mg/kg/day for 3 - 6 months
Only for: i) Patients in whom before being tapered off to
donor specific transplantation zero by 1 year of
cannot be carried out and in transplantation
young children to minimise iii) 3 mg/kg/day in 2 divided
side-effects of steroids doses for first 6 weeks. May
ii) Follow-up cases of bone increased gradually to
marrow transplant maximum 5 mg/kg.
iii) Patients with severe Treatment withdrawn if no
rheumatoid arthritis not response after 3 months
responding to other second iv) ADULT: 5 mg/kg/day in 2
line drugs divided doses. CHILD: 6
L04AD01000C1002X
332 Ciclosporin 100 mg Capsule A* iv) Patients with idiopathic mg/kg/day in 2 divided
X
nephrotic syndrome who are doses. Patients with
steroid toxic or poor permitted levels of kidney
response to failure, the starting dose must
cyclophosphamide not more than 2.5 mg/kg/day
v) Severe aplastic anemia, v) 12 mg/kg/day.
pure red cell aplasia vi) 2.5 mg/kg/day in 2 divided
vi) Cases of recalcitrant doses increasing if there is
psoriasis and atopic eczema no improvement after 4
vii) Treatment of chronic weeks by 0.5 -1 mg/kg/month
ocular inflammatory up to maximum 5 mg/kg/day
disorders/uveitis vii) 5 mg/kg/day in 2 divided
doses, may increase to 7
mg/kg/day in resistant cases.
Maintenance: Less than 5
mg/kg/day especially during
remission

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
54 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
i & ii) Initially 12.5 - 15
mg/kg/day, beginning on the
day before transplant.
Maintenance approx 12.5
Only for : i) Patients in whom mg/kg/day for 3 - 6 months
donor specific transplantation before being tapered off to
cannot be carried out and in zero by 1 year of
young children to minimise transplantation iii) 3
side-effects of steroids mg/kg/day in 2 divided doses
ii) Follow-up cases of bone for first 6 weeks. May
marrow transplant increased gradually to
iii) Patients with severe maximum 5 mg/kg.
Rheumatoid arthritis not Treatment withdrawn if no
Ciclosporin 100 mg/ml Drink L04AD01000L5002X responding to other second response after 3 months
333 A*
Solution X line drugs iv) ADULT: 5 mg/kg/day in 2
iv) Patients with idiopathic divided doses. CHILD: 6
nephrotic syndrome who are mg/kg/day in 2 divided
steroid toxic or poor doses. Patients with
response to permitted levels of kidney
cyclophosphamide failure, the starting dose must
v) Severe aplastic anaemia, not more than 2.5 mg/kg/day
pure red cell aplasia v) 12 mg/kg/day
vi) Cases of recalcitrant vi) 2.5 mg/kg/day in 2 divided
psoriasis and atopic eczema doses increasing if there is
no improvement after 4
weeks by 0.5 -1 mg/kg/month
up to maximum 5 mg/kg/day

i & ii) Initially 12.5 - 15


mg/kg/day, beginning on the
day before transplant.
Maintenance approx 12.5
Only for: i) Patients in whom
mg/kg/day for 3 - 6 months
donor specific transplantation
before being tapered off to
cannot be carried out and in
zero by 1 year of
young children to minimise
transplantation
side-effects of steroids
iii) 3 mg/kg/day in 2 divided
ii) Follow-up cases of bone
doses for first 6 weeks. May
marrow transplant
increased gradually to
iii) Patients with severe
maximum 5 mg/kg.
rheumatoid arthritis not
Treatment withdrawn if no
responding to other second
response after 3 months
line drugs
L04AD01000C1001X iv) ADULT: 5 mg/kg/day in 2
334 Ciclosporin 25 mg Capsule A* iv) Patients with idiopathic
X divided doses. CHILD: 6
nephrotic syndrome who are
mg/kg/day in 2 divided
steroid toxic or poor
doses. Patients with
response to
permitted levels of kidney
cyclophosphamide
failure, the starting dose must
v) Severe aplastic anemia,
not more than 2.5 mg/kg/day
pure red cell aplasia
v) 12 mg/kg/day
vi) Cases of recalcitrant
vi) 2.5 mg/kg/day in 2 divided
psoriasis and atopic eczema
doses increasing if there is
vii) Treatment of chronic
no improvement after 4
ocular inflammatory
weeks by 0.5 -1 mg/kg/month
disorders/uveitis
up to maximum 5 mg/kg/day
vii) 5 mg/kg/day in 2 divided
doses, may increase to 7
mg/kg/day in resistant cases.

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
55 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
Maintenance: Less than 5
mg/kg/day especially during
remission

i) 3 - 5 mg/kg/day until
i) Post bone marrow tolerate orally
Ciclosporin 50 mg/ml L04AD01000P3001X
335 A* transplant ii) 2 - 3 mg/kg/day for
Injection X
ii) Solid organ transplant recipients who are unable to
take orally
Improvement of the maximal
and pain-free walking
distances in patients with
B01AC00000T1002X
336 Cilostazol 100 mg Tablet A* intermittent claudication, who 100 mg twice daily
X
do not have rest pain and
who do not have evidence of
peripheral tissue necrosis.
Traditionally used for the
Cimicifuga Racemosa
HG03WA5001T1001 relief of hot flushes,
337 Rhizome Extract 20 mg A 20 mg twice daily
XX sweating, restlessness
Tablet
associated with menopause
N07CA02000T1001X
338 Cinnarizine 25 mg Tablet B Vestibular disorders One tablet 3 times daily
X
ADULT: the dosage range is
100-400mg twice daily
Gonorrhoea: 100mg single
dose Upper and Lower
Urinary Tract Infection:
Treatment of infections due 100mg bd Upper and Lower
Ciprofloxacin 100 mg/50 ml J01MA02125P3001X
339 A to susceptible bacterial Respiratory Tract Infection:
Injection X
strains 200mg bd-400mg twice daily
Cystic Fibrosis with
psuedomonal Lower RTI:
400mg bd Others: 200-
400mg bd inhalation Anthrax:
400mg bd

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
56 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
Suggest to rephrase ADULT:
the dosage range is 100-
400mg twice daily
Gonorrhoea: 100mg single
dose Upper and Lower
Urinary Tract Infection:
Treatment of infections due
Ciprofloxacin 200 mg/100 J01MA02125P3002X 100mg bd Upper and Lower
340 A to susceptible bacterial
ml Injection X Respiratory Tract Infection:
strains
200mg bd-400mg twice daily
Cystic Fibrosis with
psuedomonal Lower RTI:
400mg bd Others: 200-
400mg bd inhalation Anthrax:
400mg bd
Treatment of infections due ADULT: 125-750 mg twice
J01MA02110T1001X
341 Ciprofloxacin 250 mg Tablet A to susceptible bacterial daily. Acute gonorrhoea: a
X
strains single dose of 250 mg
Treatment of infections due ADULT: 125-750 mg twice
J01MA02110T1002X
342 Ciprofloxacin 500 mg Tablet A to susceptible bacterial daily. Acute gonorrhoea: a
X
strains single dose of 250 mg
i) 2 drops every 15 minutes
for the first 6 hours, then 2
drops every 30 minutes for
the rest of the first day.
Second day: 2 drops every
hour. Subsequent days (3rd -
Treatment of bacterial
14th day): 2 drops every 4
infections caused by
Ciprofloxacin HCl 0.3% S01AX13110D2001X hours. Treatment may be
343 A* susceptible strains in
Ophthalmic Solution X continued after 14 days if
i) corneal ulcers
corneal re-epithelialization
ii) bacterial conjunctivitis
has not occured
ii) 1 - 2 drops every 2 hours
into the conjunctival sac
while awake for 2 days and
1-2 drops every 4 hours while
awake for the next 5 days
Administered as bolus
intravenous injection. May be
As an adjunct to general administered as infusion in
anaesthesia to facilitate ICU patients at a rate of
endotracheal intubation, to 3mcg/kg/min. Adult dose:
provide skeletal muscle a) Induction: 0.15mg/kg over
Cisatracurium Besylate 2 M03AC11197P3001
344 A* relaxation during surgery and 5-10 secs,
mg/ml Injection XX
to facilitate mechanical b) Maintenance: 0.03 mg/kg.
ventilation. Restricted to
patients with lung problem Children 2-12 years:
such as asthma. a) Induction: 0.1 mg/kg over
5-10 secs,
b) Maintenance: 0.02 mg/kg

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
57 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
Germ cell tumours: 20
mg/m2 daily for 5 days every
3 weeks for 3 - 4 courses.
Ovarian tumours: 75 mg/m2
once every 3 weeks as part
of combination therapy with
paclitaxel or 50-60mg/m2 IV
once every 3 weeks as a
Germ cell tumours, ovarian single agent. Baseline
L01XA01000P3001X
345 Cisplatin 10 mg Injection A tumours, adult solid tumours, creatinine clearance,
X
lymphomas pretreatment hydration and
forced diuresis are
mandatory. CHILD:
100mg/m2 over 6 hours once
every 3 weeks. Lymphomas:
Refer to protocols CHILD:
100mg/m2 over 6 hours once
every 3 weeks. Lymphomas:
Refer to protocols
Germ cell tumours: 20
mg/m2 daily for 5 days every
3 weeks for 3 - 4 courses.
Ovarian tumours: 75 mg/m2
once every 3 weeks as part
of combination therapy or
100 mg/m2 IV once every 3
weeks as a single agent.
Germ cell tumours, ovarian
L01XA01000P3002X Baseline creatinine
346 Cisplatin 50 mg Injection A tumours, adult solid tumours,
X clearance, pretreatment
lymphomas
hydration and forced diuresis
are mandatory. CHILD:
100mg/m2 over 6 hours once
every 3 weeks. Lymphomas:
Refer to protocols CHILD:
100mg/m2 over 6 hours once
every 3 weeks. Lymphomas:
Refer to protocols
CHILD: 8 - 12 years: 30 - 40
kg 10 mL, 4 - 8 years: 20 - 29
Treatment of complicated
kg 7.5 mL, 2 - 4 years: 12 -
Clarithromycin 125 mg/5 ml J01FA09000F1001X respiratory tract infections not
347 A* 19 kg 5 mL, 1 - 2 years: 8 -
Granules X responding to standard
11 kg 2.5 mL, less than 8 kg:
macrolides
7.5 mg/kg. To be given twice
daily. Maximum dose: 1g/day
Only for
i) treatment of complicated i) 250 - 500 mg twice daily.
respiratory tract infection not Up to 6 - 14 days
Clarithromycin 250 mg J01FA09000T1001X
348 A* responding to standard ii) 500 mg twice daily with
Tablet X
macrolides omeprazole & amoxicillin. Up
ii) eradication of Helicobacter to 2 weeks
pylori infection

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
58 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
Susceptible infections Adult:
500 mg bid for 2-5 days.
Dose to be infused over 60
minutes in a 0.2% solution;
revert to oral therapy
Only for treatment of
whenever possible. Child: 1
Clarithromycin 500 mg J01FA09000P3001X complicated respiratory tract
349 A* mth-12 yr: 7.5 mg/kg every
Injection X infection not responding to
12 hr. Dose to be given via
standard macrolides
infusion into proximal vein.
Dosage Recommendation
CrCl (ml/min)<30 : Half the
dosage or double dosing
interval
i) ADULT: 150 - 300 mg
every 6 hours; up to 450 mg
i) Skin and soft tissue every 6 hours in severe
infections, bone& joint infections; Max: 1.8g/day
infections CHILD: 3 - 6 mg/kg every 6
ii) Cerebral toxoplasmosis hours. Children weighing <10
Clindamycin HCl 300 mg J01FF01110C1001X
350 A* iii) Children less than 8 years kg should receive at least
Capsule X
old:Treatment and 37.5 mg every 8 hr.
prophylaxis of malaria in ii) 600 mg 6 hourly for 6
combination with quinine, as weeks iii) 10mg/kg twice a
an alternative to doxycline day, in combination with
quinine. The combination to
be given for 7 days
i) ADULT: 0.6 - 2.7 g daily (in
2 - 4 divided doses); up to
4.8 g daily;
i) Skin and soft tissue CHILD over 1 month, 20 - 40
Clindamycin Phosphate 150 J01FF01162P3001X infections, bone & joint mg/kg/day or 350 mg/m2/day
351 A*
mg/ml Injection X infections in 3 - 4 divided doses
ii) Cerebral toxoplasmosis ii) 1200 mg every 6 hours for
3 weeks followed by 300 mg
orally every 6 hours for
another 3 weeks
The initial dose in adults and
adolescents >15 yr should be
low (5 to15mg daily), if
necessary, increased
gradually to a maximum daily
As adjunctive therapy in dose of about 80mg. Doses
N05BA09000T1001X patients with epilepsy not of up to 30mg may be taken
352 Clobazam 10 mg tablet A*
X adequately stabilised with as a single dose in the
their basic medication. evening. The initial dose in
children from 3 to15 yr is
normally 5mg. A
maintenance dose of 0.3 to
1.0mg/kg body weight daily is
usually sufficient.
Apply sparingly once or twice
Short term treatment only of
daily, changing to lower
more resistant dermatoses
potency therapy as soon as
Clobetasol Propionate D07AD01133G1001 eg. psoriasis, recalcitrant
353 A condition is controlled. For
0.05% Cream XX eczemas, lichen planus,
mild to moderate use
discoid lupus erythematosus
maximum for 2 weeks. For
and other conditions which
moderate to severe

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
59 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
do not respond satisfactorily maximum duration 4
to less potent steroids consecutive weeks. Max: 50
g/week
Apply sparingly once or twice
Short term treatment only of daily, changing to lower
more resistant dermatoses potency therapy as soon as
eg. psoriasis, recalcitrant condition is controlled. For
Clobetasol Propionate D07AD01133G5001 eczemas, lichen planus, mild to moderate use
354 A
0.05% Ointment XX discoid lupus erythematosus maximum for 2 weeks. For
and other conditions which moderate to severe
do not respond satisfactorily maximum duration 4
to less potent steroids consecutive weeks. Max:50
g/week
Apply up to four times daily
Clobetasone Butyrate D07AB01255G1001 Eczema and dermatitis of all
355 A/KK until condition improves, then
0.05% Cream XX types
reduce frequency
Apply up to four times daily
Clobetasone Butyrate D07AB01255G5001 Eczema and dermatitis of all
356 A until condition improves, then
0.05% Ointment XX types
reduce frequency
M05BA02011T1011 Treatment of hypercalcaemia 2 tablets in single or two
357 Clodronate 800 mg Tablet A*
XX due to malignancy divided doses
i) ADULT: 100 mg each other
day or 50 mg daily with
100mg Dapsone & 300mg
once a month with 600mg
rifampicin under supervision.
Maximum: 200 mg/day.
CHILD: 10-14 yr: 50mg
i) Previously untreated
clofazimine on alternate days
leprosy patients
with 50mg dapsone & 150
Clofazimine 100 mg J04BA01000C1002X ii) Leprosy patients resistant
358 B mg clofazimine with 450 mg
Capsule X to sulphones
rifampicin once a
iii) Suppression of lepra
month.Maximum: 100
reactions
mg/day.
ii) 100 mg daily
iii) 200-300mg usually
effective. Treatment with
minimum suppression dose
continued for at least 6
months
i) ADULT: 100 mg each other
day or 50 mg daily with
100mg Dapsone & 300mg
once a month with 600mg
rifampicin under supervision.
Maximum: 200 mg/day.
i) Previously untreated
CHILD: 10-14 yr: 50mg
leprosy patients
clofazimine on alternate days
J04BA01000C1001X ii) Leprosy patients resistant
359 Clofazimine 50 mg Capsule B with 50mg dapsone & 150
X to sulphones
mg clofazimine with 450 mg
iii) Suppression of lepra
rifampicin once a
reactions
month.Maximum: 100
mg/day.
ii) 100 mg daily
iii) 200-300mg usually
effective. Treatment with
minimum suppression dose

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
60 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
continued for at least 6
months

50 mg daily from 2nd - 6th or


5th - 9th day of menstrual
cycle. Increase dose
gradually by increments of 50
mg if there is no response
until a dosage of 200 mg
Clomiphene Citrate 50mg G03GB02136T1001 daily is achieved (starting as
360 A Anovulatory infertility
Tablet XX early as 30 days afer the
previous course). Further
treatment may not be
recommended if pregnancy
has not occurred after a total
of 6 treatment cycles.

Initially 10 mg daily,
increased gradually as
necessary to 30 - 150 mg
daily in divided doses or as a
single dose at bedtime; max
250 mg daily. ELDERLY
initially 10 mg daily increased
carefully over approximately
Clomipramine HCI 25 mg N06AA04110T1001X Depression, obsessive-
361 A 10 days to 30 - 75 mg daily;
Tablet X compulsive disorder.
Child: ≥10 yr: Initially, 25 mg
daily, increased gradually
over 2 wk. Max: 3 mg/kg/day
or 100 mg daily, whichever is
smaller. Give in divided
doses. Once titrated, dose
may be given as a single
dose at bedtime.
i) & ii) ADULT: Initial dose
should not exceed 1.5mg/day
divided into 3 doses, may be
increased in increments of
0.5mg every 3 days until
seizures are controlled.
Maintenance dose: 3-
6mg/day. Maximum:
20mg/day. CHILD up to 10
years: initial dose 0.01-0.03
N03AE01000T1001X i) Epilepsy
362 Clonazepam 0.5 mg Tablet B mg/kg/day in 2-3 divided
X ii) Non-epileptic myoclonus
doses, increased by no more
than 0.25-0.5mg every third
day, maximum 0.2mg/kg/day.
CHILD 10-16 years: initial
dose 1-1.5mg/day in 2-3
divided dose, may be
increased by 0.25-0.5mg
every third day until individual
maintenance dose of 3-
6mg/day is reached.
N03AE01000T1002X i) Epilepsy i) & ii) ADULT: Initial dose
363 Clonazepam 2 mg Tablet B
X ii) Non-epileptic myoclonus should not exceed 1.5mg/day

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
61 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
divided into 3 doses, may be
increased in increments of
0.5mg every 3 days until
seizures are controlled.
Maintenance dose: 3-
6mg/day. Maximum:
20mg/day. CHILD up to 10
years: initial dose 0.01-0.03
mg/kg/day in 2-3 divided
doses, increased by no more
than 0.25-0.5mg every third
day, maximum 0.2mg/kg/day.
CHILD 10-16 years: initial
dose 1-1.5mg/day in 2-3
divided dose, may be
increased by 0.25-0.5mg
every third day until individual
maintenance dose of 3-
6mg/day is reached.

Rapid detoxification in 4-5


days (use with naltrexone): 6
mcg/kg ORALLY divided in 3
doses 6 to 8 hours apart the
first day, increasing to 11
Rapid opiod detoxification
Clonidine HCl 0.025 mg N02CX02110T1001X mcg/kg divided in 3 doses
364 A combination use with
Tablet X given day two, tapering to 0.6
naltrexone
mcg/kg the third day. Rapid
opioid detoxification for 7
days (use with naltrexone) :
0.1 to 0.2 mg every 4 hours
as needed
Prevention of myocardial
infarct, stroke or established
peripheral arterial disease.
B01AC04192T1001X
365 Clopidogrel 75 mg Tablet A* As second/third line 75 mg once daily
X
treatment in patients who are
sensitive to acetylsalicylic
acid & intolerant to ticlopidine
i) Focal dystonias
Clostridium Botulinum Toxin M03AX01000P4001 ii) Hemifacial spasm
366 A* 20 - 200 units 3 months once
Type A 100 units XX iii) Spasticity including
cerebral palsy
Initially 20 U/kg divided
between both calf muscles.
May be titrated 10-30 U/kg
Clostridium Botulinum Type i) Focal dystonias
up to max of not >1000
A toxin haemagglutinin M03AX01000P4003 ii) Hemifacial spasm
367 A* U/patient. Should only be
complex 300 units/vial XX iii) Spasticity including
used in children > 2 years of
powder for injection cerebral palsy
age. Repeat injections given
not less than 3 months from
previous injection.
Initially 20 U/kg divided
Clostridium botulinum Type i) Focal dystonias
between both calf muscles.
A toxin haemagglutinin M03AX01000P4002 ii) Hemifacial spasm
368 A* May be titrated 10-30 U/kg
complex 500U/vial powder XX iii) Spasticity including
up to max of not >1000
for injection cerebral palsy
U/patient. Should only be

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
62 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
used in children > 2 years of
age. Repeat injections given
not less than 3 months from
previous injection.

Rub in gently onto affected


and surrounding skin 2 or 3
Cutaneous candidiasis, Tinea
D01AC01000G1001 times daily continuing for
369 Clotrimazole 1% Cream B corporis, Tinea cruris, Tinea
XX about 2 weeks beyond the
pedis and Tinea versicolor
dissapearance of all
symptoms
Otomycosis; concomitant
S02AA00000D1002X
370 Clotrimazole 1% Ear Drop B therapy with antibiotics and 4 to 5 drops 3 to 4 times daily
X
corticosteroid ear drops
Apply gently onto affected
Cutaneous candidiasis, tinea
D01AC01000L6001X and surrounding skin area 2
371 Clotrimazole 1% Solution A orporis, tinea cruris, tinea
X or 3 times daily continuing for
pedis and tinea versicolor
2-4 weeks
200 mg once daily, preferably
Clotrimazole 200 mg G01AF02000S1002X
372 B Vaginal candidiasis at bedtime for three
Vaginal Tablet X
consecutive days
Clotrimazole 500 mg G01AF02000S1003X 500 mg as a single one-time
373 B Vaginal candidiasis
Vaginal Tablet X dose
Treatment of susceptible
Cloxacillin Sodium 125 J01CF02520L8001X bacterial infections, notably Child: 50-100 mg/kg in
374 B
mg/5 ml Suspension X penicillinase-producing divided doses every 6 hr
staphylococci
Treatment of susceptible
ADULT: 250 - 500 mg every
Cloxacillin Sodium 250 mg J01CF02520C1001X bacterial infections, notably
375 B 6 hours. Child: 50-100 mg/kg
Capsule X penicillinase-producing
in divided doses every 6 hr.
staphylococci
ADULT: 250 to 500 mg every
Treatment of susceptible 6 hours depending on type
Cloxacillin Sodium 250 mg J01CF02520P4001X bacterial infections, notably and severity of infection.
376 B
Injection X penicillinase-producing CHILD less than 20 kg: 25 to
staphylococci infections 50 mg/kg/day in equally
divided doses every 6 hours
Treatment of susceptible
ADULT: 250 - 500 mg every
Cloxacillin Sodium 500 mg J01CF02520C1002X bacterial infections, notably
377 B 6 hours. Child: 50-100 mg/kg
Capsule X penicillinase-producing
in divided doses every 6 hr.
staphylococci
ADULT: 250 to 500 mg every
Treatment of susceptible 6 hours depending on type
Cloxacillin Sodium 500 mg J01CF02520P4002X bacterial infections, notably and severity of infection.
378 B
Injection X penicillinase-producing CHILD less than 20 kg: 25 to
staphylococci infections 50 mg/kg/day in equally
divided doses every 6 hours
Initial dose: 12.5 mg (once or
twice) daily, increase slowly
N05AH02000T1002X Treatment of resistant in steps of 25 - 50 mg up to
379 Clozapine 100 mg Tablet A
X schizophrenia 300 mg daily within 2 - 3
weeks. Maximum 900
mg/day

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
63 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
Initial dose: 12.5 mg (once or
twice) daily, increase slowly
N05AH02000T1001X Treatment of resistant in steps of 25 - 50 mg up to
380 Clozapine 25 mg Tablet A
X schizophrenia 300 mg daily within 2 - 3
weeks. Maximum 900
mg/day
Coal Tar 1- 6 % in Dandruff, seborrhoeic
D05AA00946G5003 Apply to the affected areas
381 Betamethasone 17 - B dermatitis, atopic dermatitis,
XX sparingly 1-2 times daily
Valerate 0.01 % Ointment eczema and psoriasis
Dandruff, seborrhoeic
dermatitis, atopic dermatitis,
eczema and psoriasis. Used Apply sparingly to the
D05AA00000G5001 as a mild astringent for the affected area 1-3 times daily
382 Coal Tar 1-9% Ointment B
XX skin, as a soothing and starting with low strength
protective application in preparations
eczema and as a protective
to slight excoriation
Dandruff, seborrhoeic
D05AA00000L5201X
383 Coal Tar 20% Solution B dermatitis, atopic dermatitis, Use 100 ml in a bath
X
eczema and psoriasis
Coal Tar and Salicylic Acid Dandruff, seborrhoeic
D05AA00946G5002
384 (various concentrations) B dermatitis, atopic dermatitis, Apply to the affected areas
XX
Ointment eczema and psoriasis
Coal Tar with Salicylic Acid Dandruff, seborrhoeic
D05AA00000L5202X Apply to the affected areas or
385 (various concentrations) B dermatitis, atopic dermatitis,
X as in product leaflet
Solution eczema and psoriasis
Maximum total dose
To produce local anaesthesia
recommended for application
or vasoconstriction during
N01BC01110L5001X to the nasal mucosa in
386 Cocaine 10% Solution B endoscopic nasal surgery,
X healthy adult is 1.5 to 2
turbinectomy septoplasty,
mg/kg of a 10% cocaine
polypectomy etc
solution
D05AA00946G5001 Scalp psoriasis and severe Rub a small amount into the
387 Cocois Co. Ointment B
XX seborrhoeic dermatitis scalp gently
i) Initial dose, 0.5-1.2 mg,
and then 0.5-0.6 mg every
hour until relief of pain is
i) Acute gout and prophylaxis
obtained or vomiting or
of recurrent gout.
diarrhoea occurs (Maximum:
ii) Leucocytoclastic Vasculitis
8 mg). The course should not
either cutaneous or systemic
be repeated within 3 days.
M04AC01000T1001 involvement, Behcet's
388 Colchicine 0.5 mg Tablet B Prevention of attacks during
XX syndrome, Urticarial
initial treatment with
vasculitis, Systemic sclerosis,
allopurinol or uricosuric
Sweet's syndrome and
drugs: 0.5 mg 1-3 times daily.
severe recalcitrant aphthous
ii) 0.5 mg 1-3 times daily
stomatitis
depends on disease and
severity, up to a maximum of
3 mg/day

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
64 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
A minimum of 5 days
treatment is generally
recommended. For the
treatment of respiratory
exacerbations in cystic
fibrosis patients, treatment
should be continued up to 12
days. Children and adults
(including elderly): Up to
60kg: 50,000 units/kg/day to
a maximum of 75,000
units/kg/day. The total daily
dose should be divided into
three doses given at
Intravenous administration
approximately 8-hour
for the treatment of serious
intervals. Over 60kg: 1-2
infections caused by Gram
million units three times a
Colistimethate Sodium 1 negative bacteria, when more
J01XB01520P4001X day. The maximum dose is 6
389 million IU per vial A* commonly used systemic
X million units in 24 hours.
(Polymyxin E) antibacterial agents may be
Renal impairment: In
contraindicated or may be
moderate to severe renal
ineffective because of
impairment, excretion of
bacterial resistance.
colistimethate sodium is
delayed. Therefore, the dose
and dose interval should be
adjusted in order to prevent
accumulation. Suggested
Dosage Adjustment in Renal
Impairment (for over 60 kg
body weight): - Mild (CrCl 20-
50 ml/min): 1-2 million units
every 8 hr. - Moderate (CrCl
10-20 ml/min): 1 million units
every 12-18 hr. - Severe
(CrCl <10 ml/min): 1 million
units every 18-24 hr.
Eradication therapy for
Colloidal Bismuth Subcitrate A02BX05136T1001X Helicobacter Pylori in 240 mg twice daily for 1-2
390 A
120 mg Tablet X combination with antibiotics weeks
and antisecretory drugs
Replacement of extracellular
100-1000 ml by IV or
Compound Sodium Lactate B05XA30125P6001X losses of fluid and
391 C according to the needs of the
(Hartmanns Solution) X electrolytes, as an alkaliniser
patient
agent
i) Osteoporosis associated
with oestrogen deficiency
ii) Female hypoestrogenism i) 0.3 - 0.625 mg daily
Conjugated estrogens 0.3 G03CA57000T1003 iii) Vasomotor symptoms ii) 0.3- 1.25mg daily for
392 A
mg Tablet XX associated with oestrogen 3weeks, then off for 1 week
deficiency iii) & iv) 0.3mg-1.25mg daily
iv)atrophic vaginitis and
urethritis
Management of moderate to
Conjugated Estrogens
severe vasomotor symptoms
0.625 mg & G03FA12295T1002X
393 A associated with menopause, 1 tablet daily
Medroxyprogesterone X
prevention and management
Acetate 2.5 mg Tablet
of postmenopausal

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
65 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
osteoporosis, atropic vaginitis
and atropic urethritis in post
menopausal woman with
intact uterus

i) Osteoporosis associated
with oestrogen deficiency
ii) Female hypoestrogenism i) 0.3 - 0.625 mg daily
Conjugated Oestrogens G03CA57000T1001 iii) Vasomotor symptoms ii) 0.3- 1.25mg daily for
394 A
0.625 mg Tablet XX associated with oestrogen 3weeks, then off for 1 week
deficiency iii) & iv) 0.3mg-1.25mg daily
iv)atrophic vaginitis and
urethritis
Intravaginally or topically 0.5-
2g daily depending on
severity of condition.
Administration should be
cyclic, with 3 weeks on
conjugated estrogens and
one week off. Estrogens
Atrophic vaginitis and post should be used for the
Conjugated Oestrogens G03CA57000G1001
395 A menopausal atrophic shortest duration possible
0.625 mg/g Cream XX
urethritis when treating atrophic
vaginitis. Every 3 to 6 months
attempts should be made to
taper or discontinue therapy
and conjugated estrogens
should be titrated to give the
lowest possible dosage to
control symptoms
Continuous Ambulatory
For chronic renal diseases
Peritoneal Dialysis (CAPD)
requiring dialysis and acute
Solution containing 2.3% B05DB00908H2504 Dose depending on clinical
396 B therapy-resistance renal
glucose (Calcium XX cases
failure eg. prior to transfer to
1.75mmol/L) & (Calcium
a dialysis centre
1.25mmol/L)
For chronic renal diseases
Continuous Ambulatory requiring dialysis and acute
B05DB00908H2501 Dose depending on clinical
397 Peritoneal Dialysis Solution B therapy-resistance renal
XX cases
containing 1.5% Dextrose failure eg. prior to transfer to
a dialysis centre
For chronic renal diseases
Continuous Ambulatory requiring dialysis and acute
B05DB00908H2502 Dose depending on clinical
398 Peritoneal Dialysis Solution B therapy-resistance renal
XX cases
containing 2.5% Dextrose failure eg. prior to transfer to
a dialysis centre
For chronic renal diseases
Continuous Ambulatory requiring dialysis and acute
B05DB00908H2503 Dose depending on clinical
399 Peritoneal Dialysis Solution B therapy-resistance renal
XX cases
containing 4.25% Dextrose failure eg. prior to transfer to
a dialysis centre
One unit intrauterine device
to be inserted into the uterine
Copper 250 mm2 G02BA02000M9001 cavity on the last day of the
400 B Intrauterine contraception
Intrauterine Device XX menstrual flow or in the first
days afterwards. It is advised
that the Multiload Cu 250

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
66 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
devices are replaced every 3
years

One unit intrauterine device


to be inserted into the uterine
cavity on the last day of the
Copper 375 mm2 G02BA02000M9002 menstrual flow or in the first
401 B Contraception
Intrauterine Device XX days afterwards. It is advised
that the Multiload Cu 375
devices are replaced every 5
years
The tip of the crystal should
D08A000183F9901X be moistened by dipping in
402 Copper Sulphate Crystal C Wounds
X water and applied carefully to
the lesion
Controlled Ovarian
Stimulation (COS) in
combination with a GnRH Women with Body Weight
antagonist for the ≤60 kg: A single dose of 100
development of multiple mcg should be administered.
Corifollitropin Alfa
G03GA09000P5001 follicles in woman Women with Body Weight
403 100mcg/0.5ml solution for A*
XX participating in an Assisted >60 kg: A single dose of 150
injection
Reproductive Technology mcg should be administered.
(ART) program Restriction: Details : Refer to Product
As second line treatment Information
alternative to other
recombinant FSH
Controlled Ovarian
Stimulation (COS) in
combination with a GnRH
Women with Body Weight
antagonist for the
≤60 kg: A single dose of 100
development of multiple
mcg should be administered.
Corifollitropin Alfa follicles in woman
G03GA09000P5002 Women with Body Weight
404 150mcg/0.5ml solution for A* participating in an Assisted
XX >60 kg: A single dose of 150
injection Reproductive Technology
mcg should be administered.
(ART) program Restriction:
Details : Refer to Product
As second line treatment
Information
alternative to other
recombinant FSH

For salt losing congenital 20-30 mg/m2 daily. Doses


Cortisone Acetate 5 mg H02AB10122T1002X adrenal hyperplasia in may be divided with two-
405 B
Tablet X newborn and paediatric thirds in the morning and
patients one-third late in the afternoon
i) and iii) Massage into
affected area until the
medication is completely
absorbed. Repeat as
i) Pruritus needed. Apply 2 or 3 times
P03A000000G1001X
406 Crotamiton 10 % Cream A/KK ii) Scabies daily
X
iii) Insect bite reactions ii) Apply to the whole body
from below the chin. 2nd
application is applied 24 hr
later. May need to use once
daily for up to 5 days.

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
67 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
i) Prophylaxis of anaemia:
250-1000 mcg IM every
month
ii) Uncomplicated pernicious
anaemia or Vitamin B12
malabsorption: Initial 100
mcg daily for 5-10 days
i) Prophylaxis of anaemia
followed by 100-200 mcg
Cyanocobalamin 0.1 mg B03BA01000P3001X ii) Uncomplicated pernicious
407 B monthly until complete
Injection X anaemia or Vitamin B12
remission is achieved.
malabsorption
Maintenance: up to 1000
mcg monthly. CHILD 30-50
mcg daily for 2 or more
weeks (to a total dose of 1-
5mg). Maintenance: 100 mcg
monthly to sustain remission
OR AS PRESCRIBED.
i) Prophylaxis of anaemia:
250-1000 mcg IM every
month
ii) Uncomplicated pernicious
anaemia or Vitamin B12
i) Prophylaxis of anaemia
malabsorption: Initial 100
associated with Vitamin B12
mcg daily for 5-10 days
Cyanocobalamin 1 mg B03BA01000P3002X deficiency
408 B followed by 100-200 mcg
Injection X ii) Uncomplicated pernicious
monthly until complete
anaemia or Vitamin B12
remission is achieved.
malabsorption
Maintenance: up to 1000
mcg monthly. CHILD 30-50
mcg daily for 2 or more
weeks (to a total dose of 1-
5mg). OR AS PRESCRIBED.
ADULT 50-150 mcg daily.
Cyanocobalamin 50 mcg B03BA01000T1002X Vitamin B12 deficiency of
409 B CHILD 50-105 mcg daily in 1-
Tablet X dietary origin
3 divided doses
1 drop every 5 - 10 minutes;
Cyclopentolate 0.2% with not exceeding three times to
S01GA55990D2001 Dilating agent for premature
410 Phenylephrine 1% Eye A produce rapid mydriasis.
XX babies
Drops Observe infants closely for at
least 30 minutes
1 drop of solution in eye(s);
may repeat after 5 to 10
minutes if needed. INFANT :
Single instillation of 1 drop of
0.5% solution in the eye;
Cyclopentolate 0.5% Eye S01FA04000D2001X apply pressure to
411 A Mydriasis and cycloplegia
Drops X nasolacrimal sac for 2 to 3
minutes; observe infant
closely for at least 30
minutes for signs or
symptoms of systemic
absorption

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
68 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
ADULT: 1 drop of solution in
eye(s); may repeat after 5-10
minutes if needed. CHILD: 1
drop of solution in eye(s);
may repeat after 5-10
Cyclopentolate 1% Eye S01FA04000D2002X
412 A Mydriasis and cycloplegia minutes if needed. Pre-
Drops X
treatment on the day prior to
examination is usually not
necessary. If desirable, 1 or 2
drops may be instilled the
evening prior to examination.
i) ADULT: 600 - 750 mg/m2
IV once every 3 weeks as
part of combination regime.
CHILD: Dose variable
depending on disease and
protocol. Range 600 mg/m2
to 2 g/m2 infusion over 1
hour to 6 hours (lower doses
can be given as bolus). Care
with pre and post-hydration.
Mesna to be given with
doses more than 1 g/m2.
Higher doses are used in
i) Solid tumours (adult and haematopoetic stem cell
paediatric), leukaemia, non- transplant-refer to specific
Hodgkin's lymphoma, protocols
multiple myeloma ii) 750 mg/m2 BSA monthly
ii) Severe lupus nephritis for 18 months
Cyclophosphamide 1 g L01AA01000P4002X (Class III and IV) iii) 750 mg/m2 BSA monthly
413 A
Injection X iii) Other systemic vasculitis for 6 months. Dose can be
iv) Systemic lupus adjusted up to 1,000 mg/m2
erythematosus, rheumatoid BSA to achieve adequate
arthritis, polyarteritis nodosa, leucocyte suppression
wegener granulomatosis iv) 500 - 1000 mg
v) Pemphigus vulgaris intravenously (Regime varies
according to indication).
Starting dose may be given
fortnightly then at monthly
intervals followed by 3
monthly intervals
v) 500 mg infusion on the
2nd day of the
dexamethasone-
cyclophosphamide pulsed
regime, the cycle is repeated
every 4 weeks up to 6 cycles
or till remission followed by
oral cyclophosphamide

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
69 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
i) ADULT: 600 - 750 mg/m2
IV once every 3 weeks as
part of combination regime.
CHILD: Dose variable
depending on disease and
protocol. Range 600 mg/m2
to 2 g/m2 infusion over 1
hour to 6 hours (lower doses
can be given as bolus). Care
with pre and post-hydration.
Mesna to be given with
doses more than 1 g/m2.
Higher doses are used in
i) Solid tumours (adult and haematopoetic stem cell
paediatric), leukaemia, non- transplant-refer to specific
Hodgkin's lymphoma, protocols
multiple myeloma ii) 750 mg/m2 BSA monthly
ii) Severe lupus nephritis for 18 months iii) 750 mg/m2
Cyclophosphamide 200 mg L01AA01000P4001X (Class III and IV) BSA monthly for 6 months.
414 A
Injection X iii) Other systemic vasculitis Dose can be adjusted up to
iv) Systemic lupus 1,000 mg/m2 BSA to achieve
erythematosus, rheumatoid adequate leucocyte
arthritis, polyarteritis nodosa, suppression
wegener granulomatosis iv) 500 - 1000 mg
v) Pemphigus vulgaris intravenously (Regime varies
according to indication).
Starting dose may be given
fortnightly then at monthly
intervals followed by 3
monthly intervals
v) 500 mg infusion on the
2nd day of the
dexamethasone-
cyclophosphamide pulsed
regime, the cycle is repeated
every 4 weeks up to 6 cycles
or till remission followed by
oral cyclophosphamide
i) Solid tumours, leukaemia,
lymphoma, autoimmune
disorders, autoimmune i) ADULT: 50 - 100 mg/day.
bullous diseases, connective Monitor full blood count
tissue disease, pyoderma (FBC), liver function, urine
gangrenosum microscopy and renal
ii) For severe lupus nephritis function. CHILD, up to 1
Cyclophosphamide 50 mg L01AA01000T1001X (Class III & IV), systemic year: 10 - 20 mg daily, 1 - 5
415 A
Tablet X vasculitis and steroid years: 30 - 50 mg daily, 6 -
resistant/dependent 12 years: 50 - 100 mg daily
nephrotic syndrome ii) 2 mg/kg/day for 3 - 4
iii) Systemic lupus months
erythematosus (SLE), iii) 1 - 1.5 mg/kg/day orally in
rheumatoid arthritis, divided doses
polyarteritis nodosa, wegener
granulomatosis
ADULT: Initial: 250 mg every
Cycloserine 250 mg J04AB01000C1001X Multi-Drug Resistance
416 A* 12 hours for 14 days, then
Capsule X Tuberculosis treatment
administer 0.5 - 1 g daily in 2

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
70 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
failure. (For respiratory divided doses for 18 - 24
physicians) months (maximum daily
dose: 1 g). CHILD: 2-12 yr: 5
mg/kg bid; 12-18 yr: 250 mg
bid for 2 wk then adjusted to
a max dose of 1 g daily

To increase tear production


in patients whose tear
production is presumed to be
suppressed due to ocular
inflammation associated with 1 drop twice a day in each
Cyclosporine Ophthalmic S01XA18000D2001X
417 A* keratoconjunctivitis sicca. eye approximately 12 hours
Emulsion 0.05% X
Increased tear production apart.
was not seen in patients
currently taking anti
inflammatory drugs or using
punctal plugs.
1 tablet daily for 21 days on
the first day of the cycle,
followed by 7 tab free days.
Cyproterone Acetate 2 mg
G03HB01954T1001 Androgen dependent Starting on day 2 to 5 is
418 & Ethinyloestradiol 0.035 A*
XX diseases in women allowed, but during the first
mg Tablet
cycle a barrier method is
recommended for the first
7days of tablet taking.
i) After orchidectomy, 100 mg
once daily or twice daily
ii) If used together with LHRH
agonists, the initial dose is
Cyproterone Acetate 50 mg G03HA01122T1001 100 mg twice daily for 5 to 7
419 A* Carcinoma of prostate
Tablet XX days before the start of
LHRH agonist, then 100 mg
twice daily for 3 to 4 weeks
together with the LHRH
agonist
Standard doses 100 - 200
mg/m2 daily over 5 - 10 days.
i) Central nervous system
Higher doses for
lymphoma
intensification/consolidation:
ii) Meningeal leukemia
1000 - 3000 mg/m2 daily
iii) Non Hodgkin's Lymphoma
over 3 - 5 days depending on
iv) High dose cytarabine as
specific protocols. CHILD:
conditioning to cytoreduce
Dose variable depending on
the disease before stem cell
disease and protocol. Range
transplant for relapsed or
L01BC01000P4004X from 100 mg/m2 to 3 g/m2
420 Cytarabine 1 g Injection A refractory leukemia
X twice daily. May be given as
v) As salvage for acute
SC, IV bolus or infusion.
lymphocytic leukemia
Intrathecal dose: Less than 1
vi) As salvage for acute
year: 15 mg, 1 - 2 years: 20
myeloid leukemia
mg, 2 - 3 years: 25 mg, more
vii) As palliative
than 3 years: 30 mg.
chemotherapy in elderly
(ENSURE THAT
acute myeloid leukemia/
PREPARATION IS
myelodysplastic syndrome
SUITABLE FOR
INTRATHECAL USE)

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
71 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
Standard doses 100 - 200
mg/m2 daily over 5 - 10 days.
i) Central nervous system
Higher doses for
lymphoma
intensification/consolidation:
ii) Meningeal leukemia
1000 - 3000 mg/m2 daily
iii) Non Hodgkin's Lymphoma
over 3 - 5 days depending on
iv) High dose cytarabine as
specific protocols. CHILD:
conditioning to cytoreduce
Dose variable depending on
the disease before stem cell
disease and protocol. Range
transplant for relapsed or
L01BC01000P4002X from 100 mg/m2 to 3 g/m2
421 Cytarabine 100 mg Injection A refractory leukemia
X twice daily. May be given as
v) As salvage for acute
SC, IV bolus or infusion.
lymphocytic leukemia
Intrathecal dose: Less than 1
vi) As salvage for acute
year: 15 mg, 1 - 2 years: 20
myeloid leukemia
mg, 2 - 3 years: 25 mg, more
vii) As palliative
than 3 years: 30 mg.
chemotherapy in elderly
(ENSURE THAT
acute myeloid leukemia/
PREPARATION IS
myelodysplastic syndrome
SUITABLE FOR
INTRATHECAL USE)
Standard doses 100 - 200
mg/m2 daily over 5 - 10 days.
i) Central nervous system
Higher doses for
lymphoma
intensification/consolidation:
ii) Meningeal leukemia
1000 - 3000 mg/m2 daily
iii) Non Hodgkin's Lymphoma
over 3 - 5 days depending on
iv) High dose cytarabine as
specific protocols. CHILD:
conditioning to cytoreduce
Dose variable depending on
the disease before stem cell
disease and protocol. Range
transplant for relapsed or
L01BC01000P4003X from 100 mg/m2 to 3 g/m2
422 Cytarabine 500 mg Injection A refractory leukemia
X twice daily. May be given as
v) As salvage for acute
SC, IV bolus or infusion.
lymphocytic leukemia
Intrathecal dose: Less than 1
vi) As salvage for acute
year: 15 mg, 1 - 2 years: 20
myeloid leukemia
mg, 2 - 3 years: 25 mg, more
vii) As palliative
than 3 years: 30 mg.
chemotherapy in elderly
(ENSURE THAT
acute myeloid leukemia/
PREPARATION IS
myelodysplastic syndrome
SUITABLE FOR
INTRATHECAL USE)

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
72 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
i) Following total knee
replacement: Initially ADULT
110mg (ELDERLY, 75 mg)
within 1- 4 hours after
surgery, then 220 mg
(ELDERLY, 150 mg) once
daily thereafter for 6-10 days
Following total hip
replacement: Initially ADULT
110 mg (ELDERLY, 75 mg)
within 1- 4 hours after
surgery, then 220 mg
(ELDERLY, 150 mg) once
daily thereafter for 28-35
days
ii) Recommended daily dose
i) Prevention of venous
is 300mg taken orally as
thromboembolic events in
150mg hard capsule twice
patients who have undergone
daily. Therapy should be
total knee replacement or
continued lifelong.
total hip replacement
iii) Recommended daily dose
surgery.
is 300mg taken as one
ii) Reduction of the risk of
150mg capsule BD following
Dabigatran Etexilate 110 B01AE07999C1002X stroke and systemic
423 A* treatment with a parenteral
mg Capsule X embolism in patients with
anticoagulant for at least 5
non-valvular atrial fibrillation
days. The duration of therapy
(AF).
should be individualized after
iii) Treatment of deep vein
careful assessment of the
thrombosis (DVT) and
treatment benefit against the
pulmonary embolism (PE)
risk for bleeding. ii) & iii) For
and prevention of recurrent
the following groups, the
DVT and PE in adults.
recommended daily dose is
220 mg taken as one 110mg
capsule twice daily: - Patients
aged 80 years or above -
Patients who receive
concomitant verapamil
Special patient population for
renal impairment: Renal
function should be assessed
by calculating the creatinine
clearance (CrCl) prior to
initiation of treatment with
Dabigatran to exclude
patients for treatment with
severe renal impairment (i.e.
CrCl < 30 ml/min).
Following total knee
replacement: Initially ADULT
110 mg (ELDERLY, 75 mg)
Prevention of venous within 1- 4 hours after
thromboembolic events in surgery, then 220 mg
Dabigatran Etexilate 75 mg B01AE07999C1001X
424 A* patients who have undergone (ELDERLY, 150 mg) once
Capsule X
total knee replacement or daily thereafter for 6-10 days
total hip replacement surgery Following total hip
replacement: Initially ADULT
110 mg (ELDERLY, 75 mg)
within 1- 4 hours after

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
73 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
surgery, then 220 mg
(ELDERLY, 150 mg) once
daily thereafter for 28-35
days
i) Recommended daily dose
is 300mg taken orally as
150mg hard capsule twice
daily. Therapy should be
continued lifelong.
ii) Recommended daily dose
is 300mg taken as one
150mg capsule BD following
treatment with a parenteral
anticoagulant for at least 5
days. The duration of therapy
i) Reduction of the risk of should be individualized after
stroke and systemic careful assessment of the
embolism in patients with treatment benefit against the
non-valvular atrial fibrillation risk for bleeding. For the
Dabigatran Etexilate150 mg B01AE07999C1003X (AF). following groups, the
425 A*
Capsule X ii) Treatment of deep vein recommended daily dose is
thrombosis (DVT) and 220 mg taken as one 110mg
pulmonary embolism (PE) capsule twice daily: - Patients
and prevention of recurrent aged 80 years or above -
DVT and PE in adults. Patients who receive
concomitant verapamil
Special patient population for
renal impairment: Renal
function should be assessed
by calculating the creatinine
clearance (CrCl) prior to
initiation of treatment with
Dabigatran to exclude
patients for treatment with
severe renal impairment (i.e.
CrCl < 30 ml/min).
i) Malignant melanoma,
i) 250 mg/m2 for 5 days, may
sarcomas, neuroblastomas
Dacarbazine 100 mg L01AX04000P4001X be repeated every 3 weeks
426 A* and other childhood solid
Injection X ii) 375 mg/m2 IV every 2
tumours
weeks
ii) Hodgkin's Disease
i)200 - 800 mg daily for max
i)Endometriosis and
of 9 months
gynaecomastia
G03XA01000C1001 ii)200 mg daily for 12 weeks
427 Danazol 100 mg Capsule A/KK ii)Menorrhagia
XX ii)400 mg daily. Reduce to
iii)Prophylaxis of hereditary
200 mg daily after 2 months
angioedema
attack free period
i) 200 - 800 mg daily for max
i) Endometriosis and
of 9 months
gynaecomastia
G03XA01000C1002 ii) 200 mg daily for 12 weeks
428 Danazol 200 mg Capsule A/KK ii) Menorrhagia
XX ii) 400 mg daily. Reduce to
iii) Prophylaxis of hereditary
200 mg daily after 2 months
angioedema
attack free period
i) ADULT: 6 - 10 mg/kg
J04BA02000T1001X i)Leprosy weekly/ 1.4mg/kg daily
429 Dapsone 100 mg Tablet B
X ii) Dermatitis herpetiformis (around 50 - 100 mg daily).
CHILD: 1 - 2 mg/kg/day.

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
74 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
Maximum: 100 mg/day
ii) ADULT: 50 - 300 mg daily
i) 45 - 60 mg/m2 IV daily for 3
- 5 days
ii) 25 - 45 mg/m2 once a
week for first 4 weeks during
induction phase. Caution:
Total cumulative dose of
daunorubicin and doxorubicin
i) Acute myeloblastic must not exceed 500 mg/m2
Daunorubicin HCl 20 mg L01DB02110P4001X leukaemia (AML) due to risk of cardiotoxicity.
430 A*
Injection X ii) Acute lymphoblastic CHILD: 30-45 mg/m2/dose
leukemia (ALL) infusion over 6 hours.
Schedule depends on
protocol. Need to check
cardiac function closely by
echocardiography every
cumulative dose of
100mg/m2 to max. 360
mg/m2
Myelodysplastic syndromes
(MDS) including: Previously
treated and untreated de
novo and secondary MDS of
15 mg/m2 by continuous IV
all French-American-British
infusion over 3 hours
subtypes (refractory anemia,
repeated every 8 hours for 3
refractory anemia with ringed
days. Repeat this treatment
sideroblasts, refractory
cycle every 6 weeks for a
L01BC08000P3001X anemia with excess blasts,
431 Decitabine 50 mg Injection A* minimum of 4 cycles.
X refractory anemia with
However, complete or partial
excess blasts in
response may take longer
transformation, and chronic
than 4 cycles. Treatment may
myelomonocytic leukemia)
be continued as long as there
and Intermediate-1,
is continued
Intermediate-2, and High-
Risk International Prognostic
Scoring System (IPSS)
groups
Treatment of chronic iron
Initial 20 mg/kg/day. Starting
overload due to blood
dose can also be based on
Deferasirox 125 mg V03AC03000T4001X transfusions (transfusional
432 A* transfusion rate and existing
Dispersible Tablet X haemosiderosis) in adult and
iron burden. Max is 30
pediatric patients aged 2
mg/kg/day
years and above
Treatment of chronic iron
Initial 20 mg/kg/day. Starting
overload due to blood
dose can also be based on
Deferasirox 500 mg V03AC03000T4002X transfusions (transfusional
433 A* transfusion rate and existing
Dispersible Tablet X haemosiderosis) in adult and
iron burden. Max is 30
pediatric patients aged 2
mg/kg/day
years and above
Treatment of iron overload in
patients with thalassemia
25 mg/kg 3 times a day for
major for whom
V03AC02000T1001X total daily dose of 75 mg/kg.
434 Deferiprone 500 mg Tablet A* desferrioxamine therapy is
X Doses greater 100 mg/kg are
contraindicated or
not recommended
inadequate. Add on therapy
to desferrioxamine for

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
75 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
thalassemia patients with
cardiac complication
A single subcutaneous
Post-Menopausal injection of 60 mg
Denosumab in 1.0 mL
Osteoporosis. (To be used by administered once every 6
solution (60 mg/mL) Pre‐ M05BX04000P4001
435 A* Orthopaedic Specialist, months. Patients should
filled syringe (subcutaneous XX
Rheumatologist and receive calcium and vitamin
injection)
Endocrinologist) D supplements whilst
undergoing treatment.
i) 2 g by IM immediately and
5 g by mouth after gastric
i) Acute iron poisoning in lavage
children ii) 0.5 - 1.5 g by IM injection
ii) Investigation and treatment daily
of haemochromatosis iii) Diagnosis: 5 mg per kg by
Desferrioxamine B
V03AC01196P3001X iii) Diagnosis and treatment slow intravenous infusion
436 Methanesulphonate 0.5 g A
X of aluminium toxicity in during the last hour of
Injection
patients with renal failure and haemodialysis. Treatment: 5
dialysis mg per kg once a week by
iv) Chronic iron toxicity or slow intravenous infusion
overload during the last hour of
dialysis
iv) 30 - 50 mg/kg
ADULT: Induction, initially
3% in oxygen or nitrous
oxide/oxygen and increased
by 0.5%-1% every 2-3
i) Induction and maintenance breaths or as tolerated (up to
of anaesthesia in adult 11%), until loss of
N01AB07000L5001X
437 Desflurane Liquid A ii) Maintenance of consciousness. Maintenance:
X
anaesthesia in infants & 2.5%-8.5% with or without
children concomitant nitrous oxide
CHILD: maintenance, inhaled
in concentrations of 5.2%-
10% with or without
concomitant nitrous oxide
Adults and Adolescents (12
R06AX27000T1001X Allergic rhinitis and chronic years of age and older): 5mg
438 Desloratadine 5 mg Tablet A*
X idiopathic urticaria once a day regardless of
mealtime.
i)ADULT and CHILD : 0.1-
0.2mg 3 times daily, up to
i) Central diabetes insipidus 0.1-1.2mg daily
ii) Primary nocturnal enuresis ii) ADULT & Child≥5 yr 0.2-
Desmopressin 0.1 mg H01BA02122T1001X
439 A iii) Treatment of nocturia 0.4mg at night
Tablet X
associated with nocturnal iii)Initially 0.1 mg at night.
polyuria in adult May be increased to 0.2 mg
and then to 0.4 mg by means
of weekly increase
i) ADULT and CHILD : 0.1-
i) Central diabetes insipidus
0.2mg 3 times daily, up to
ii) Primary nocturnal
0.1-1.2mg daily
Desmopressin 0.2 mg H01BA02122T1002X enuresis
440 A ii) ADULT & Child≥5 yr 0.2-
Tablet X ii) Treatment of nocturia
0.4mg at night
associated with nocturnal
iii) Initially 0.1 mg at night.
polyuria in adult
May be increased to 0.2 mg

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
76 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
and then to 0.4 mg by means
of weekly increase

i) ADULT: 10 - 20 mcg 1-2


Desmopressin 100 mcg/ml H01BA02122A4101X i) Diabetes Insipidus times daily. CHILD: 5 -
441 A
Nasal Spray X ii) Primary nocturnal enuresis 10mcg 1-2 times daily
ii) 10-40 mcg nocte
Desmopressin Acetate 4 H01BA02122P3001X ADULT: 1 - 4 mcg IV daily.
442 A Diabetes insipidus
mcg/ml Injection X CHILD :0.4 mcg daily
Tablets must be taken in the
order directed on the
package every day at about
Contraception. Only for
the same time with some
women who should not take
Desogestrel 0.075 mg G03AC09000T1001 liquid as needed. One tablet
443 A* combined oral contraceptives
Tablet XX is to be taken daily for 28
(COCs) eg Obese, smoker,
consecutive days. Each
migraine, breast feeding
subsequent pack is started
immediately after finishing
the previous pack.
One tablet daily for 21 days
Desogestrel 150 mcg &
G03AA09954T1002X starting on 1st day of menses
444 Ethinylestradiol 20 mcg A/KK Oral contraception
X followed by 7 tablet-free
Tablet
days.
1 tablet daily for 21 days,
Desogestrel 150 mcg & subsequent courses
G03AB05954T1001X
445 Ethinylestradiol 30 mcg C+ Contraception repeated after 7 day interval
X
Tablet (during which withdrawal
bleeding occurs)
Desvenlafaxine Succinate Recommended dose is 50mg
N06AX23999T5002X
446 50 mg Extended Release A* Major depression once daily, with or without
X
Tablet food.
i) Prophylaxis and
management of nausea and
vomiting in cancer
chemotherapy, post- 0.5mg to 10mg daily is given
operation and palliative care, for oral administration,
Dexamethasone 0.5 mg H02AB02000T1001X
447 A ii) Treatment of depending upon the disease
Tablet X
adrenocortical function being treated. Up to 15 mg
abnormalities, daily in severe disease.
iii) Any other treatment
requiring corticosteroid
therapy.
i) Prophylaxis and
management of nausea and
vomiting in cancer
chemotherapy, post-
0.5mg to 10mg daily is given
operation and palliative care,
Dexamethasone 4mg H02AB02000T1003X for oral administration,
448 A ii) Treatment of
Tablet X depending upon the disease
adrenocortical function
being treated.
abnormalities,
iii) Any other treatment
requiring corticosteroid
therapy.

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
77 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
Treatment of ocular
Apply 1 - 1.5 cm 3 - 4 times
Dexamethasone and inflammation when
S01CA01990G5101 daily, may be used
449 Neomycin Sulphate and A concurrent use of an
XX adjunctively with drops at
Polymyxin B Eye Ointment antimicrobial is judged
bedtime
necessary
Treatment of ocular
Dexamethasone and
inflammation when 1 - 2 drops hourly for severe
Neomycin Sulphate and S01CA01990D2001
450 A concurrent use of an cases and 4 - 6 hourly for
Polymyxin B Sulphate XX
antimicrobial is judged mild infection
Ophthalmic Suspension
necessary
Acute steroid responsive
Dexamethasone Sodium S01BA01162D2001X
451 A inflammatory and allergic 1 - 2 drops 4 - 6 times a day
Phosphate 0.1% Eye Drops X
conditions
i) Prophylaxis and
management of nausea and
vomiting in cancer
chemotherapy, post-
Initially 0.5 - 9 mg IM, IV or
Dexamethasone Sodium operation and palliative care,
H02AB02162P3001X infusion daily, depending
452 Phosphate 4 mg/ml B ii) Treatment of
X upon the disease being
Injection adrenocortical function
treated
abnormalities,
iii) Any other treatment
requiring corticosteroid
therapy.
Symptomatic treatment of ADULT: 2 mg 3 times daily.
Dexchlorpheniramine R06AB02253T1001X
453 B allergic rhinitis and allergic CHILD : 2 - 12 years : 2 mg 3
Maleate 2 mg Tablet X
dermatoses times daily
CHILD 2 - 5 years : 0.5 mg
Dexchlorpheniramine R06AB02253L9001X Symptomatic treatment of every 4 - 6 hours; 6 - 11
454 B
Maleate 2 mg/5 ml Syrup X allergic rhinitis years : 1 mg every 4 - 6
hours
i) Not to be infused for more
i) Sedation of intubated and than 24 hours, 1 mcg/kg over
mechanically ventilated ICU 10 minutes as loading dose.
patients. For use only by Maintenance dose: 0.2 - 0.7
Dexmedetomidine HCl 100 N05CM18110P4001 specialist anaesthetist mcg/kg/hr
455 A*
mcg/ml Injection XX ii) For sedation of non- ii) Not to be infused for more
intubated patients prior to than 24 hours, 1 mcg/kg over
and/or during surgical and 10 minutes as loading dose.
other procedures Maintenance dose: 0.2 - 0.7
mcg/kg/hr
Condition associated with
Initially 500-1000 ml by
peripheral local slowing of
B05AA05000P6001X infusion, further doses are
456 Dextran 40 Injection A* the blood flow, prophylaxis of
X given according to the
post surgical thromboembolic
patient's condition
disease
For parenteral replenishment
of fluid and minimal
B05BA03000P6002X According to the needs of the
457 Dextrose 10% Injection B carbohydrate calories as
X patient
required by the clinical
condition of the patient
For parenteral replenishment
of fluid and minimal
B05BA03000P6003X According to the needs of the
458 Dextrose 20% Injection B carbohydrate calories as
X patient
required by the clinical
condition of the patient

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
78 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
For parenteral replenishment
of fluid and minimal
B05BA03000P3004X According to the needs of the
459 Dextrose 30% Injection B carbohydrate calories as
X patient
required by the clinical
condition of the patient
For parenteral replenishment
of fluid and minimal
B05BA03000P6001X According to the needs of the
460 Dextrose 5% Injection B carbohydrate calories as
X patient
required by the clinical
condition of the patient
For parenteral replenishment
of fluid and minimal
B05BA03000P3005X According to the needs of the
461 Dextrose 50% Injection B carbohydrate calories as
X patient
required by the clinical
condition of the patient
V04CA02000F2101X Use as a diagnostic agent for
462 Dextrose Powder B 75 g stat
X diabetes
i) ADULT and CHILD more
than 10 year, ORALLY: 60 -
100 ml RECTALLY, contrast
medium should be diluted
with 3-4 times its volume of
water. ORALLY: CHILD less
i) Contrast medium for the
than 10 years,: 15- 30 ml
radiological examination of
NEWBORN, INFANT
the gastrointestinal tract
contrast medium should be
(primarily in cases in which
Diatrizoate Meglumine and diluted with 3 times its
V08AA01254L9901X barium sulphate is
463 Sodium Amidotrizoate A volume of water. RECTALLY:
X contraindicated)
Solution CHILD more than 5 years,
ii) Computerised tomography
contrast medium should be
in abdominal region
diluted with 4-5 times its
iii) Treatment of Mecolinium
volume of water. Younger
ileus
patients a dilution with 5
times its volume is
recommended
ii) Adult, orally, 25-77 mL in
1000 mL tap water 15-30
minutes prior to imaging
i) ADULT: 2-10 mg 3-4 times
daily. CHILD 6 months and
older: 0.12 - 0.8 mg/kg daily
in divided doses, every 6-8
hours
i) Muscle spasm of varied
N05BA01000T1001X ii) ADULT: 2 mg 3 times
464 Diazepam 2 mg Tablet B aetiology, including tetanus
X daily, increased in severe
ii) Anxiety disorders
anxiety to 15 - 30 mg daily in
divided doses. ELDERLY (or
delibitated) half adult dose.
CHILD (night terrors), 1 - 5
mg at bedtime
Status epilepticus - ADULT:
0.5 mg/kg repeated after 12
hours if necessary. CHILD
Diazepam 5 mg Rectal N05BA01000G2001 Status epilepticus, skeletal
465 C (febrile convulsions,
Solution XX muscle spasm
prolonged or recurrent): 0.5
mg/kg (maximum 10 mg),
repeated if necessary. Not

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
79 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
recommended for children
below 2 years
i) ADULT: 2-10 mg 3-4 times
daily. CHILD 6 months and
older: 0.12 - 0.8 mg/kg daily
in divided doses, every 6-8
hours
i) Muscle spasm of varied
N05BA01000T1002X ii) ADULT: 2 mg 3 times
466 Diazepam 5 mg Tablet B aetiology, including tetanus
X daily, increased in severe
ii) Anxiety disorders
anxiety to 15 - 30 mg daily in
divided doses. ELDERLY (or
delibitated) half adult dose.
CHILD (night terrors), 1 - 5
mg at bedtime
i) Status epilepticus, by slow
IV: 5-10 every 10-15 minute
(rate not more than 5
mg/min), to a total dose of 30
mg, may repeat in 2 hour if
needed. Infants 30 days to 5
years, 0.05-0.3 mg/kg/dose
given over 2-3 minutes, every
15-30 minutes to a total dose
of 5 mg, repeat in 2-4 hours if
necessary. CHILD more than
5 years, 1 mg by slow IV,
every 2-5 minutes, maximum
i) Status epilepticus
N05BA01000P3001X 10 mg, repeat in 2-4 hours if
467 Diazepam 5 mg/ml Injection B ii) Skeletal muscle spasm
X necessary
iii) Anxiety disorders
ii) Skeletal muscle spasm, by
slow IV or IM, 5-10 mg
repeated if necessary in 3-4
hours. CHILD (tetanus): 30
days - 5 years, 1-2 mg IM or
IV slowly every 3-4 hours as
needed. 5 years and above,
5-10 mg IM or IV slowly
every 3-4 hours if needed
iii) Anxiety disorders, 2-10
mg by slow IV (not more than
5 mg/min). Repeat if
necessary every 3-4 hours
Post-traumatic inflammation
of the tendons, ligaments &
M02AA15520G3001 Apply 3 - 4 times daily and
468 Diclofenac 1% Gel A joints. Localised forms of soft
XX gently rubbed in
tissue rheumatism and
degenerative rheumatism
Diclofenac Suppositories are
Pain and inflammation in normally inserted one, two or
Diclofenac 100mg M01AB05520S2004
469 A rheumatic disease and three times a day up to a
Suppository XX
juvenile arthritis maximum total daily dose of
150 mg.
Pain and inflammation in ADULT: 75 - 150 mg daily in
Diclofenac 12.5 mg M01AB05520S2001
470 A rheumatic disease and divided doses. CHILD 1-12
Suppository XX
juvenile arthritis years, 12.5- 25 mg daily

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
80 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
Pain and inflammation in ADULT: 75 - 150 mg daily in
Diclofenac 25 mg M01AB05520S2002
471 A rheumatic disease and divided doses. CHILD 1-12
Suppository XX
juvenile arthritis years, 12.5- 25 mg daily
ADULTS: Initial dose of 150
mg daily. Mild or long term:
75 - 150 mg daily in 2 to 3
divided doses after food.
M01AB05520T1001 Pain and inflammation in Maximum 200mg/day.
472 Diclofenac 50 mg Tablet B
XX rheumatic disease PAEDS more than 6 months:
1 - 3 mg/kg body weight daily
in divided doses. Maximum
3mg/kg/day (Max
150mg/day).
ADULTS: 75 - 150 mg daily
in divided doses. Maximum
Pain and inflammation in 150mg/day. PAEDS more
Diclofenac Sodium 50 mg M01AB05520S2003
473 A rheumatic disease and than 6 months: 1 - 3 mg/kg
Suppository XX
juvenile arthritis body weight daily in divided
doses. Maximum 3mg/kg/day
(Max 150mg/day).
IM 75 mg once daily (2 times
daily in severe cases) for not
Diclofenac Sodium 75 mg/3 M01AB05520P3001 Pain and inflammation in
474 A/KK more than 2 days. Max
ml Injection XX rheumatic disease
150mg/day. Not suitable for
children.
ADULT less than 60 kg: 125
mg twice daily or 250 mg
once daily; more than 60 kg:
400 mg once daily or 200 mg
Didanosine 100 mg Tablet J05AF02000T1002X HIV infection, in combination
475 A* twice daily. CHILD: 2 weeks
(ddI) X with other antiretrovirals
to less than 3 months:
50mg/m2 twice daily; 3-8
months: 100mg/m2 twice
daily
ADULT less than 60 kg: 125
mg twice daily or 250 mg
once daily; more than 60 kg:
400 mg once daily or 200 mg
Didanosine 2 g Oral J05AF02000F2101X HIV infection, in combination
476 A* twice daily. CHILD: 2 weeks
Solution (ddI) X with other antiretrovirals
to less than 3 months:
50mg/m2 twice daily; 3-8
months: 100mg/m2 twice
daily
ADULT less than 60 kg: 125
mg twice daily or 250 mg
once daily; more than 60 kg:
400 mg once daily or 200 mg
Didanosine 25 mg Tablet J05AF02000T1001X HIV infection, in combination
477 A* twice daily. CHILD: 2 weeks
(ddI) X with other antiretrovirals
to less than 3 months:
50mg/m2 twice daily; 3-8
months: 100mg/m2 twice
daily
ADULT less than 60 kg: 250
mg once daily; 60 kg or
Didanosine 250 mg Enteric J05AF02000C1001X HIV infection, in combination
478 A* greater: 400 mg once daily.
Coated Capsule X with other antiretrovirals
Dose may varies if taken in
combination with tenofovir

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
81 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
ADULT less than 60 kg: 250
mg once daily; 60 kg or
Didanosine 400 mg Enteric J05AF02000C1002X HIV infection, in combination
479 A* greater: 400 mg once daily.
Coated Capsule X with other antiretrovirals
Dose may varies if taken in
combination with tenofovir
One tablet daily. Treatment
can be started on any day of
G03DB08000T1001 menstrual cycle. Tablets
480 Dienogest 2mg tablet A/KK Treatment of endometriosis
XX must be taken continously
without regard to vaginal
bleeding.
i) 1 mg/kg on the first day
and increased gradually over
3 days to 6 mg/kg daily in
i) Bancrofti filariasis,
divided doses. This dosage is
onchocerciasis, loasis,
Diethylcarbamazine Citrate P02CB02136T1001X maintained for 21 days.
481 B creeping eruption
50 mg Tablet X ii) 13 mg/kg once daily for 7
ii) Ascariasis
days. CHILD : 6 - 10 mg/kg 3
iii) Tropical eosinophilia
times daily for 7 days
iii) 6 mg/kg/day in 3 divided
doses for 21 days
Rapid digitalisation: 0.75 -1.5
mg in divided doses over 24
hours; less urgent
digitalisation, 250 mcg-500
mcg daily (higher dose may
Heart failure , with atrial be divided). Maintenance :
C01AA05000T1001X fibrillation, supraventricular 62.5mg -500 mcg daily
482 Digoxin 0.25 mg Tablet B
X arrhythmias (particularly, (higher dose may be divided)
atrial fibrillation) according to renal function
and in atrial fibrillation,on
heart rate response; usual
range, 125-250 mcg daily
(lower dose may be
appropriate in elderly)
Rapid digitilisation: ADULT &
Heart failure with atrial
CHILD over 10 years, initially
Digoxin 250 mcg/ml C01AA05000P3001X fibrillation, supraventricular
483 A 0.75 - 1.5 mg, followed by
Injection X arrhythmias (particularly atrial
250 mcg 6 hourly until
fibrillation)
digitilisation is complete
Rapid digitalization, give in
divided doses;
PREMATURE: 20-30
mcg/kg; FULLTERM: 25-35
mcg/kg; CHILD 1-2 years :
35 to 60 mcg/kg; CHILD 2-5
years: 30-40 mcg/kg; CHILD
Heart failure, supraventricular 5-10 years: 20- 35 mcg/kg;
C01AA05000L1001X
484 Digoxin 50 mcg/ml Elixir B arrhythmias (particularly atrial CHILD over 10 years: 10-15
X
fibrillation) mcg/kg. For daily
maintenance doses or for
gradual digitalization, give
20% to 30% of oral
digitalizing dose for
premature infants or 25% to
35% of oral digitalizing dose
for all other pediatric patients

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
82 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
Rapid digitalisation: 1-1.5 mg
in divided doses over 24
hours; less urgent
digitalisation, 250 mcg-500
mcg daily (higher dose may
Heart failure, with atrial be divided). Maintenance:
C01AA05000T1002X fibrillation, supraventricular 62.5 - 500 mcg dailly (higher
485 Digoxin 62.5 mcg Tablet B
X arrhythmias (particularly, dose may be divided)
atrial fibrillation) according to renal fuction,
and in atrial fibrillation, on
heart-response; usual range
:125 - 250 mcg daily (lower
doses may be appropriate in
the elderly)
ADULT: 30 - 60 mg every 4 -
Dihydrocodeine Tartrate 30 N02AA08123T1001X For the control of moderate 6 hours. PAED, over 4 yrs:
486 B
mg Tablet X to severe chronic pain 0.5 - 1 mg/kg body weight
every 4-6 hours
Adjunct in elderly with mild to
Dihydroergocristine or Co-
C04AE01196T1001X moderate dementia,
487 dergocrine Mesilate 1 mg A/KK 3-6 mg daily in divided doses
X prevention of migraine and
Tablet
vascular headache
Treatment of angina pectoris
in the following cases:
i) inadequate response or Initially 30mg tds, may
C08DB01110T1001X intolerance to beta-blockers increase to 60mg tds (elderly
488 Diltiazem HCl 30 mg Tablet B
X and Isosorbide Dinitrate initially twice daily; increased
ii) contraindication to beta- if necessary to 360 mg daily.
blockers
iii) coronary artery spasm
Usual Adult & Adolescent
Dose: Antiemetic; or
Antivertigo agent:
Intramuscular, 50 mg
repeated every four hours as
needed. Intravenous, 50 mg
in 10 mL of 0.9% sodium
chloride injection,
administered slowly over a
period of at least two
Prevention and relief of
minutes, repeated every four
motion sickness, treatment of
hours as needed. Usual
vertigo, nausea or vomiting
Pediatric Dose: Antiemetic;
Dimenhydrinate Injection N07CA00000P2001 associated with electroshock
489 B or Antivertigo agent:
10ml/vial (50mg/ml) XX therapy, anaesthesia and
Intramuscular, 1.25 mg per
surgery; labyrinthine
kg of body weight or 37.5 mg
disturbances and radiation
per square meter of body
sickness.
surface, every six hours as
needed, not to exceed 300
mg per day. Intravenous,
1.25 mg per kg of body
weight or 37.5 mg per square
meter of body surface, in 10
ml of 0.9% sodium chloride
injection, administered slowly
over a period of at least two
minutes, every six hours as

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
83 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
needed, not to exceed 300
mg per day.
For prevention and treatment ADULT: 50-100 mg every 4
of motion sickness. Also hours as needed. For motion
used as anti-emetic agent in sickness, take medicine at
irradiation sickness, least 30 minutes, and
postoperative vomiting, drug preferably 1-2 hours before
Dimenhydrinate Syrup N07CA00000L9003X
490 B induced nausea and travelling. Usual adult
15mg/5ml X
vomiting, and for prescribing limit: Up to 400
symptomatic treatment of mg daily. CHILD: Children 6-
nausea and vertigo due to 12 years: 25-50 mg every 6-8
Meniere`s disease and other hours as needed (maximum
labyrinthine disturbances. of 150 mg daily).
ADULT: 50-100 mg every 4
hours as needed. For motion
Prevention and treatment of
sickness, take medicine at
the nausea, vomiting and
least 30 minutes, and
dizziness associated with
preferably 1-2 hours before
Dimenhydrinate Tablet N07CA00000T1001X motion sickness.
491 B travelling. Usual adult
50mg X Symptomatic treatment of
prescribing limit: Up to 400
nausea and vertigo caused
mg daily. CHILD: 6-12 years:
by Meniere's disease and
25-50 mg every 6-8 hours as
other vestibular disturbances.
needed (maximum of 150 mg
daily).
By IM: 2.5 - 3 mg/kg every 4
hours for 2 days, 2 - 4 times
Poisoning by antimony,
on the third day, then 1 - 2
arsenic, bismuth, gold,
times daily for 10 days or
Dimercaprol 50 mg/ml V03AB09000P3001X mercury, possibly thallium;
492 B until recovery. For ophthalmic
Injection X adjunct (with calcium
use : instillation of 50 mg/ml
disodium edetate) in lead
oily solution in conjunctival
poisoning
sac, within 5 minutes of
contamination
3 mg vaginal tablet to be
inserted high into the
Dinoprostone (Prostagladin G02AD02000S1001 posterior formix. A second 3
493 A Induction of labour
E2) 3 mg Vaginal Tablet XX mg tablet may be inserted
after 6-8 hours if labour is not
established. Max 6 mg
i) Acute attack: 6 tablets daily
for the first 4 days, then 4
i) Haemorrhoids tablets daily in 2 divided
Diosmin 450 mg and C05CA53931T1001X
494 A/KK ii) Chronic venous doses for 3 days and 2
Hesperidin 50 mg Tablet X
insufficiency tablets thereafter. Chronic: 2
tablets daily
ii) 2 tab daily with meals

Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016)
84 / 314
MINISTRY OF HEALTH MEDICINES FORMULARY
(MARCH 2016)

PRESCRIBER
NO. GENERIC NAME MDC INDICATION(S) DOSAGE
CATEGORY
Allergic rhinitis
1) Adults & Children over 12
years of age: 25 to 50 mg 3
to 4 times a day
2) Children 6 to 12 years of
age: 10 mg 3 to 4 times a
day
3) Children 1 to 6 years of
age: 5 mg 3 to 4 times a day.
Diphenhydramine Maximum daily dosage <300
R06AA02110L1001X
495 Hydrochloride 10 mg/5 ml C Cough and allergic rhinitis mg (adults and children)
X
Oral solution Cough and cold
1) Adults: 25 mg every 4 hrs.
Not to exceed 150 mg in 24
hours
2) Children (6 to 12years):